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ABSTRACT 
Plasmodium knowlesi is the most common cause of malaria in Malaysian Borneo, 
with reporting limited to clinical cases presenting to health facilities and scarce data 
on the true extent of transmission. Serological estimations of transmission have 
been used with other malaria species to garner information about epidemiological 
patterns. However, there are a distinct lack of suitable serosurveillance tools for this 
neglected disease. Using in silico tools, we designed and expressed a panel of P. 
knowlesi protein products to address the distinct lack of suitable serosurveillance 
tools. Antibody prevalence to these antigens was determined by ELISA, Multiplex 
Bead Assay (MBA) and Protein Microarray for three time-points post-treatment from 
a hospital-based clinical treatment trial in Sabah, Malaysia (n=110 individuals; 298 
total samples for all time points), a small community survey in Sabah, Malaysia 
(~2000), and Palawan, The Philippines (~550), and a large cross sectional survey in 
Sabah, Malaysia (~10,000). 
Both ELISA and MBA showed similar results, with higher responses observed for the 
PkSERA3 antigen 2, both at the clinical level across all time points and at the 
community level. This antigen is suggested to be a short term marker of exposure as 
reactivity to it tended to decline by day 28 of diagnosis. It was possible to determine 
that P. knowlesi is prevalent in Sabah, Malaysia (37.8%, 3,827/10,125). 
Seropositivity was found to be associated with an increase of age (p<0.0001) as well 
as seeing macaques (p<0.0001). The protein microarray, which was used to 
determine isotype reactivity profiles (IgM, IgG and IgA) obtained results concordant 
with the ELISA and MBA results, with PkSERA3 antigen 2 eliciting the highest 
response for all isotypes. IgM decreased significantly across time while IgG tended 
to increase across time. We find it necessary to further develop and expand our 
current panel of P. knowlesi antigens in order to better dissect the epidemiology of P. 
knowlesi in Southeast Asia.  
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Merozoite Surface Protein 1, C-terminal 19-kilodaldon 
region 
MUSCLE Multiple Sequence Comparison by Log-Expectation 
NHP Non-Human Primates 
o/n overnight 
OD Optical Density 
OR Odds ratio 
PBS Phosphate Buffered Saline 
PBS/T Phosphate Buffered Saline and Tween 20 
PCR Polymerase Chain Reaction 
PE phycoerythrin 
PHE Public Health England  
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Qdot Quantum dot 
RBC Red Blood Cells 
RT room temperature 
RT- Reverse Transcriptase without oligo d(T)20 primers 
RT+ Reverse Transcriptase with oligo d(T)20 primers 
SERA Serine Repeat Antigen 
SLIC Sequence and Ligation Independent Cloning strategy  
SOC Super Optimal Broth 
SP Signal Peptide 
SPATR 
secreted protein with altered thrombospondin type I 
repeat 
SSP2 Sporozoite Surface Protein 2 
TM Transmembrane 
TRAP thrombospondin-related adhesion protein 
TSERA Truncated Serine Repeat Antigen 
WHO World Health Organisation 
X-Gal 5-Bromo-4-Chloro-3-Indolyl β-D-Galactopyranoside 
XSS Sabah cross-sectional survey 
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Chapter 1 : INTRODUCTION 
1.1. MALARIA AND GLOBAL IMPACT 
The term “malaria” comes from Middle Age Italian “mala aria”, literally meaning “bad 
air”, as it was believed the disease came from swampy marshy areas with bad 
smelling air1, related to the miasma theory (diseases caused by noxious polluting 
air). Malaria is a mosquito borne protozoal disease caused by members of the genus 
Plasmodium. The disease caused imposes a huge public healthcare burden on 
endemic populations, inhibiting social and economic development in endemic 
regions around the world2,3. In humans, the disease is caused by a number of 
different Plasmodium spp. of which five are the best characterised, Plasmodium 
falciparum, P. vivax, P. ovale (sub-species P. o. wallikeri and P. o. curtisi4), P. 
malariae and, most recently confirmed, the zoonotic infection P. knowlesi2,3,5. There 
has been some evidence of P. cynomolgi infecting humans6-8 but it has yet to be 
acknowledged as an established human pathogen. It is genetically similar to P. 
knowlesi and P. vivax9 and frequently confused with P. vivax morphologically10. 
Malaria affects up to 200 million individuals worldwide2,3 (Figure 1.1).  
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Figure 1.1 Indigenous malaria cases from 2000 and status of countries and territories by 2016. Image from 
published source3. 
 
Mortality from malaria in 2016 was approximately 445,000 deaths, with a large 
proportion of infections due to P. falciparum with P. vivax not far behind, having the 
highest rates of mortality in Southeast Asia2,3,11. The most prevalent malaria parasite 
in sub-Saharan Africa is P. falciparum, which is responsible for 99% of estimated 
cases reported in 20163 (Figure 1.2). 
 
Figure 1.2 Estimated malaria cases in 2016 (millions) by WHO regions. Circle area is proportional to number of 
estimated cases per region. Image from published source3. 
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The greatest burden of disease is largely borne by children under 5 and pregnant 
women, primarily women undergoing their first pregnancy (primagravidae)11. Severe 
anaemia, organ failure, and rarely, cerebral malaria are symptoms caused by the 
blood stage of infection and it is at this point that the disease can be fatal. Recent 
research suggests that the burden of disease caused by P. vivax infection has been 
grossly under reported12,13. P. vivax is now regarded as a significant public health 
challenge responsible for at least 75% of all infections in East Africa, Oceania, 
Central, South and Southeast Asia, the Middle East, Central and South America14-16 
(Figure 1.2). P. knowlesi is a simian parasite with a close genetic relationship to P. 
vivax and has recently been shown to cause human malaria in Southeast Asia17, 
including Thailand, Cambodia, Myanmar, Vietnam, the Philippines and Singapore18-
27 (Figure 1.3).  
 
Figure 1.3 Prediction of P. knowlesi malaria risk in Southeast Asia. The coloured scale from 0 to 1 indicates risk 
of P. knowlesi malaria. The colours indicates regions with higher risk of P. knowlesi malaria, labelled as dark red, 
and regions with lower risk or no known risk, labelled in green. Image from published source28. 
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From the total number of malaria notifications in Sabah, Malaysia, in 2013 (Figure 
1.4), 62% were caused by P. knowlesi and/or P. malariae29. The World Health 
Organisation (WHO) Southeast Asia region accounted for 6% of all malaria deaths in 
2016, although it was also the region which recorded the largest reduction in 
mortality rates since 2010 (44% reduction)3. Recent evidence suggests that human 
P. knowlesi infections are a growing public health threat in South East Asia, 
particularly in Malaysia17,29-32. It is now the most common cause of clinical malaria in 
the Malaysian state of Sabah, particularly the Kudat district, where in 2009 87% of 
157 patients admitted with malaria infection in Kudat District Hospital were caused 
by P. knowlesi33. In 2012, the most common species diagnosed was P. knowlesi, 
with 130 out of 295 (44%) patients recorded as positive34. Between 2014 and 2015, 
82.9% of malaria diagnosed cases were in fact P. knowlesi in Sarawak 
(http://jknsarawak.moh.gov.my/en/). 
 
Figure 1.4 Malaria notifications by Plasmodium species between 2004 and 2013 in Sabah, Malaysia. 
Percentage of total malaria notifications for P. falciparum (blue), P. vivax (red), P. knowlesi/P. malariae (green) 
and mixed infections (purple) in Sabah. Image adapted from published source29. 
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1.2. HISTORICAL CONTEXT OF PLASMODIUM KNOWLESI 
P. knowlesi was first described in 1927, as an infection showing morphological 
similarity to P. malariae35. A few years later this same observation was made by Dr. 
H. Campbell, yet it was Dr. Napier who inoculated 3 different macaques with this 
unknown Plasmodium spp. to scrutinize the effects36. It was observed that one of the 
inoculated macaques developed a severe infection, an event that caught the 
attention of Dr. Biraj Das Gupta, assistant to Dr. Robert Knowles at the time. The 
original strain was passaged in Rhesus macaques by Dr. Gupta, who also 
demonstrated the ability of the parasite to establish infection in humans and 
observed different blood forms of the parasite37. The parasite was named in honour 
of Dr. Knowles, by Colonel Sinton and Dr. Mulligan who described the 24 hour 
shizogonic cycle, an observation that classified this organism as a new species of 
Plasmodium38,39. 
Up until 1955, P. knowlesi was used in the treatment of neurosyphilis, the most 
severe form of which is general paralysis of the insane. This treatment used to be 
called malariotherapy or Malaria Fever Therapy40. The high temperatures caused by 
the malaria fever seemed to supress and kill the spirochete Treponema pallidum, the 
causative agent of syphilis. This method was the standard method of treatment up 
until the discovery of penicillin and, even then, this therapy was used in combination 
with penicillin, as penicillin was not widely accepted41,42.  At the time P. knowlesi 
required no treatment, but after 170 transfers from patient to patient, the infection 
became nearly as virulent as neurosyphilis and this type of treatment had to be 
terminated43,44. The earliest reported case of a natural infection with P. knowlesi was 
in 1965 when an American traveller returned to the USA with an infection after 
visiting peninsular Malaysia45. This incident indicated that P. knowlesi could be 
transmitted to a human host from mosquitoes. 
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P. knowlesi is commonly misdiagnosed as P. malariae10,46, but also as P. falciparum 
and P. vivax31,34,47,48 by microscopy due to morphological similarities, which can 
cause a delay in treatment and mismanagement of the disease, potentially leading 
to case fatalities48-50. P. knowlesi has the potential to cause severe disease in 
Malaysian Borneo and other endemic regions49, and is now the most common cause 
of clinical malaria in Malaysia33,51.  
In a study started by Singh et. al.52 in the year 2000 it was shown that more than half 
of all malaria cases were misdiagnosed microscopically as P. malariae. In the state 
of Sarawak, Malaysian Borneo, thick blood films previously identified by microscopy 
as P. malariae were tested by nested PCR assay and 35 out of 36 slides were 
actually P. knowlesi53. However, it has been shown that the primers used for this 
Polymerase Chain Reaction (PCR) assay randomly cross react with P. vivax, 
creating opportunities for an increase in false positive results54,55. 
Moreover, Lucchi et. al.55 have developed a single-step PCR assay that accurately 
detects P. knowlesi sequences with 100% specificity, though it requires a specific set 
of skills and infrastructure making it less field applicable. 
To date, no reliable and cost effective serosurveillance tools have been established 
to identify and monitor P. knowlesi infections in endemic regions. The development 
of species-specific tools are a necessity to better distinguish human serological 
responses between Plasmodium spp. to improve our understanding of immunity to 
these infections and help define the geographical boundaries of infection. 
Serosurveillance is a powerful approach that utilizes species-specific antibodies as 
tools to improve the monitoring of exposure, transmission and immunity towards 
diseases. Such reagents are currently lacking for P. knowlesi. The few recombinant 
reagents that do exist are not truly species-specific and as a result are unable to 
distinguish between the two infections due to the high level of sequence homology at 
the protein level. The development of well validated species-specific tools would 
represent a vital resource that would be of great importance to the malaria research 
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community. These protein reagents will also serve as an important tool to help 
identify potential correlates of immunity. 
1.3. PLASMODIUM KNOWLESI HOSTS AND VECTORS 
Transmission of the parasite is by the Anopheles leucosphyrus group of mosquito 
vectors, which is attracted to both monkeys and humans, meaning the geographic 
boundaries of P. knowlesi is restricted by the distribution of these vectors and their 
macaque hosts30 (Figure 1.5). In the 1960s A. hackeri was the first mosquito to be 
identified as a vector for transmission of P. knowlesi in macaques56, though it is not 
attracted to humans. More recently, A. latens57,58 in Sarawak, A. cracens59,60 in 
peninsular Malaysia and A. balabacensis were found to be transmission vectors, 
with the later found to be the predominant vector species for P. knowlesi in Sabah, 
Malaysia, in mosquito collections using human landing catches61,62.  
The langur (Presbytis melalophos) and the Old World pig-tailed (Macaca 
nemestrina) and long-tailed, or crab-eating, macaques (M. fascicularis) are the 
natural hosts for P. knowlesi.  
P. knowlesi can also be maintained in one of its experimental host, with usually fatal 
outcomes, the Rhesus macaque (M. mullata)10, which is hypothesised to have 
diverged from a long-tailed macaque ancestor63. These macaques are also the 
natural host for four other Plasmodium species: P. cynomolgi, P. fieldi, P. coatneyi 
and P. inui10,64. 
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Figure 1.5 Distribution of P. knowlesi natural hosts and vectors in Southeast Asia. Green lines delineate limits 
of natural distribution of the mosquito vectors, red lines delineate limits of natural distribution of long-tailed 
macaques, yellow areas represent the natural distribution of pig-tailed macaques, blue areas represent areas 
with humans infected with P. knowlesi and red dots represent areas with macaques infected with P. knowlesi. 
Image from published source31. 
 
Compared to any other non-human primates (NHP) genus, Macaca spp. occupy a 
range of different habitats under different climates, making these the most widely 
distributed NHPs65. The preference for these different habitats is different for each 
species, contributing to species diversification. Macaques’ ability to coexist with 
humans surpasses that of all other non-human primates. As a result, much of the 
data on macaque behaviour and ecology come from settings in which the monkeys 
derive large parts of their food either directly or indirectly from humans65. Macaques 
occupy a wider range of habitats and climates than any other NHP genus. Even 
more, the habitat preferences and foraging strategies for individual species vary in 
many ways, a factor that has contributed to the diversity of species. The ecological 
differences among macaques have been most clearly documented for the pig-tailed 
and the long-tailed macaques65. The pig-tailed macaques have a preference for 
DEVELOPMENT OF PK SPECIES SPECIFIC REAGENTS TO CHARACTERISE ANTIBODY ISOTYPE PROFILES | LOU HERMAN 
9 | P a g e  
 
living in upland and hilly environments, travelling more on the ground and frequently 
feeding in trees with mostly quadrupedal walking and running65. The long-tailed 
macaques, on the other hand, prefer living in lowland secondary forests near rivers 
and are usually found in the lower levels of the main canopy as they are mainly an 
arboreal species, where they feed and travel, although they use all tree levels 
including the ground65. Interestingly, the long-tailed macaque was shown to easily 
control P. knowlesi infections, unlike the closely related Rhesus66, which requires 
several infections cycles before giving any indication of parasitemia control67. 
The most common laboratory primates are macaques, particularly the Rhesus 
macaque but others as well, due to them being thoroughly studied throughout the 
years on many different diseases68 such as human immunodeficiency virus (HIV)69, 
cytomegalovirus (CMV)70 and tuberculosis (TB)71, just to name a few. The 
physiology of these animals, as well as their captured behaviour, are well known, 
enabling researchers to study pathogenic mechanisms, new treatments and 
vaccines. With P. knowlesi being a simian malaria, many studies used rhesus 
macaques as experimental animal models to gain more insight about this particular 
malaria parasite such as antigenic variation and protective immunity67,72-75. Studies 
have predicted that simian and human malaria species share similar regulatory 
mechanisms76-78. 
1.4. PLASMODIUM LIFE CYCLE AND CLINICAL PRESENTATION 
Plasmodium spp. parasites are obligate intracellular organisms. The life cycle of P. 
knowlesi64 is similar to other Plasmodium infections with notable exceptions. In 
contrast to P. falciparum, P. vivax and P. ovale, which follow a 48 hour erythrocytic 
cycle, and P. malariae a 72 hour cycle, P. knowlesi follows a 24 hour quotidian cycle, 
meaning a mild infection could quickly progress to a complicated or severe disease 
which could lead to increased mortality38,39,64,79. The parasites life cycle begin when 
the female Anopheles mosquito takes a blood meal from one of the vertebrate hosts, 
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a human or a primate, injecting sporozoites into the blood stream which then takes 
the parasites into the liver, beginning the liver stage of the cycle64 (Figure 1.6). The 
sporozoites invade the hepatocytes, where they undergo asexual multiplication and 
mature into liver stage schizonts. Mature hepatic schizonts will rupture, releasing 
merozoites into the blood stream where they invade reticulocytes, young red blood 
cells (RBC), initiating the blood stage of the life cycle. P. knowlesi produces fewer, 
larger merozoites per schizonts (10 to 16), compared to P. falciparum (20 to 30)10. 
The merozoite within the RBC develops into a trophozoite which matures and 
undergoes asexual multiplication, forming a blood stage schizont which then erupts, 
releasing numerous merozoites. Some merozoites will invade new RBCs and repeat 
the cycle while others will develop into male or female gametocytes, within the 
RBCs. Once these gametocytes are taken up in a blood meal by a mosquito vector, 
they continue their development and undergo sexual multiplication (Figure 1.6). 
 
Figure 1.6  Plasmodium knowlesi life cycle in human and macaque vectors. Sporozoites are innoculated into 
the vertebrate host from an infected mosquito via the skin during a blood meal. The invasive sporozoites then 
migrate to the liver via  the blood stream, invading hepatocytes developing into mature liver stage schizonts. 
The merozoites enter the blood stream following rupture of the liver stage schizont going on to invade 
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reticulocytes and initiating the blood stage of infection. A proportion of the invading merozoites develop into 
male and female gametocytes that are then taken up during a mosquito blood meal. Verbal consent was 
obtained from Gabriel Fowler to use and adapt single images for this figure. 
 
The rapid replication rate means P. knowlesi can reach high parasite densities 
(>5000 parasites/µL of blood) in a short amount of time52,64. The high parasitemia 
may be due to P. knowlesi preferring to invade young RBCs (reticulocytes), but can 
adapt to invade RBCs of any age80. Clinical signs and symptoms are absent during 
the liver stage of the parasite life cycle and only start to manifest during the blood 
stage, which can vary in duration64. If left untreated, parasitemia burden will increase 
with each replicative cycle. 
Severe disease is caused by high parasite densities, similarly to P. falciparum51, and 
parasite adaptation allows an increase in proliferation in human hosts and in 
virulence of infections. In the natural hosts, P. knowlesi infection causes a mild and 
ephemeral disease with chronically low parasitemia levels10,36. Antigenic variation 
was first shown to occur in P. knowlesi72, indicating that antigenic variation is 
associated with parasite virulence, underlining chronic infections. It is an essential 
process within the parasite life cycle, securing transmission and avoidance of the 
host immune system. However, in the human host, the disease can cause a range of 
different symptoms including fever patterns associated with the release of merozoite, 
fatigue and hyperparasitemia34,50,51. Paradoxically, anaemia and cerebral malaria 
have so far not been observed50, although P. knowlesi parasites have been found in 
the brain81. 
1.5. IMPACT OF DEFORESTATION ON P. KNOWLESI INCIDENCE 
It is hypothesized that the dominance of P. knowlesi in the Borneo region is caused 
by a change in the behavioural patterns between humans and macaques due to 
deforestation82. Another hypothesis is the reduction of competition with P. vivax and 
P. falciparum, or the cross-species protection from these resulting from the reduction 
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in the prevalence of these species. It has been previously suggested that the main 
driver for this emergence of P. knowlesi in Malaysia are the changes in land usage 
and deforestation for the expansion of agriculture31,82 (Figure 1.7), which affects 
vector populations globally83.
 
Figure 1.7 Mapping of land coverage changes in Sabah, Malaysia. Study site in February 2014 (A) and May 2014 
(B). Image from published source84. 
 
One of the reasons for the lack of a large scale P. knowlesi epidemic is because 
transmission is restricted to the A. leucosphyrus mosquito vector, which is attracted 
to both monkeys and humans, but prefers to feed in the forest and forest fringe after 
dusk57,62. This shows that P. knowlesi can be transmitted from monkeys to humans if 
they share the same environment, which is being propelled by the increase in 
urbanisation and deforestation, bringing humans and macaques closer together85. In 
a study led by Barber et. al.34, farmers and plantation workers had higher 
parasitemia than patients with other occupations. Another study led by Fornace et. 
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al.82 in Sabah, Malaysia, also strongly suggests an association between 
environmental changes and an increase in P. knowlesi incidence (Figure 1.8). 
 
Figure 1.8 Plasmodium knowlesi infection incidence (A) compared to forest coverage (B) between 2008 and 
2012 in Sabah, Malaysia. The incidence is shown as the mean of estimated annual parasite incidence, expressed 
as cases per 1,000 person per year. Image from published source82.  
  
These environmental changes, in addition to the change in distribution of people, 
have a great impact on infectious disease risks and have been proposed as a driver 
of infectious disease emergence and transmission86-89. Total annual notifications of 
P. knowlesi infections in Sabah, Malaysia, have increased from 1% to 35% between 
1992 and 2013, acknowledging and increase in P. knowlesi incidence29,90. It is still 
open to question if these values are due to an increase in the accuracy of 
identification or an actual emergence of the species. This increase in P. knowlesi 
could compromise malaria elimination strategies in several countries if not attended 
to as soon as possible. 
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1.6. SEROLOGY AND ANTIBODIES 
Serology has been extensively used as an epidemiological tool in malaria research 
by measuring antibody reactivity at the community level in endemic countries91-93. 
Recent and historical changes in malaria transmission and disease exposure can be 
measured using different serological methods of identifying antibody responses94-100. 
Natural antimalarial antibody acquisition and maintenance is dependent on exposure 
to malarial infection and these antibodies can be used as markers to measure 
transmission intensity95,101. A slow and gradual loss of antibody levels indicates 
different levels of exposure to infection and that memory antibody response exists, 
though these responses are not yet established in children as they are in 
adults102,103. Sensitive and specific serosurveillance tools are a necessity to measure 
and monitor malaria incidence in areas of declining transmission104,105, particularly 
for P. knowlesi, as none currently exist. It is important to know how appropriate the 
antigenic target is, ensuring it detects the correct species for instance, as well as the 
sensitivity of the antibody detecting assay. 
Serosurveillance tests in epidemiological studies have specific requirements and the 
surveys done to predict levels of transmission and disease exposure are generally 
very large. The serological test should be high throughput compatible, quick, 
reproducible in the field and preferably low cost. Multiple tests have been developed 
to detect malarial antibodies in epidemiological studies, such as the Complement 
Fixation Test (CFT)106,107, which was one of the earliest developed, the Indirect 
Haemagglutination Assay (IHA)108, the Immunofluorescence Antibody Test (IFAT), 
the Enzyme-Linked Immunosorbent Assay (ELISA)109, the protein microarray110,111 
and the Multiplex Bead Assay (MBA)112-115. 
For the purpose of this thesis we will focus more on the Enzyme-Linked 
Immunosorbent Assay (ELISA), protein microarray and cytometric bead assays 
(MBA). The latter two are high throughput methods, which are currently being 
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successfully adapted to study antibody responses to malarial antigens. Most studies 
have used the ELISA method to determine malaria endemicity99,101,116,117. The ELISA 
was first used to detect malarial antibodies in a study led by Voller et. al. in 1975109. 
Crude P. knowlesi antigens were successfully used to detect antibody in P. 
falciparum and P. vivax positive individuals. Protein microarrays and MBAs have a 
very similar technique to the ELISA but can screen hundreds of recombinants in a 
single assay and are more sensitive assays. Both methods are fairly new as 
serosurveillance platforms but because these are easily multiplexed, there is a 
possibility of looking at a much wider range of serological responses using minimal 
resources. 
Until recently, most epidemiological studies on malaria have used the ELISA to look 
at total immunoglobulin G (IgG) reactivity in endemic populations101,116,118-121. 
Immunoglobulins (Igs) are produced by B cells and have an important role in the 
human immune response as these recognise and bind to potentially threatening 
antigens to help destroy them122. 
Igs play an important role against malaria as repeated exposure to malaria parasites 
induces the development of antibodies against the parasites. Antibodies that target 
blood-stage malarial antigens have a number of possible functions and specificities 
such the inhibition of RBC invasion by merozoites, inhibition of rosette formation, 
reducing hepatocyte invasion and reducing infectivity after being ingested by 
mosquitoes, just to name a few123. 
Igs are glycoproteins made up of four polypeptide chains that consist of two identical 
light chains (L) and two identical heavy chains (H) which are connected by disulfide 
bridges. Both L and H chains contain a variable domain, forming the antigen-binding 
site or paratope, and constant domain, which determines the antibody functional 
class and location in the body (Figure 1.9). The different types of Igs can be 
DEVELOPMENT OF PK SPECIES SPECIFIC REAGENTS TO CHARACTERISE ANTIBODY ISOTYPE PROFILES | LOU HERMAN 
16 | P a g e  
 
distinguished by the type of H chain they contain, grouping the Igs into specific 
classes, or isotypes124. 
 
 
Figure 1.9  Immunoglobulin basic unit characteristics. 1) Fab region; 2) Fc region; 3) Heavy chain with one 
variable domain followed by one constant domain and two more constant domains; 4) Light chain with one 
variable domain followed by one constant domain; 5) Paratope; 6) hinge regions. SS in red represent disulfide 
bridges. Copyright (C) 2000,2001,2002 Free Software Foundation, Inc. 
 
The immune response changes according to the antigens being presented to the 
immune system, therefore knowing different isotype levels can help interpret the 
immune response. 
In humans there are 5 different isotypes, or classes, each with their own structure, 
function and ability to recognise different antigens125. These are differentiated by 
differences in the H chains: IgG contain H chains known as γ-chains, IgM contain μ-
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chains, IgA contain α-chains, IgE contain ε-chains and IgD contain δ-chains (Figure 
1.10). 
  
Figure 1.10 Immunoglobulin isotypes and functional characteristics. Image from published source124. 
 
The major class of Igs is IgG, a monomer, having 75% abundance in serum in 
relation to total Igs present125 and has the longest serum half-life of all isotypes126. It 
is the only Ig with the ability to cross the placenta and penetrate extravascular areas 
and it is also the main antibody of secondary responses125. IgG is thought to be the 
main antibody to mediate protection in new-borns during the first months of life as it 
is transferred to the foetus during the last trimester of pregnancy127-130. There are 4 
different IgG subclasses in human, with the differences found in the structure of the 
H chains and are ranked in the order of abundance in serum 
(IgG1>IgG2>IgG3>IgG4)126,131. IgG and its subclasses are the most studied 
antibodies in malaria and have been associated with protection against malaria 
infection132-137. 
IgM, usually presented as a pentamer and more rarely as an hexamer, is the first 
antibody during an immune response and it is the first Ig to be produced by 
neonates125. It is responsible for agglutination and is involved in complement 
activation. A single IgM molecule can activate the classical complement system, 
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whilst several IgG molecules are needed for this125. IgM can have high avidity due to 
the multimeric interactions between the pentameric molecule and the antigen126. 
Because IgM is the first Ig to be expressed during B cell development, the H chains 
associate with variable components that have not undergone much somatic 
mutation, meaning they are more immature and have lower affinity, tending to be 
more poly-reactive and stickier than other isotypes126. Merozoite Surface Protein 1-
specific (MSP1) IgM expressing memory B cells were found to be early responders 
to malarial re-infections, followed by IgG expressing memory B cells138. In a separate 
study, IgM antibody responses to a number of P. falciparum antigens were shown to 
be associated with protection to malaria in Ghanaian children139. It was also 
observed that IgM responses were significantly higher in a malaria protected ethnic 
group compared to the other140,141. IgM is potentially an important antibody in the 
study of malarial infections and there has been an increased interest in this isotype.   
IgA is the third major class of Ig, representing approximately 15% of all Igs in serum, 
more than IgM and considerably less than IgG126 and it is generally presented as a 
monomer142. In mucosal tissue and in secretions (secretory IgA), including saliva 
and breast milk, IgA is presented as a dimer and levels are much higher than IgG143, 
contributing up to at least 50% of protein in colostrum. Secretory IgA in breastmilk 
has been shown to inhibit parasite growth in vitro144. Most of IgA is secretory. In 
humans there are two known IgA subclasses, IgA1, which is the most dominant in 
serum (over 85% of IgA) eliciting a good immune response to protein antigens, and 
IgA2, which is the most dominant in mucosal surfaces (60% of IgA) eliciting a good 
immune response to polysaccharide and lipopolysaccharide antigens125,145. The 
main role of IgA is to protect mucosal surfaces from invading pathogens and toxins. 
IgA responses appear to follow IgM and IgG responses in malaria infections146. With 
most information about IgA coming from malaria-caused nephropathy cases147,148, 
the role of this antibody in malaria infection is yet to be described.  
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IgE, presented as a monomer, is the least common Ig having the lowest 
concentration in serum with a short half-life and is associated with hypersensitivity, 
allergies and worm parasite infections126. It is a very potent Ig due to its high affinity 
and is mostly present on the surface of mast cells, Langerhans cells, eosinophils and 
basophils125,126. When cell bound IgE encounter multivalent antigens, these stimulate 
the degranulation of cells and the release of inflammatory mediators such as 
histamine and prostaglandins, causing the typical symptoms of allergies such as 
mucus secretion and sneezing for the expulsion of remaining allergens125,149. The 
measurement of IgE levels in individuals with allergic conditions can be used for 
diagnostic purposes. In a study led by Dottorini et. al.150 an association was found 
between IgE reactivity profiles and atopic diseases (i.e. asthma, eczema) indicating 
that particular patterns of reactivity were related to asthmatic individuals. IgE 
antibody levels, contrary to IgG, have been shown to be higher in individuals 
suffering from severe malaria when compared to uncomplicated malaria and this 
was positively correlated with high parasitemia levels, suggesting a pathogenic role 
for this isotype151-153. IgE antibody-antigen complexes induce the production of 
tumour necrosis factor (TNF) cytokines153-155, which are involved in P. falciparum 
disease severity when excessively produced156,157. However, the opposite has also 
been seen, with low IgE levels seen in individuals suffering from severe malaria, 
although not statistically significant158. Higher levels of this antibody were seen in 
asymptomatic individuals in a study in Tanzania159 and the same was observed in a 
malaria protected tribe (Fulani tribe) when compared to the less protected 
neighbouring tribe (Dogon tribe) in Mali160. The role of this antigen in malaria 
infections is still unclear. 
Lastly, IgD, presented as monomers, are also the least common Ig with a short half-
life161, mostly due to its sensitivity to proteolysis126. The function of this Ig is largely 
unknown. IgD was has been identified in bony cartilaginous fishes from a time when 
the adaptive immune system first evolved162, indicating that this antibody is highly 
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preserved. This implies that this antibody has important functions in the survival of 
the host163. These antibodies are usually found on the surface of B cells and 
participate in B cell receptor signalling alongside membrane IgM, although the 
quantity of IgM is much lower than IgD125,126. Geisberger et. al. have proposed that 
this Ig could be associated with the regulation of B cells at specific developmental 
stages164. Research has suggested that IgD is part of an immune surveillance 
strategy at mucosal sites of antigen entry such as nasopharyngeal cavities161,165-167. 
One study reported that chronic malaria infections raised the concentration of serum 
IgD168, although it was also reported that changes in IgD levels were not very evident 
in children from The Gambia with acute P. falciparum infection169. Another study 
around the same time period reported no relationship between IgD and malaria 
infection, although serum levels appeared to slowly rise throughout childhood170. 
Most of the available research on IgD has been about membrane bound IgD161. 
Children in Kenya from malaria endemic regions were found to have suppressed 
circulating IgD+CD27+ memory B cells compared to children living in areas with 
unstable malaria transmission, indicating that early exposure to P. falciparum could 
dysregulate the development of B cell subsets in children171. 
The importance and activity of the different isotypes and their relationship to one 
another in malaria has only been studied for IgG and IgM, with the other isotypes 
poorly studied. The differing isotype profiles in infections may be related to disease 
progression and severity, therefore it is important to measure and interpret these in 
order to better understand host immune responses towards malaria infection. 
The full genome of P. knowlesi (H strain, Pk1 (A+) clone) has recently been 
sequenced by whole-genome shotgun sequencing. The size of the P. knowlesi 
genome is approximately 23.5 Mb across 14 chromosomes ranging from 0.84 Mb 
and 3.16 Mb172. With this data available to interrogate, it is now possible to develop 
novel sensitive and specific P. knowlesi tools tailored for the serosurveillance of 
malaria caused by this organism.
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Chapter 2 : HYPOTHESIS, AIMS AND OBJECTIVES 
The following chapters will discuss the development of novel serological tools for the 
detection of P. knowlesi and the subsequent antibody profiling using high throughput 
multiplex platforms. My central hypothesis was based on the premise that 
paralogous proteins previously described as targets of immunity in other 
Plasmodium spp., will also be of immunogenic importance in P. knowlesi. I intend to 
demonstrate that P. knowlesi-specific proteins may be useful as serosurveillance 
tools in Southeast Asia and that these could be used to dissect the antibody 
response profiles within endemic populations. 
 
Overall aim: 
The overall aim of this PhD project was to develop P. knowlesi-specific serological 
tools to help dissect and improve our current understanding of human and macaque 
responses to P. knowlesi infections. I envisage that this information could be used to 
build a foundation for describing the geographical boundaries of P. knowlesi 
infections. 
 
Objectives: 
1. To develop and validate a small panel of novel P. knowlesi-specific recombinant 
antigen reagents, based on paralogous genes as a proof-of-concept towards the 
development of potential serosurveillance tools for P. knowlesi with greater 
specificity than those currently available, based on an in silico rational design 
approach. 
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2. To expand the panel of available reagents using our recently developed in silico 
approach to include non-paralogous targets present in P. knowlesi alone and 
determine their utility as potential serosurveillance tools. 
3. To characterise the antibody isotype responses (IgM, IgG and IgA responses) to 
the panel of P. knowlesi-specific recombinant antigens in clinical samples from 
an endemic setting, and use the data to contribute to our current understanding 
of immunity to P. knowlesi. 
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Chapter 3 : MATERIALS AND METHODS  
3.1. SDS-PAGE AND WESTERN BLOT 
Affinity purified proteins were electrophoresed on a Mini-PROTEAN® TGX™ 
Precast Gel (Bio-Rad, UK) using TGx buffer (3.03 g/L Trisma base, 14.44 g/L glycine 
and 0.1% SDS, all at pH 8.3) at 200V for 35 min under non-denaturing and 
denaturing conditions at approximately 0.4 mg/ml and visualised after an o/n 
incubation using Coomassie blue stain (BioSafe, BioRad USA) or Pierce® Silver 
staining as per manufacturer’s instructions (ThermoFisher Scientific, USA). Briefly, 
for the Silver staining, the gel was washed twice in ultrapure H2O for 5 minutes each 
wash and fixed twice in 30% ethanol:10% acetic acid solution for 15 minutes each 
time. The gel was washed twice in 10% ethanol for 5 minutes each wash and again 
twice in ultrapure H2O for 5 minutes each. Sensitizer working solution was prepared 
as indicated in the kit instructions and the gel incubated for 1 minute before being 
washed twice in ultrapure H2O for 1 minute each wash. Stain working solution was 
prepared as indicated in the kit instructions and the gel was incubated for 30 minutes 
before being washed twice in ultrapure H2O for 20 seconds each wash. Developer 
working solution was prepared as indicated in the kit instructions and the gel was 
incubated until protein bands started to appear (2-3 minutes maximum) before being 
replaced by 10% acetic acid stop solution and incubated for 10 minutes. The gels 
were dried using a gel drying solution (30% methanol and 5% glycerol in H2O) and 
preserved in gel drying film (Promega). The empirical sizes of each protein were 
calculated with the PageRuler prestained marker (Fermentas) using the ImageLab 
(BioRad) software. 
For the Western blots, a gel containing expressed antigens was transferred onto 
nitrocellulose using a Hoeffer semi-dry blotter and processed using a BioRad 
general protocol for Western blotting. Briefly, the transferred membrane blocked in 
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5% (w/v) skimmed milk in 1x Phosphate Buffered Saline, 0.05% Tween 20 (PBS/T) 
solution and either left overnight (o/n) at 40 C or incubated at room temperature (RT) 
on a rolling platform for 1 h. Once blocked, it was washed 3-5 x in 1x PBS/T then 
probed with a 1/1000 dilution of pooled Pk human sera prepared in 1x PBS/T and 
incubated at RT for 1 h or o/n. Once the incubating was finished, the blot was 
washed as before and probed with a 1/10,000 dilution of secondary antibody, horse-
radish peroxidase (HRP) conjugate polyclonal rabbit anti-human IgG antibody (Dako, 
Denmark), also prepared in 1x PBS/T and incubated at RT for 1 h and washed again 
before being developed. Further blots were generated using single well SDS-PAGE 
for Slots blots and were prepared following the Western protocol, except the 
transferred membranes were assembled in a Miniblotter® 28 (Immunetics, USA) slot 
blot manifold. All other steps are as described above. Both blots were developed 
using a Pierce™ ECL western blotting substrate kit (ThermoFisher Scientific) and 
incubated at RT for 5 minutes before being exposed to an X-ray film (Amersham 
hyperfilm™ ECL chemoluminescence film) or read using the Azure c600 (Azure 
Biosystems, USA). Exposure times varied between 15 secs, 30 secs, 1 min and 10 
min before being developed using an appropriate developing solution and fixative. 
Blots using the Miniblotter were read using the Azure c600 and were not included 
here as the figure was unreadable due to lack of expertise with the equipment 
resulting in inappropriate exposure. 
3.2. SNP AND PHYLOGENETIC ANALYSIS 
Full-length sequence data from PlasmoDB and construct-specific truncated 
sequences generated in-house using Sanger sequencing were mapped to an in-
house reference sequence strain (P. knowlesi H strain) using the Burrows-Wheeler 
Aligner (BWA) software (v0.7.5a-r405)1. Single nucleotide polymorphisms (SNPs) 
were called using the SAMtools (v1.3) (Sequence Alignment/Map) software using 
default settings2 and were filtered to increase stringency and target only high quality 
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variants (missingness<10%, mixed calls<10%). Overlap between these SNPs and 
the gene candidates was then found using custom perl scripts. SNP variants were 
annotated using snpEFF (v4.3i) (http://snpeff.sourceforge.net/)3 to retrieve the amino 
acid position and type effect of the variant. Maximum likelihood phylogenetic trees 
were constructed from protein sequences using RAxML4 with a fixed empirical 
substitution matrix and 200 bootstraps  and was visualised using iTOL 
(http://itol.embl.de)5. This work was done with Dr. Jody Phelan. 
3.3. HUMAN TEST SAMPLES AND ETHICS APPROVAL 
3.3.1. SABAH HOSPITAL CASE SAMPLES 
Written informed consent was obtained from all study participants6,7. Samples were 
collected as part of a hospital-based clinical trial in Malaysia, Sabah, details of which 
have been described elsewhere7,8 (www.clinicaltrials.gov: #NCT01708876). The 
study was approved by the human research ethics committees of Malaysia (MREC) 
(#NMRR-12-537-12568), the Menzies School of Health and Research, Australia 
(#HREC-2012-1814), and the London School of Hygiene and Tropical Medicine, UK 
(#6244). Serum and dried blood spot (BS) samples were collected from malaria 
diagnosed individuals at day 0 (n=154; P. knowlesi positive n=102), 7 (n=120; P. 
knowlesi positive n=76) and 28 (n=122; P. knowlesi positive n=81) post hospital 
admission and bloodspot samples at 1 (n=46; P. knowlesi positive n=37) and 2 (n=3; 
P. knowlesi positive n=2) year follow ups after that, with drug treatment also taking 
place at day 0 (Table 3.1). Only samples from day 0, 7 and 28 were tested using the 
ELISA and the protein microarray platforms. The Luminex multiplex bead assay 
(MBA) platform was used to test all time points. 
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Table 3.1 Hospital case control sample number by species, time point, sample type and serological platform 
used 
 P. knowlesi P. vivax P. falciparum P. malariae 
Time point 0 7 28 Y1 Y2 0 7 28 Y1 Y2 0 7 28 Y1 Y2 0 7 28 Y1 Y2 
Serum 92 72 77 0 0 31 28 27 0 0 14 14 13 0 0 0 0 0 0 0 
BS 10 4 4 37 2 4 2 0 5 0 1 0 0 3 0 1 0 0 1 0 
Total 102 76 81 37 2 35 30 27 5 0 15 14 13 3 0 1 0 0 1 0 
ELISA 92 72 77 0 0 31 28 27 0 0 14 14 13 0 0 0 0 0 0 0 
Luminex 102 76 81 37 2 35 30 27 5 0 15 14 13 3 0 1 0 0 1 0 
Microarray 12 12 12 0 0 1 1 1 0 0 1 1 1 0 0 0 0 0 0 0 
3.3.2. SABAH AND PALAWAN CASE STUDY COMMUNITIES SURVEY SAMPLES 
Written informed consent was obtained from all participants in this study9. A survey 
of case study communities in Malaysian Borneo and Palawan, Philippines, was 
approved by the Medical Research Sub-Committee of the Malaysian Ministry of 
Health (#NMRR-14-713-21117), the institutional Review Board of the Research 
Institute for Tropical Medicine (The Philippines), and the London School of Hygiene 
and Tropical Medicine (UK) (#8340) Research Ethics Committee. The survey was 
performed between October 2014 and January 2015 in Matunggong, Kudat 
(n=1162) and Limbuak, Pulau Banggi Island (n=795), Malaysian Sabah, and in 
September 2014 in Bacungan (n=546), Palawan, The Philippines; regions endemic 
for P. knowlesi (Figure 3.1). The study sites were selected based on previously 
reported P. knowlesi clinical cases. Each site had a specific characteristic: largely 
deforested (Kudat, Malaysia), patches of secondary forest bordering oil palm 
plantations (Pulau Banggi, Malaysia) and intact primary and secondary forest 
(Bacungan, The Philippines). The total sample size used from this project was 
~2503 individuals with a median age of 24 years (age range 3 months – 99 years) 
and similar proportions of sampled men and women in all study sites. Community 
wide surveys in these intensive study areas describe age specific patterns of 
exposure to P. knowlesi and other malaria species. Individuals less than 3 months of 
age were excluded from this study as well as individuals who had not resided in the 
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area of study for the past month. Filter paper bloodspot samples were collected and 
processed as previously described10. 
 
Figure 3.1 Map of community survey collection sites in Sabah, Malaysia. Stars indicate villages where samples 
were collected: Matunggong in Kudat and Limbuak in Pulau Banggi, Sabah, Malaysia, and Bacugan in Palawan, 
The Philippines. Figure generated by Kim Fornace and from published source9. 
 
3.3.3. SABAH CROSS-SECTIONAL SURVEY (XSS) STUDY 
All samples used came from the Monkeybar project collected by groups led by 
Timothy William in Malaysia. Briefly, the Monkeybar project is a P. knowlesi-focused, 
multidisciplinary collaborative research project on the environmental characterisation 
of infection of both the hosts and vectors, determining risk factors for exposure and 
implementing control measures. Written and informed consent was obtained from all 
participants in this study and procedures were performed according to relevant 
guidelines. As for the community survey study mentioned previously, this study was 
approved by the Medical Research Sub-Committee of the Malaysian Ministry of 
Health (NMRR-14-713-21117) and the Research Ethics Committee of the London 
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School of Hygiene and Tropical Medicine (8340). The Sabah cross-sectional survey 
(XSS) was performed in 4 districts, Kudat, Kota Marudu (KM), Pitas and Ranau, in 
northern Sabah, Malaysia (Figure 3.2). These districts represent high-risk areas for 
P. knowlesi transmission and the purpose of this larger survey was to estimate the 
transmission intensity of P. knowlesi across the different environmental conditions 
within those areas. 
 
Figure 3.2 Collection sites for Sabah cross-sectional survey (XSS). Samples were collected from communities in 
Ranau, Kota Marudu, Pitas, Kudat and Pulau Banggi in Sabah, Malaysia. Map generated by Kim Fornace 
(personal communication). 
 
3.3.4. MICROSCOPY AND PCR DIAGNOSIS OF HUMAN SAMPLES 
Finger-prick blood samples were collected from all individuals enrolled in the 
different studies; these included approximately 200 µl of whole-blood specimens 
collected in tubes containing EDTA (Ethylenediaminetetraacetic acid) (Becton-
Dickinson, Franklin Lakes, USA), three 20 µl blood spots stored on filter paper 
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(3MM, Whatman, UK), dried and stored with desiccant at 4°C and blood smears for 
microscopy detection of malaria parasites. A number of the clinical samples were 
collected on a thinner type of filter paper for which we do not have any information 
on. These were stored in the same way as described above. The thin filter paper 
spot samples that were also collected as serum were the only ones analysed (n=26). 
All clinical whole blood samples were PCR screened for species specificity as 
described by Grigg et. al.7 in order to validate the microscopy results and to detect 
low parasitemia infections that would not be detected by standard microscopy. 
Similarly to the clinical samples, samples from the community surveys were all PCR 
screened from whole blood for plasmodium species infection as by Singh et. al. 11 
and Fornace et. al. 9,12. All products were visualised on a 2% agarose gel. The teams 
led by Kim Fornace both collected all samples and performed this work at the 
Universiti Sabah Malaysia in Malaysia and at the Research Institute for Tropical 
Medicine in the Philippines.  
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Chapter 4 : IDENTIFICATION AND VALIDATION OF A NOVEL PANEL 
OF PLASMODIUM KNOWLESI SEROLOGICAL 
BIOMARKERS OF EXPOSURE, AND THEIR SUBSEQUENT 
USE IN THE MEASUREMENT OF EXPOSURE AND 
INFECTION IN MALAYSIA AND THE PHILIPPINES  
The work presented in this chapter is adapted and extended from Herman et. al. 
20181 (Appendix I) with additional contributions from Fornace et. al. 20182 (Appendix 
II), both with respective research paper cover sheets. 
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4.1. INTRODUCTION 
P. knowlesi has the potential to cause severe disease in endemic regions3, and is 
now the most common cause of clinical malaria in Malaysia4-6. Due to morphological 
similarities to P. malariae7,8, historical misdiagnoses of P. knowlesi infections as P. 
malariae9 have been found to be very common. As previously mentioned in Chapter 
1, misdiagnosis of P. knowlesi as P. vivax and P. falciparum10-12 is also fairly 
common, with potential delay of appropriate treatment associated with case 
fatalities3,13,14. 
Studies have shown that antibodies to some Plasmodium spp. proteins persist for 
long periods15-17, even in the context of limited exposure or absence of infection and 
have been shown to be correlated to malarial infection18-21. Such antibodies can be 
utilised in serological assays, accurately estimating both recent and historical18,21 
incidence and exposure to Plasmodium parasites22-26. 
Currently, the incidence of P. falciparum and P. vivax is reducing due to the progress 
in malaria elimination programmes in endemic areas27,28. However, P. knowlesi 
poses a challenge to the malaria elimination programme due to increased 
agricultural activities, deforestation and changes in the macaque population. An 
increase of P. knowlesi incidence has recently been acknowledged29 and very little is 
known about the true extent of P. knowlesi exposure, infection and geographical 
boundaries. Associations have been shown between increases in P. knowlesi 
incidence in villages and deforestation30, however, as this was only shown for clinical 
cases, this is not necessarily reflected in the broader population. Additionally, studies 
have identified numerous asymptomatic P. knowlesi infections, including individuals 
who will not definitely report to local health facilities31-33, making it difficult to 
determine if those associations can be applied to the broader community. 
It is famously difficult to detect malaria parasites in both infected humans31,34 and 
mosquitos35,36 in areas of low endemicity. A useful tool to detecting long lasting 
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antibody responses37 are serologic biomarkers of exposure. Serology is more 
attractive than other methods due to the cheaper and simpler laboratory procedures 
involved, allowing the processing and testing of more samples in less time, and its 
sturdiness in determining short-term fluctuations in transmission23,38. Different 
antigens elicit a range of antibody responses in individual hosts, showing different 
magnitudes and kinetics, which can give us a more detailed analysis of a 
population’s exposure. This said, it would be suggested that biomarkers for exposure 
should group several different specific antigens to analyse malarial infections. 
Epidemiology has long used serology as a way of measuring malaria incidence and 
disease exposure in endemic countries 39-41. Previous studies have shown that the 
prevalence of malaria can be determined using species-specific recombinant 
antigens as serosurveillance tools, determining the boundaries of infection as well as 
the progress of elimination interventions 23,38,42. 
These serological markers can detect antibodies against malaria parasites, 
determining exposure to current infections as well as previous infections43. allowing 
the identification of areas or groups within a community with higher transmission23 as 
well as lower transmission37, where detection of an infection is normally very low. 
There are several antigens currently in use as serological markers, such as MSP1-
19 (merozoite surface protein 1-19) and AMA1 (apical membrane antigen 1) for P. 
falciparum and P. vivax21,44-46, as described later. Previous infections can be 
reflected by the presence of certain antibodies in the system, which can determine 
the level of transmission in a certain region37. In a study led by Drakeley et. al.45, it 
was shown that altitude and rainfall were correlated with parasite prevalence. 
Recombinant proteins do exist for P. knowlesi, however of these, the amino acid 
identity between P. knowlesi and other Plasmodium spp. is high and therefore these 
are not applicable to identifying species-specific antibody responses.  
Previously known as PK66 due to its size (66kDa), PkAMA-1 is highly conserved 
amongst Plasmodium spp.47. AMA-1 is expressed in the micronemes of the 
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sporozoite (invasive pre-erythrocytic stage) and merozoite (invasive asexual blood 
stage) forms of the parasite48. 
In P. falciparum,  AMA-1 (previously PF83)49 is recognised after exposure to malarial 
infection48,50-52. Similarly, macaques that were immunized with PkAMA-1 developed 
antibodies inhibiting red blood cell (RBC) invasion by merozoites, demonstrating 
some degree of immunity towards being challenged50,53. The PfAMA1 antigen is 
routinely used as a serological tool in epidemiology studies alongside PvAMA138,39,54. 
The SPATR (secreted protein with altered thrombospondin type I repeat) domain 
was first identified in chromosome 2 of P. falciparum55, and it was suggested that, 
since it is on the surface of the sporozoite form56, it is involved in the parasite 
invasion of host cells, therefore a potential P. falciparum vaccine candidate57. It is 
one of the few identified P. falciparum protein antigens to be expressed during 
multiple stages of the parasite life cycle57, alongside AMA1 and several others 
(MAEBL etc)48. These multi-stage antigens are important in inducing protective 
immune responses to all parasite life stages. A gene encoding a novel P. knowlesi 
multistage secreted protein was characterised and named PkSPATR due to its 
homology to PfSPATR58 (61% amino acid identity). It was suggested by Mahajan et. 
al. that PkSPATR is involved in sporozoite invasion of liver cells as it was found to 
bind to a human hepatoma cell line58. PkAMA-1 and PkSPATR share 86% and 85% 
amino acid identity respectively with P. vivax (https://is.gd/MzISez), potentially 
making it difficult to distinguish between the two species where infections are co-
endemic. 
The 195kDa merozoite surface protein 1 (MSP-1), a major surface protein on the 
surface of the merozoite59,60, is a well described blood stage vaccine candidate61-64 
and serosurveillance tool52,54,60. The result of a series of proteolytic cleavage steps of 
this protein is MSP1-1965 which has been shown to be highly immunogenic, both in 
P. falciparum66 and P. vivax67, with antibodies targeting this region associated with 
protection52,54,60,68. 
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Although PkMSP1-19 is not an adequate antigenic candidate for P. knowlesi specific 
serosurveillance due to high amino acid identity with other Plasmodium spp. 
(appendix IV), it is still worth looking at P. knowlesi-unique sections of the PkMSP-1 
sequence. 
Sporozoite surface protein 2 (SSP2), also known as thrombospondin-related 
adhesion protein (TRAP), is expressed in the pre-erythrocytic stages of the parasite 
life cycle. This protein is located on micronemes and the sporozoite cell-surface of P. 
falciparum and contributes to cell invasion or hepatocyte recognition56,69-71. 
SSP2/TRAP is composed by a short cytoplasmic region (~40 amino acids) with an 
acidic carboxy-terminus and a single trans-membrane region69. It was found that P. 
falciparum TRAP contributes to immunity against sporozoites, inhibiting hepatocyte 
and HepG2 cell invasion by sporozoites56,70,72. SSP2/TRAP antibodies were 
produced by malaria exposed individuals showing age dependent differences and 
seasonal fluctuations72. Similarly, evidence for SSP2/TRAP suggested an 
immunogenic antigen involved in protection from disease in mice73. 
The serine repeat antigen (SERA) family had previously attracted attention as a 
source of both drug and vaccine candidates74. The SERA antigens are asexual 
antigens, members of the SERA multigene family 75 that are expressed during the 
trophozoite and schizont stages76,77. PfSERA5 is the most abundant parasitophorous 
vacuole protein and is essential to blood stage growth of the parasite 78-80, with 
antibodies against this antigen thought to inhibit parasite growth 81,82 and to induce 
protection against blood stage in vivo infection83. Although possessing a papain-like 
enzymatic domain, recent evidence suggests that the protein plays a non-enzymatic 
role80. PfSERA3 has also been shown to be a highly immunogenic antigen with an 
important, although not essential role in the erythrocytic cycle84 and has also been 
implicated as having a role in liver stage merozoite release in P. berghei85. PfSERA5 
was also shown to be a vaccine immunogen86, therefore a strong vaccine candidate 
(SE36)87,88. To date, the number of SERA genes is different in each species, but all 
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Plasmodium species seem to have at least one gene from the SERA group and they 
show gene synteny conservation of the family cluster 89-92. 
Pain et. al. 93 have recently sequenced the full genome of P. knowlesi (H strain, Pk1 
(A+) clone) by whole-genome shotgun sequencing and the genome coverage has 
been improved since 94, giving us the opportunity to further characterise this 
organism. 
The 2011 WHO consultation panel on the public health importance of P. knowlesi 
recommended the urgent development of P. knowlesi-specific diagnostic tools95. Key 
to achieving this goal would be the development of sensitive and accurate tools to 
help monitor the transmission of infection. In this chapter, we describe the 
development and evaluation of a panel of recombinant antigens based on P. 
knowlesi-specific amino acid sequences, using publically available in silico tools. 
This is the first such description of species-specific tools against P. knowlesi. We 
also measure the reactivity of one of these tools in a community sample set from 
Malaysian Borneo and The Philippines in order to determine the level of exposure to 
P. knowlesi in those regions. The development of such well-validated species-
specific tools represent a potentially important serosurveillance tool for the 
monitoring of historical and current P. knowlesi infections in endemic areas. These 
reagents will also serve as an important set of tools to help identify correlates of 
immunity to P. knowlesi.   
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4.2. METHODS 
4.2.1. IDENTIFICATION OF CANDIDATE SEQUENCES AND PRIMER DESIGN 
A panel of 18 genes were originally selected based on available evidence from 
existing literature on P. falciparum (MSP152,54,60, apical membrane antigen 1 
(AMA1)48,51,54, thrombospondin-related adhesion protein/sporozoite surface 2 
(TRAP/SSP2)56,96, serine repeat antigen (SERA)78,79,87-90), P. vivax (MSP154, AMA154, 
SERA89,90,97) and P. knowlesi antigens (MSP198-103, AMA-150,53,104-107, 
circumsporosoite protein (CSP)108,109, SERA89,90, hypothetical proteins93), together 
with in silico mining of existing P. knowlesi sequence data (www.plasmodb.org).  
Each candidate gene was further screened against other Plasmodium spp. 
corresponding to P. knowlesi AMA-1, MSP1, SERA3, secreted protein with altered 
thrombospondin type I repeat (SPATR) and TRAP/SSP2 candidate, as well as P. 
knowlesi hypothetical proteins (HP) (Table 4.1) in order to identify P. knowlesi-
specific regions that would form the basis of each construct. From the original panel, 
10 antigens were successfully cloned and expressed. Gene accession codes are 
found in Table 4.2. Full-length protein sequences for each gene were initially 
screened using a number of packages in the DNASTAR Lasergene software suite 
(DNASTAR), NCBI protein BLAST (Basic Local Alignment Search Tool) 
(https://is.gd/MzISez) and PlasmoDB (https://is.gd/XOs7vd110), identifying any 
regions of shared identity between the human infecting Plasmodium spp. Sequence 
alignments at the amino-acid level were generated for each gene target using 
Multiple Sequence Comparison by Log-Expectation (MUSCLE) 
(http://www.ebi.ac.uk/Tools/msa/muscle/)111. Any full-length sequences and 
sequence regions with a high level of shared identity with other human Plasmodium 
spp. were excluded from further analysis and the selected P. knowlesi-specific 
truncated regions were screened again in the same manner to ensure specificity 
(Table 4.1).
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Table 4.1 Gene and candidate homology between P. knowlesi and other Plasmodium spp.  For the PlasmoDB BLASTa analysis, values are shown as amino acid identities between the P. 
knowlesi candidates and other Plasmodium spp. followed by the respective percentage. For the NCBI BLASTp analysis the sequence coverage is shown as a percentage, followed by the amino 
acid identities, also shown as a percentage. 
P. knowlesi gene 
candidate 
Protein 
length 
Homology (%) 
P. vivax P. falciparum P. malariae P. ovale 
PlasmoDB NCBI PlasmoDB NCBI PlasmoDB NCBI PlasmoDB NCBI 
Identities (%) 
query 
cover 
Ident Identities (%) 
query 
cover 
Ident Identities (%) 
query 
cover 
Ident Identities (%) 
query 
cover 
Ident 
AMA-1 563 480/563 (85%) 100 86 307/525 (58%) 92 59 388/564 (69%) 100 69 410/565 (73%) 100 73 
MSP1 1821 1167/1861(63%) 98 63 428/1081(40%) 99 45 444/974 (46%) 52 46 860/1888(46%) 99 46 
- MSP1-19 92 71/86 (83%) 96 83 47/94 (50%) 96 50 50/89 (56%) 100 57 50/89 (56%) 95 56 
- MSP1 ag2 88 - - - - - - - - - - - - 
SERA3 1079 623/1080 (58%) 100 58 400/989 (40%) 96 39 428/877(49%) 98 47 348/760 (46%) 89 47 
- SERA3 ag1 116 23/58 (40%) - - 16/70 (23%) 48 30 32/115 (28%) 55 25 27/104 (26%) 24 39 
- SERA3 ag2 173 42/173 (24%) - - 21/73 (29%) - - 19/101 (19%) - - 26/100 (26%) - - 
TRAP/SSP2 580 399/581 (69%) 100 69 243/593 (41%) 100 40 287/636 (45%) 100 45 281/587 (48%) 100 50 
- SSP2 frag 120 40/93 (43%) 77 45 - 47 49 - - - 37/118 (31%) 85 31 
TSERA2 526 185/277 (67%) 100 62 144/433 (33%) 99 34 93/231 (40%) 85 40 94/218 (43%) 100 38 
- TSERA2 ag1 191 108/178 (61%) - - 51/106 (48%) 52 48 57/172 (33%) 89 36 47/113 (42%) 51 43 
- TSERA2 ag2 46 35/44 (80%) 95 80 19/44 (43%) 95 43 16/44 (36%) 95 36 18/44 (41%) 95 39 
PKH_021580 208 - - - 15/33 (45%) - - - - - 21/63 (33%) - - 
- PKH_021580 frag 155 19/52 (37%) - - 15/33 (45%) - - - - - 21/63 (33%) - - 
PKH_031930 212 16/40 (40%) - - 14/33 (42%) - - 28/98 (29%) - - 18/51 (35%) - - 
- PKH_031930 ag1 93 - 65 23 19/56 (34%) - - - - - - - - 
- PKH_031930 ag2 112 16/40 (40%) 39 34 14/33 (42%) - - 17/41 (41%) - - 12/32 (38%) - - 
PKH_080030 406 98/247 (40%) 55 41 - - - - - - 48/160 (30%) 53 23 
- PKH_080030 frag 269 56/130 (43%) 44 43 - - - 23/68 (34%) - - 30/81 (37%) - - 
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P. knowlesi gene 
candidate 
Protein 
length 
Homology (%) 
P. simiovale P. coatneyi P. cynomolgi P. inui 
PlasmoDB NCBI PlasmoDB NCBI PlasmoDB NCBI PlasmoDB NCBI 
Identities (%) 
query 
cover 
Ident Identities (%) 
query 
cover 
Ident Identities (%) 
query 
cover 
Ident Identities (%) 
query 
cover 
Ident 
AMA-1 563 - 99 85 492/563 (87%) 100 88 481/563 (85%) 100 86 441/563 (78%) 100 78 
MSP1 1821 - 98 67 1265/1905 (66%) 98 67 517/695 (74%) 98 69 469/710 (66%) 53 59 
- MSP1-19 92 - 95 76 70/89 (79%) 95 79 72/89 (81%) 96 82 65/87 (75%) 96 77 
- MSP1 ag2 88 - - - - - - 15/28 (54%) - - - - - 
SERA3 1079 - 89 66 628/867 (72%) 100 72 668/1080 (62%) 100 62 437/1078 (41%) 100 60 
- SERA3 ag1 116 - - - 43/91 (47%) 77 47 30/110 (27%) 50 35 23/75 (31%) - - 
- SERA3 ag2 173 - - - 30/158 (19%) - - 21/51 (41%) - - 20/73 (27%) - - 
TRAP/SSP2 580 - - - 452/582 (78%) 100 79 437/582 (75%) 100 75 340/629 (54%) 100 54 
- SSP2 frag 120 - - - 52/88 (59%) 96 61  62/111 (56%) 95 57 34/69 (49%) 57 49 
TSERA2 526 - 81 41 343/517 (66%) 100 67 217/364 (60%) 100 60 104/288 (36%) 95 36 
- TSERA2 ag1 191 - 83 64 126/191 (66%) 99 66 115/173 (66%) 89 66 61/191 (32%) 92 32 
- TSERA2 ag2 46 - 95 89 37/44 (84%) 95 84 36/44 (82%) 95 82 18/44 (41%) 95 41 
PKH_021580 208 - - - - - - - - - - - - 
- PKH_021580 frag 155  -  - -  - - - -  - - 16/35 (46%) - - 
PKH_031930 212 - - - 24/77 (31%) - - 28/129 (22%) - - 22/81 (27%) - - 
- PKH_031930 ag1 93 - - - - - - 15/62 (24%) - - - - - 
- PKH_031930 ag2 112 - - - 21/93 (23%) - - - - - 15/30 (50%) - - 
PKH_080030 406 - - - 139/278 (50%) 68 50 92/233 (39%) - - - - - 
- PKH_080030 frag 269 - - - 74/137 (54%) 50 54 47/125 (38%) - - - - - 
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Table 4.2 Plasmodium spp. PlasmoDB accession codes for candidate genes. 
Species MSP1 AMA1 SERA TSERA2 SSP2/TRAP 
P. knowlesi PKNH_0728900 PKNH_0931500 PKNH_0413400 PKNH_0413500 PKNH_1265400 
P. vivax PVX_099980 PVX_092275 PVX_003810  PVX_003805 PVX_082735 
P. falciparum PF3D7_0930300 PF3D7_1133400 PF3D7_0207600 PF3D7_0207800 PF3D7_1335900 
P. malariae PmUG01_07042000 PmUG01_09042600 PmUG01_04024800 PmUG01_04024900 PmUG01_12028900 
P. ovale curtisi PocGH01_07037900 PocGH01_09039800 PocGH01_04022100 Pocgh01_04022100 PocGH01_12027200 
P. coatneyi PCOAH_00016080 PCOAH_00026700 PCOAH_00008610 PCOAH_00008610 PCOAH_00042390 
P. cynomolgi PCYB_073770 PCYB_093930 PCYB_042270  PCYB_042280 PCYB_122680  
P. inui C922_01162 C922_02330 C922_02820 C922_02816 C922_01849  
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At this time, the constructs were screened for the presence or absence of signal 
peptides (SP) and any transmembrane (TM) domains using the TMHMM server 
(http://www.cbs.dtu.dk/services/TMHMM/) and designed to exclude these features 
which, in addition to the Glutathione Sepharose Transferase (GST) solubility tag, aid 
in the expression of soluble proteins 112,113. It has been previously shown by Vedadi 
et. al.114, and from previous experience from our group, that protein expression and 
solubility can be hindered by the presence of SP and TM domains. The target genes 
were further analysed using domain prediction software to determine putative 
domain boundaries (http://gene3d.biochem.ucl.ac.uk/ and http://smart.embl-
heidelberg.de/). These screening steps were necessary to ensure P. knowlesi-
specificity in order to limit potential antibody cross-reactivity in regions co-endemic 
with other Plasmodium spp., as this would reduce the usefulness of these reagents 
as serosurveillance tools. Following this selection criteria, 10 P. knowlesi-specific 
constructs (Table 4.3) were designed for insertion into the pGEX-2T GST-tagged 
expression vector (GE Healthcare Life Sciences), a vector designed to facilitate the 
expression of soluble protein. Each sequence was checked for the presence of 
BamHI, EcoRI and SmaI restriction sites on DNASTAR to ensure their absence and 
prevent conflict with the vector specific restriction sites. Using the same software, 
predicted antigenic residues were targeted based on the Jameson-Wolf antigenicity 
index (Protean 4.0, DNAStar), to help predict full or partial sequences within the 
candidates with a high antigenicity index, although it was not used as a selection 
criteria. 
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Table 4.3 Summary of P. knowlesi-specific recombinant antigen construct characteristics. Predicted sizes are indicated both with and without the GST tags. Values in parenthesis indicate the 
empirical sizes of protein aggregates. 
Gene ID Antigen Description Chromosome AA position 
Expression 
(mg/L)   
Size (kDa) 
Predicted  Empirical 
PKNH_0728900 MSP1 ag2 merozoite surface protein 1 7 974 - 1061 16.32 
w/ GST 34.8 
44.7 
(106.6) 
w/o GST  8.3 n/a 
PKNH_0413400 SERA3 ag1 
cysteine protease (Serine 
repeat-like antigen) 
4 25-140 20.5 
w/ GST 37.7 
49.6 
(118.9) 
w/o GST 11.3 n/a 
PKNH_0413400 SERA3 ag2 
cysteine protease (Serine 
repeat-like antigen) 
4 826-998 15 
w/ GST 44.9 
68.7 
(162.7) 
w/o GST 18.4 n/a 
PKNH_1265400 SSP2 
sporozoite surface protein 
2, putative, 
thrombospondin-related 
anonymous protein (TRAP) 
12 381-500 17 
w/ GST 39.7 
53.1 
(132.5) 
w/o GST 13.2 n/a 
PKNH_0413500 TSERA2 ag1 Truncated cysteine protease 4 60-251 11.9 
w/ GST 46.8 
59.7 
(117.9) 
w/o GST 20.4 n/a 
PKNH_0413500 TSERA2 ag2 Truncated cysteine protease 4 324-369 1.8 
w/ GST 31.7  38.3  
w/o GST 5.2 n/a 
PKNH_0216300 PKH_021580 HP 2 54-208 9.1 
w/ GST  44.3 38.2  
w/o GST  17.9 n/a 
PKNH_0321300 PKH_031930_ag1 HP 3 8 - 100 6.3 
w/ GST  36.1 25.2  
w/o GST  9.6 n/a 
PKNH_0321300 PKH_031930_ag2 HP 3 101-212 5.7 
w/ GST  39.1  27.2 
w/o GST  12.6 n/a 
PKNH_0800300 PKH_080030 HP 8 24-292 35.7 
w/ GST  57.6 25  
w/o GST  31.1 n/a 
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4.2.2. DETERMINATION OF TRANSCRIPTIONAL STATUS OF P. KNOWLESI CANDIDATE 
GENES 
RNA was prepared and provided by Dr. Rob Moon (PMB, LSHTM). Briefly, blood 
stage messenger RNA (mRNA) was isolated from culture adapted P. knowlesi 
parasites, A1-H1 strain115 to determine the transcriptional status of each of the 
selected candidate genes. Based on previously described protocols115, parasites 
were cultured in modified RPMI medium (Roswell Park Memorial Institute; Life 
Technologies) at 2% haematocrit, asynchronous parasite cultures (at approximately 
5% parasitemia) were centrifuged and 10 volumes of Trizol Reagent (ThermoFisher 
Scientific) were added per 1 volume of parasite pellet. The modifications to the RPMI 
medium were: 2.3 g/L sodium bicarbonate, 4 g/L dextrose, 5.95 g/L Hepes, 0.05 g/L 
hypoxanthine, 5 g/L AlbuMAX II (Thermo Fisher Scientific), 0.025 g/L gentamycin 
sulfate, 0.292 g/L L-glutamine, and 10% serum. For routine parasite culture 10% 
(vol/vol) equine serum (Life Technologies) was used. RNA was purified from the 
sample as per the Trizol Reagent manufacturer’s instructions and the resultant 
pellets were resuspended in DEPC (diethylpyrocarbonate) treated water. Briefly, 75 
µl of dH2O, 10 µl of RDD buffer and 15 µl of DNAse (Qiagen) were added to the 
RNA pellet, incubated at RT for 15 minutes the purified over RNA easy mini column 
(Qiagen) as per manufacturer’s instructions. RNA quality and quantity was measured 
on a DNA gel and nanodrop (NanoDrop® Spectrophotometer ND-1000; 
ThermoFisher Scientific). Genomic DNA was removed from the purified RNA 
preparation using the Turbo DNase free kit (ThermoFischer Scientific). Briefly, in a 
50 µl reaction, 10 µg of purified RNA was added to 5 µl buffer and 1 µl Turbo DNase, 
then incubated at 37°C for 30 minutes in a thermos cycler (Thermomixer C, 
Eppendorf). After the incubation, 5 µl of DNase inactivation reagent, as described in 
the kit specifications, was added to the 50 µl reaction and incubated at room 
temperature (RT) for 5 minutes. The sample was briefly centrifuged (10.000 x g for 
DEVELOPMENT OF PK SPECIES SPECIFIC REAGENTS TO CHARACTERISE ANTIBODY ISOTYPE PROFILES | LOU HERMAN 
 
54 | P a g e  
 
1.5 minutes) and the supernatant containing the purified and genomic DNA free RNA 
was removed to a fresh tube. Dr. Rob Moon performed the assay up to this point. 
The SuperScript® IV Reverse Transcriptase (RT) kit (Thermo Fisher Scientific) with 
oligo d(T)20 primers (RT+) was used for the first strand synthesis as per 
manufacturer’s instructions, using 2 µg of the previously prepared total RNA in a 40 
µl reaction. An identical reaction was set up as a negative control (RT-) where the 
SuperScript® IV RT was not added. For PCR analysis of the generated cDNA 
transcripts, RT+ and RT- samples (diluted at 1:10 in nuclease free H2O), alongside 
genomic DNA controls, were used as templates for transcript specific PCR primers 
for each of the candidate gene sequences (Table 4.4). PkCTRP (circumsporozoite 
protein and thrombospondin-related adhesive protein [TRAP]-related protein) and 
PkCSP (circumsporozoite protein), both previously confirmed to be pre-erythrocytic 
stage targets, were included in the panel as negative controls. Target specific primer 
pairs designed to flank introns where possible were used to distinguish amplicons 
from cDNA and gDNA template (Table 4.4). PCRs were carried out using GoTaq 
Green Master Mix (Promega) using the RTPCR program conditions listed in Table 
4.5 on a thermos cycler. The amplified products were run on a 1.2% agarose gel.
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Table 4.4 P. knowlesi gene name and ID, primer sequences, primer length, fragment size with and without intron for transcriptional analysis. 
Gene Oligo name Sequence: (5' to 3') length 
(bp) 
Size with 
intron (bp) 
Size without 
intron (bp) 
MSP1 PKH072850R1 CCAGTGGACTACACCACGTC 20 463 - 
MSP1 PKH072850F1 CCGAACAGGGGTAGAGTGAT 20   
SERA3 PKH041230F1 GCTCCAAGGGGAAAACATTA 20 401 250 
SERA3 PKH041230R1 GCAAGTTTGTATTCGCCAGA 20   
SSP2 PKH121770F1 GGAAACCCATTCGAAGAAAA 20 419 - 
SSP2 PKH121770R1 TTTCTGTGTGGTTTGGGGTA 20   
TSERA2 PKH041240F1 TGTGCAAGTACACAGCACGA 20 468 264 
TSERA2 PKH041240R1 GTCGTATATTGGGGCTTCCT 20   
PKH_021580 PKH021580F1 AATGGTACGTTCGCACATTTT 21 401 277 
PKH_021580 PKH021580R1 CATGTTGGAAGGTATCGTTTG 21   
PKH_031930 PKH031930F1 TGTCAGCAAATGACAGCAAA 20 476 239 
PKH_031930 PKH031930R1 TCACCCGGCTTATAGCCTAC 20   
PKH_080030 PKH080030F1 ATCTCTTAGGAAACTTCCTCTATTCA 20 401 226 
PKH_080030 PKH080030R1 GGAGCGCATTAATTTGTCCT 20   
CTRP PKCTRPF1 TCCTCACGAGAACAATGCAG 20 436 - 
CTRP PKCTRPR1 TCACTGTCGCTTCCACTGTC 20   
CSP PKCSPF1 GAAACAACCGAATGAAGGACA 21 467 - 
CSP PKCSPR1 CGTTTCTTCCTTGTCGTGGT 20   
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Table 4.5 PCR programs and conditions. 
*Elongation time varies according to fragment length. Program U75 is used for PCR products up to 
0.75kb. Program O75 is used for PCR products from 0.75kb. 
Program 
name 
PCR step 
Temperature 
(°C) 
Duration Cycles 
U75* 
Initial denaturation 94 2min x1 
Denaturation 94 15s   
Annealing 45 to 65 30s x15 
Elongation 72 45s   
Denaturation 94 15s   
Annealing 45 to 65 30s x30 
Elongation 72 45s   
Final elongation 72 7min x1 
          
O75* 
Initial denaturation 94 2min x1 
Denaturation 94 15s   
Annealing 45 to 65 30s x15 
Elongation 72 1min   
Denaturation 94 15s   
Annealing 45 to 65 30s x30 
Elongation 72 1min   
Final elongation 72 7min x1 
          
RTPCR 
Initial denaturation 95 2min x1 
Denaturation 95 30s 
x25 
Annealing 52 30s 
Elongation 68 60s 
Final elongation 68 2min 
Hold 10 10min x1 
          
PCR55 
Initial denaturation 94 2min x1 
Denaturation 94 15s   
Annealing 55 30s x35 
Elongation 65 2min   
Final elongation 65 7min x1 
          
BigDye 
Initial denaturation 96 1min x1 
Denaturation 96 30s   
Annealing 50 15s x25 
Elongation 60 4min   
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4.2.3. CLONING STRATEGIES FOR P. KNOWLESI-SPECIFIC RECOMBINANT ANTIGENS 
Optimal PCR amplification conditions were determined using a gradient PCR 
approach. Essentially, primer pairs for each potential amplicon were prepared in a 
reaction mix pool with P. knowlesi genomic DNA at 70 ng/ml and aliquoted at 5 µl 
per well over 12 wells in PCR strip tubes. Assay parameters for the gradient reaction 
were programmed into the thermocycler (Table 4.6), with the annealing temperature 
adjusted to run between 45-65°C over the 12 wells under the appropriate 
programme for the amplicon size (Program U75 used for PCR products up to 0.75kb 
and program O75 for PCR products from 0.75kb; Table 4.5). The amplicons from 
each of the 12 wells were then analysed on a 1% agarose gel with ethidium bromide 
(3 µl per 100ml) (Figure 4.1). The optimal conditions were identified as those that 
yielded the highest concentration of amplicon with no contaminating, or incorrectly 
sized bands. Alternatively, optimal conditions were met if the correct size amplicon is 
achieved with clear separation between the amplicon and any contaminating, or 
incorrectly sized bands. Following PCR amplification optimisation using the gradient 
function (G-Storm Thermal Cycler), templates for each construct were PCR amplified 
from P. knowlesi (H strain) genomic DNA using high fidelity taq (Expand High 
Fidelity PCR system, Roche Applied Science) (PCR conditions U75 and O75 Table 
4.5). Vector compatible primers were designed for each completed target sequence 
(Table 4.7). Each resultant product was gel electrophoresed on a 1% agarose gel. 
Amplicons were purified using a PCR purification kit (Qiagen, UK). If incorrectly 
sized bands were evident, then amplicons were purified using a gel extraction and 
purification kit (QIAquick Gel extraction kit, Qiagen, UK) and quantified (NanoDrop® 
Spectrophotometer ND-1000; ThermoFisher) prior to cloning. Briefly, to quantify the 
DNA, 2 µl of H2O was used to calibrate and blank the machine before adding 2 µl of 
the DNA product to be quantified. 
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Table 4.6 Gradient PCR temperatures and gel positions for PCR programmes U75 (products <0.75 kb) and O75 
(products >0.75 kb). 
Position Temperature (°C) 
1 45.2 
2 45.7 
3 46.8 
4 48.7 
5 50.9 
6 53.6 
7 56.1 
8 58.9 
9 61.8 
10 63.7 
11 64.7 
12 65.4 
 
Figure 4.1 Example of a gradient PCR. Each candidate was run at 12 different temperatures in order to find the 
optimal PCR conditions. Top panel first set of 1-12 lanes are PkMSP1 antigen 1, second set of 1-12 lanes (lanes 
11 and 12 are on the bottom panel) are PkMSP1 antigen 2, bottom panel first set of 1-12 lanes are PkSERA3 
antigen 1 and second set of 1-8 are PkSERA3 antigen 2. Circles indicate temperatures chosen for that candidate. 
Failed candidates had to be rerun. Agarose gel at 1%.
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Table 4.7 P. knowlesi candidate name, primer sequences and primer length. The vector portion of each primer sequence (pGEX-2T) including restriction sites are highlighted in bold and the 
candidate portion of the sequence in italics. Stop codons are underlined.  
Antigen Oligo name Sequence : (5' to 3') Length 
MSP1 ag2 PKH072850_2_F1 GTTCCGCGTGGATCCTCGGTGACCCCTGCTGTAGTA 36 
MSP1 ag2 PKH072850_2_R1 GTCACGATGAATTCCTTAAGCTTGCACGGTTACGCCTCC 39 
SERA3 ag1 PKH041230_1_F1 GTTCCGCGTGGATCCGAGGGAACGGCGCAATCTGGA 36 
SERA3 ag1 PKH041230_1_R1 GTCACGATGAATTCCTTAAGCTTTCTGGGGGGCGACTTG 39 
SERA3 ag2 PKH041230_2_F1 GTTCCGCGTGGATCCAACACTGTTGAGGGTCAAGAC 36 
SERA3 ag2 PKH041230_2_R1 GTCACGATGAATTCCTTAGACCATTTTTGCCTTTTGCAA 39 
SSP2 PKH121770F1 CCAAAATCGGATCTGGTTCCGCGTGGATCCGCGGCACAGTACCCAGAAAAT 51 
SSP2 PKH121770R1 GCAGATCGTCAGTCAGTCACGATGAATTCCTTACTCCTCAGATGAGAAGGGACC 54 
TSERA2 ag1 PKH041240F1 GTTCCGCGTGGATCCCGATGCACGGATACTGCTATA 36 
TSERA2 ag1 PKH041240R1 ATGAATTCCCGGGGATCATGGGGTTGGTGTCTGATCTTC 39 
TSERA2 ag2 PKH041240F2 GTTCCGCGTGGATCCAGCAATGTGGAAATGAAAAAG 36 
TSERA2 ag2 PKH041240R2 ATGAATTCCCGGGGATCAAGGCATGTCGTTACTTAAGGC 39 
PKH_021580 PKH021580F1_V2 GTTCCGCGTGGATCCGAGTTACCACTCTCTCCAGACCT 38 
PKH_021580 PKH021580R1 ATGAATTCCCGGGGATCATTTAAATGAAGATTTCTG 36 
PKH_031930 ag1 PKH031930F1 GTTCCGCGTGGATCCATATATCTATTCCTCCTGCTA 36 
PKH_031930 ag1 PKH031930R1 ATGAATTCCCGGGGATCACAATCTACAGAAATATTGGAA 39 
PKH_031930 ag2 PKH031930F2 GTTCCGCGTGGATCCTGGTGCTATAGTTGTTGTACT 36 
PKH_031930 ag2 PKH031930R2 ATGAATTCCCGGGGATCATCGTTTGCTCTTCCCCTTGAG 39 
PKH_080030 PKH080030F1_V2 CGTGGATCCCCGGGGTAATTACACTTGGTACACTA 35 
PKH_080030 PKH080030R1 GTCACGATGAATTCCTTAATTTACTTTTCTAATTGGATA 39 
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To maximise the cloning success rate several cloning strategies were employed the 
Sequence and Ligation Independent Cloning strategy (SLIC)116, the Gibson cloning 
method117 and conventional ligation dependant cloning (as per manufacturer’s 
instructions) with and without using a shuttle vector (Promega pGEM-T easy).  
4.2.3.1. SEQUENCE AND LIGATION INDEPENDENT CLONING (SLIC) 
SLIC was performed as previously demonstrated by Mamie et. al.116 with minor 
alterations. The single-tube reaction mix contained 100 ng of cut pGEX-2T GST 
tagged expression vector (GE Healthcare Life Sciences) (4.9kb), 3 fold molar excess 
of insert, 1 µl NEB buffer 2, 1 µl 10x BSA, 1 µl of 0.75/µl T4 DNA polymerase and 
nuclease free H2O to adjust volume up to 10 µl. Reaction mix was incubated at RT 
for 5 minutes, 1 µl of 10 mM dGTP was added to stop the reaction and placed on ice 
for 1 minute. The reaction was placed on a heating block for 2 minutes at 500C and 
left to slowly cool down at RT before being placed on ice and transformed into 
competent Escherichia coli JM109 or DH5α cells as described below. 
4.2.3.2. GIBSON CLONING METHOD 
The Gibson method was performed as previously described 117. The reaction mix 
contained 100 ng of cut pGEX-2T vector, Gibson Assembly master mix (5x ISO 
buffer, 10 U/µl T5 exonuclease, 2 U/µl Phusion polymerase, 40 U/µl Taq ligase and 
distilled water (d H2O), all to be stored at -200C) and insert at a 1:1 ratio (1/3 dilution 
of stock was necessary to enable working volumes). The assembly reaction was 
incubated at 500C for 1 hour, placed on ice to cool down and 5 µl of the mix was 
transformed into 100 µl of competent E. coli JM109 or DH5α cells as described 
below. 
4.2.3.3. CONVENTIONAL CLONING 
Conventional cloning, or restriction site mediated cloning, was performed as per 
manufacturer’s instructions. Briefly, each insert was subjected to a restriction digest 
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reaction based on the specific restriction sites employed using High-Fidelity 
restriction enzymes where appropriate for each candidate (New England Biolabs 
(NEB) BamH1-HF® and EcoR1-HF®). Simultaneously, aliquots of the GST tagged 
pGEX-2T expression vector was also digested with the appropriate combinations of 
restriction enzymes. Following incubation at 370C for 1 hour, the digested inserts 
and vector were gel purified, analysed on a 1% agarose gel and quantified using the 
NanoDrop® spectrophotometer ND-1000 (ThermoFisher Scientific). To concentrate 
the amounts of digested inserts and vectors each sample was sodium acetate 
precipitated at -200C overnight (o/n), washed in 70% ethanol and resuspended in TE 
buffer (1/5 original volume). The purified vector digestions and inserts were ligated at 
a 3:1 vector to insert ratio using T4 ligase and incubated o/n at 40C then transformed 
into competent E. coli JM109 or DH5α cells as described below. The shuttle vector 
method was performed as described previously118 and as per manufacturer’s 
specifications with minor modifications. Briefly, the purified inserts and linearized TA 
vector (pGEM-T Easy, Promega) were ligated at a 3:1 insert to vector ratio based on 
25 ng of TA vector, using T4 DNA ligase and incubated o/n at 40C. The samples 
were purified then transformed into competent E.coli JM109 or DH5α cells as 
described below and positive colonies were picked to be sequence verified. Correct 
sequences were restriction digested with the candidate appropriate restriction 
enzyme, sub-cloned into the GST tagged expression vector as described above and 
transformed into competent E. coli JM109 or DH5α cells as described below. 
4.2.3.4. TRANSFORMATION OF E. COLI COMPETENT CELLS 
For transformations using competent E. coli JM109 cells (preparation of Mix & Go! 
Competent Cells Zymo Research), 5 µl of each purified plasmid DNA mix was added 
to 50 or 100 µl of cells and was incubated on ice for 5-10 min  before being plated 
onto Luria Bertani (LB)/ampicillin (amp)/ X-Gal (5-Bromo-4-Chloro-3-Indolyl β-D-
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Galactopyranoside)/IPTG (Isopropyl β-D-1-thiogalactopyranoside) Agar plates that 
were left o/n to grow at 370C. 
For transformations using chemically competent E. coli DH5α cells (Invitrogen, 
ThermoFisher Scientific) reactions were performed as per manufacturer’s 
instructions. Briefly, 1-5 µl of each purified plasmid were aliquoted into 50 l of 
thawed DH5α cells and incubated on ice for 30 minutes before being heat-shocked 
at 42C for 20 seconds and immediately placed on ice for 2 minutes. The samples 
were then added to 950 l of sterile SOC medium (Super Optimal Broth) pre-
warmed at 37C, mixed and incubated at 37C in a shaking incubator at ~200 rpm 
for 1 hour in order to resuscitate cells. After incubation, 100 µl of each sample was 
plated onto LB/amp/ X-Gal/IPTG agar and incubated o/n at 37C. Transformation 
controls were performed using pUC19 plasmid DNA provided by the kits. 
4.2.3.5. SCREENING FOR POSITIVE TRANSFORMANTS AND PURIFICATION 
Positive transformants were identified by colony PCR of blue/white screened 
colonies (white colonies were indicative of insertion into the vector but colony PCRs 
were run for further reassurance) using pGEX-2T or pGEM-T Easy vector specific 
primers (Sigma-Genosys, based on sequence in the GE Healthcare pGEX-2T GST 
expression vector product specification sheet: pGEX5’ transcription start 5’ 
GGGCTGGCAAGCCACGTTTGGTG 3', pGEX3’ transcription start 5’ 
CCGGGAGCTGCATGTGTCAGAGG 3’; Promega, based on sequence on Promega 
pGEM-T Easy technical manual: T7 transcription start 5’ GGGCGAATTGGGCCC 
GACGTCGCATGCTCCCGGCCGCCATGGCGGCCGCGGGAATTCGATT 3’, SP6 
transcription start 5’ ATCACTAGTGAATTCGCGGCCGCCTGCAGGTCGACCATAT 
GGGAGAGCTCCCAACGCGTTGGATGCATAGCTTGAGTAT TC 3’). Briefly, 10 µl 
of a PCR reaction mix (5 µl Biomix Red, 0.25 µl of each vector specific primers and 
4.5 µl of milli-Q H2O) together with a sample from each colony was PCR amplified 
using the PCR55 amplification conditions listed in Table 4.5.  Following completion of 
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the run, the PCR products were analysed on a 1% agarose gel. Colonies with 
positive inserts were used to seed ~5 ml of LB-amp media and incubated o/n at 370C 
in a shaking incubator (New Brunswick Scientific Innova™ 4330 Refrigerated 
Incubator Shaker). An aliquot of the overnight culture was used to make an interim 
glycerol stock (850 µl o/n culture plus 150 µl sterile glycerol) to be stored at -800C. 
The cloned plasmids from the o/n samples were then purified (QIAprep Miniprep kit, 
Qiagen) from each positive transformant, analysed on a 1% agarose gel and 
quantified by NanoDrop® Spectrophotometer ND-1000 (ThermoFisher).  
4.2.3.6. SANGER SEQUENCING-BASED VALIDATION OF CONSTRUCTS 
Each construct was sequence validated using Big Dye Terminator cycle sequencing 
chemistry (Applied Biosystems, UK) and electrophoresed on an ABi 3730x capillary 
sequencer (Applied Biosystems, UK) to ensure fidelity. Briefly, sequencing templates 
were prepared using a standard reaction mix (0.5 µl BIGDYE, 1.75 µl buffer, 3.2 µl 
pGEX5’, pGEX3’, T7 or SP6 primers, 200-500 ng template DNA and dH2O to a final 
volume of 10 µl) and amplified on a Thermal Cycler using the BigDye program 
shown in Table 4.5. A BIGDYE precipitation was performed on all samples (3 µl 3 M 
sodium acetate, 62.5 µl 95% ethanol and 24.5 µl dH2O for a final volume of 90 µl per 
well) as per product specification. The results were analysed using the EditSeq 
4.00© software (DNASTAR Lasergene, 1989-1999) or CLC Sequence Viewer 7.7. 
4.2.4. PROTEIN EXPRESSION AND PURIFICATION 
Sequence validated clones were transformed into BL21(DE3) chemically competent 
cells (TransGen Biotech) and expressed in autoinduction media (AIM) based on 
established protocols 119,120 and manufacturer’s instructions. Briefly, as performed on 
the DH5α cells, 1-5 µl of each purified plasmid were aliquoted into 50 l of thawed 
BL21(DE3) cells and incubated on ice for 30 minutes before being heat-shocked at 
42C for 45 seconds and immediately placed on ice for 2 minutes. The samples 
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were then added to 500 l of sterile SOC medium (Super Optimal Broth) pre-
warmed at 37C, mixed and incubated at 37C in a shaking incubator at ~200 rpm 
for 1 hour in order to resuscitate cells. After incubation, 100 l of each sample was 
plated onto LB/amp/ X-Gal/IPTG agar and incubated o/n at 37C. Transformation 
controls were performed using pUC19 plasmid DNA provided by the kits. 
Transformed BL21(DE3) were used to prepare long term Microbank™ storage vials 
as per manufacturer’s instructions (Pro-Lab Diagnostics). All successful E. coli 
BL21(DE3) clones were made into glycerol stocks as previously described (section 
4.2.3.5 above, screening of positive transformants) and stored at -800C. Each 
candidate transformed cells were expressed in approximately 200 – 300 ml auto 
induction media (AIM)119,120 (Table 4.8). Samples were left o/n in a shaking incubator 
at 370C. 
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Table 4.8 Autoinduction media reagents, amounts and concentrations to make 1 L of growth media. 
Reagent Amount Concentration         
   Chemical reagent Amount Concentration Notes 
ZY 928 ml - 
N-Z-amine AS 10 g -  
yeast extract 5 g -  
H2O 925 ml -  
MgSO4 1 ml  1M - - -  
5052 20 ml 50x 
0.5% glycerol 250 g -  
H2O 1 L -  
0.5% glucose 25 g -  
0.2% α-lactose 100 g -  
NPS 50 ml 20x 
H2O 900 ml -  
(NH4)2SO4 66 g  0.5 M  
KH2PO4 136 g 1 M  
Na2HPO4 142 g 1 M  
Trace metals 
mixture          
(all stocks 
prepared in 
50 mM HCl) 
1 ml 1000x 
H2O 36 ml -  
FeCL3.6H2O 50 ml 0.1 M 
dissolved 
in 0.1 M 
HCl 
Cacl2 2 ml 1 M  
MnCl2.4H2O 1 ml 1 M  
ZnSO4.7H2O 1 ml 1 M  
CoCl2.2H2O 1 ml 0.2 M  
CuCl2.2H2O 2 ml 0.1 M  
NiCl2.6H2O 1 ml 0.2 M  
Na2MoO4.2H2O 2 ml 0.1 M  
Na2SeO3.5H2O 2 ml 0.1 M  
H3BO3 2 ml 0.1 M  
ampicillin 1 ml 50 mg/ml -   -   
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Following expression, the E. coli were harvested following centrifugations (6000 x g 
for 10 min on an F10BCI-6x500y or JA-20 rotor (Avanti® JE Centrifuge, Beckman 
Coulter) using 500 ml (Beckman Coulter, USA) or 32 ml (Nalgene, UK) vials, 
respectively), resuspended in 1x Phosphate Buffered Saline (PBS) with 1/10 
concentration of protease inhibitors (COmpleteTM Ultra Protease inhibitor cocktail, 
Roche) and lysed using a cell disrupter (Stansted, UK) and processed using 
standard protocols (GE Healthcare). Expressed proteins to be used on the 
cytometric bead assay or protein microarray were not treated with protease inhibitors 
or it was removed by dialysis in order to avoid any potential interference. The lysates 
were centrifuged at 10,000 rpm for 10 minutes to remove cellular debris from the 
supernatant and the GST-tagged proteins were then purified by affinity 
chromatography (Glutathione sepharose 4B; GE Healthcare) as previously 
described121. Briefly, each clarified culture supernatant was incubated with 
approximately 1 ml of 50% glutathione sepharose 4B beads per ~30 ml of 
supernatant pre-equilibrated with 1x PBS and incubated for approximately 1 hour at 
RT. After incubation, the bead suspension is poured over reusable plastic columns 
(Qiagen, UK) assembled with a porous frit placed at the base to retain the beads, the 
flow through was discarded and the beads washed extensively with 1x PBS before 
elution with 0.5 ml of reduced glutathione elution buffer per ml of beads. Fractions 
from each purified protein were briefly assayed by Bradford assay (BioRad) purely to 
identify protein-containing fractions, pooled and finally dialysed against 1x PBS 
before quantifying the protein content later on. 
The different proteins were dialysed in order to remove unwanted small molecular 
weight substances that might interfere in future experimental procedures. Samples 
were transferred into visking dialysis membranes (Medicell Membranes Ltd, UK) at 
12-14 kDa (the GST tag on the samples is 26 kDa) previously hydrated (2% 
NaHCO3 and 1 mM EDTA incubated at 80°C for 30 minutes) and the membranes 
placed in a tub filled with 2 L of 1x PBS with a mixer and left o/n at 40C. The 
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following day, the buffer was replaced by a fresh batch and left incubating at RT for 
approximately 2 hours before transferring the individual samples to appropriately 
labelled clean tubes and stored at -20°C in 50 ml aliquots. 
A Bradford assay was done to determine the concentration of each sample using 10 
µl of Bovine Serum Albumin (BSA) serial dilutions as a standard (2, 1, 0.5, 0.25, 
0.125, 0.63, 0.31 and 0 mg/ml). To quantify each sample, a 1/5 and 1/10 dilution of 
the samples were done in 1x PBS or H2O before adding 200 µl of previously diluted 
(1/4 in H2O) Bradford dye. Samples were left to incubate at RT for 5 minutes before 
being read at 630 nm. 
The total protein concentration was also determined by using the PierceTM BCA 
protein kit (ThermoFisher Scientific) and Bovine Serum Albumin (BSA) at different 
concentrations as standard (2000x, 1500x, 1000x, 750x, 500x, 250x, 125x, 25x and 
0), as per product specifications. This was done on samples at 1/5 dilution and at 
1/10 dilution then read at 630 nm on the plate reader (Dynex Technologies MRX TC 
II). A bicinchoninic acid assay (BCA) (ThermoFisher Scientific) was also performed 
on the samples in a similar manner in order to quantify the samples as an alternative 
to the Bradford assay. 
These assays were ran alternatively to the Bradford assay as the latter initially 
showed inconsistent values for the same batch of samples tested so it was decided 
to look at alternative quantifying methods. We settled on using the Bradford assay as 
commercial non-malarial antigens used in the group were regularly assessed using 
this assay. Assayed samples were stored in small aliquots at -80°C to minimise 
damage to the proteins from freeze/thaw cycles. 
4.2.5. INDIRECT ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 
Serum and bloodspot samples were tested for total IgG antibodies against P. 
falciparum (AMA-1122,123, MSP1-19124), P. vivax (AMA-1, MSP1-19 (donated as a 
kind gift from Tony Holder)) and P. knowlesi (SERA3 antigens 1 and 2, TSERA2 
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antigen 1 and SSP21) antigens as previously described42. Antigens used to test 
hospital case serum samples were PkSERA3 antigens 1 and 2, PkSSP2, 
PkTSERA2 antigen 1 and PvMSP1-191. Antigens used to test the small case study 
community survey bloodspot samples were PkSERA3 antigen 2, PvAMA-1, 
PvMSP1-19, PfAMA-1 and PfMSP1-192. Briefly, 96-well Immunolon-4HBX plates 
were coated o/n at 40C at the required concentration of each recombinant antigen 
diluted in 50 µl of coating buffer per well. Plates were washed 3 x using PBS/T wash 
buffer and blocked using 1% skimmed milk powder in PBS/T at RT for 3 hours. 
Plates were washed 3 x using PBS/T and a 1/1,000 or 1/2,000 final dilution of sera 
(1/1,000 for all P. knowlesi antigens and MSP1-19; 1/2,000 for AMA-1) was tested 
on the different antigens o/n at 40C. The starting concentration of samples was 1/200 
for both serum and bloodspot samples before being further diluted in the ELISA 
plate itself (10 µl of sample in 40 µl blocking solution for a 1/1,000 dilution; 5 µl of 
sample in 45 µl blocking solution for a 1/2,000 dilution). Briefly, bloodspot samples 
were cut into discs using a 3 mm leather hole puncher and placed into labelled 96-
well deep-well (Costar 0.5 ml V well bottom assay block) plates before being eluted 
in 200 µl of reconstitution buffer (1 g sodium azide in 1 L PBS/Tween20) (appendix 
III). The eluted samples were sealed (96 cap sealing mat, Thermo scientific) and 
stored at 4°C and at -20°C for long-term storage. Serum samples were diluted from 
neat into 200 µl reconstitution buffer and stored under similar conditions as the 
bloodspot samples (at 4°C). The plates were then washed 5 x and HRP conjugate 
polyclonal rabbit anti-human IgG antibody was added to all wells at a dilution of 
1/15,000 in PBS/T at RT for 3 hours. The plates were washed 5 x as before and 
antibody responses were detected after development with TMB one component HRP 
microwell substrate solution (Tebu-bio laboratories) for 15 minutes and stopped with 
0.2 M sulphuric acid (H2SO4) stop solution. Plates were read at 450 nm on an ELISA 
plate reader (plates read in London, UK: Dynex Technologies MRX TC II; plates 
read in Sabah, Malaysia: MultiskanTM FC Microplate Photometer, Thermo Scientific) 
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and optical density (OD) values recorded. All samples were run in duplicates 
alongside negative and positive controls, including blank (buffer only) wells. These 
were used to help standardise across assay runs. 
Ethiopian P. vivax-positive samples were selected based on positive responses to P. 
vivax AMA-1 and MSP1-19 (n=26) and were used as the P. vivax-positive, P. 
knowlesi-negative control group for the assays using the clinical samples54. In 
addition, malaria naïve serum samples (n=29) (anonymous donors at Public Health 
England (PHE); LSHTM ethics approval #11684) were used as the P. knowlesi-
negative control group1. Written informed consent was obtained from all study 
participants. Both negative control groups were compared to the responses from the 
P. knowlesi-exposed hospital clinical case samples. OD values were corrected by 
subtracting the background of the blank wells average OD value. 
For the small community survey samples, PHE serum samples were used as a 
negative control and positive controls used were a lyophilised anti-malaria patient 
sample (NIBSC, UK; 72/96) for P. vivax, a pool of hyper-immune endemic adult 
Tanzanian pool38 for P. falciparum and pooled P. knowlesi-exposed hospital serum 
samples. Similarly to the assays using the clinical samples, OD values were 
corrected by subtracting the background of the blank wells average OD value. 
Values were normalised between plates using the appropriate standardised controls 
for P. falciparum and P. vivax, except for P. knowlesi due to the lack of a standard 
control. For all assays, values in excess of 1.5 CV between duplicates were 
considered fails and either dropped or re-ran. All samples used were anonymised 
and all serological analysis was performed at the Universiti Malaysia Sabah and the 
London School of Hygiene and Tropical Medicine.  
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4.2.6. DEVELOPING AND OPTIMISING A 384-WELL ELISA USING THE BIOMEK® FXP 
LABORATORY AUTOMATION WORKSTATION ROBOTIC PLATFORM 
A high-throughput 384-well ELISA assay was adapted from the previously 
established protocol for 96-well ELISA to be performed on the Biomek® FXP 
Laboratory Automation Workstation. Alterations were principally made on the 
volumes of reagents used per plate in order to use the least serum sample available 
and personalised programs were designed on the Biomek® in order to perform the 
necessary task (appendix IV). Samples used to optimise this platform were from 
Bioko Island, Equatorial Guinea, collected as filter paper bloodspot samples between 
July and August 2012 as part of an annual Malaria Indicator Survey125 in 18 sentinel 
sites. These samples were used to investigate dynamics of malaria transmission on 
Bioko Island. Ethics approval for this study was granted by the Equatorial Guinea 
Ministry of Health and Social Welfare. Written, informed consent was obtained from 
all heads of household prior to the survey. A number of these samples (n=160) were 
chosen for this optimisation assay as they had previously been tested by the 
standard 96-well ELISA in-house. 
 
4.2.7. STATISTICAL ANALYSIS: SABAH HOSPITAL CASE SAMPLES  
Final optical density (OD) values were obtained by subtracting blank OD values, 
reducing background reactivity. Cut off values for each P. knowlesi-specific antigen 
were calculated based on the average OD values of PHE malaria-naïve control 
serum samples ± (3xSD). Ensemble boosted regression trees were fit to determine 
predictive power of antibody responses for classification of P. knowlesi exposure. To 
quantify uncertainty around estimates, 100 datasets were assembled including all 
seronegative individuals from the malaria unexposed population and an equal 
number of randomly selected P. knowlesi seropositive individuals (from all time 
points). All models were fit using stratified 10-fold cross validation with model 
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predictive ability assessed by the area under the receiver operating curve (AUC). 
The learning rate was set at 0.001 and tree complexity set at 4, to allow for 
interactions within the dataset. Contribution of responses to each antigen to models 
was assessed using relative variable importance as described by Elith et. al.126. In 
this method, the relative importance of individual predictor variables is calculated as 
the number of times a variable is selected for splitting, weighted by the squared 
improvement to the model and averaged over all trees and scaled to 100%. Boosted 
regression tree analysis was completed by Kim Fornace in R statistical software (v 
3.4.2) using the gbm package. 
The Wilcoxon-Mann Whitney and Wilcoxon signed rank tests (run on STATA/IC 
14.2) were used to generate p values for comparisons between different populations 
(i.e. reactivity differences between Malaysia and controls) and comparisons within a 
population (i.e. reactivity differences between days, 0, 7 and 28 from diagnosis and 
treatment). Scatter plots showing reactivity between P. knowlesi recombinant 
antigens and P. vivax MSP1-19 were created using STATA and dot plots showing 
reactivity to P. knowlesi recombinant antigens were created using GraphPad 
PRISM7. 
 
4.2.8. STATISTICAL ANALYSIS: SABAH AND PALAWAN CASE STUDY COMMUNITY 
SURVEY SAMPLES  
Mixture models were used to fit normalised OD values to define seropositive 
individuals in the case study communities survey samples, with the distribution of 
OD values modelled as two Gaussian distributions. In this study, cut off values 
calculated for P. vivax and P. falciparum were defined by the average OD of the 
seronegative population ± (3xSD)2,127. Cut off values calculated for the P. knowlesi 
antigen used was defined in a similar way ± (5xSD)127, a more parsimonious cut off 
due to a lack of prior data. All OD values were corrected by subtracting the 
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background of the blank wells per plate.  Normalisation of OD readings between 
plates were done for P. vivax and P. falciparum but not for P. knowlesi due to the 
lack of a standard control. Cut off values were determined for each antigen because 
the assays were run in different laboratories. For P. falciparum and P. vivax, 
individuals were considered positive if they were positive for either MSP-1 and/or 
AMA-1. Models were fit separately for each parasite species and site. Risk factors 
associated with P. knowlesi seropositivity were evaluated using multivariate logistic 
regression. Kim Fornace performed the statistical analysis for this study. The 
percentage of responders to each antigen from the different sample sets was 
determined. It was possible to stratify responders by age, gender and region through 
the use of statistical data analysis software, STATA (StataCorp. 2015. Stata 
Statistical Software: Release 14. College Station, TX: StataCorp LP.) and R 
statistical software (RStudio Team. 2015. RStudio: Integrated Development for R. 
RStudio, Inc., Boston, MA).  
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4.3. RESULTS 
4.3.1. IDENTIFICATION, DESIGN AN EXPRESSION OF RECOMBINANT ANTIGENS 
Eighteen P. knowlesi gene targets were selected based on existing evidence from 
known serological markers in P. falciparum (AMA-148,52, MSP152,60, SSP2/TRAP56  
and SERA antigens78,79) and by interrogating the available P. knowlesi literature93 
and existing databases110,128. Figure 4.2 outlines the experimental strategy used in 
the identification of the target sequences of interest and the test samples used for 
this chapter. To identify  P. knowlesi-specific targets, sequence specificity was 
determined by aligning the amino acid sequences for each gene targets  against 
other Plasmodium spp. using the BlastP algorithm129 in non-redundant (NCBI: 
https://is.gd/MzISez) and Plasmodium specific databases (Plasmodb: 
https://is.gd/XOs7vd110) (Table 4.1; appendix IV). Using this approach, regions or 
sequences showing high amino acid identity were avoided and regions unique to P. 
knowlesi were identified within the selected genes. These regions were once again 
screened using the BlastP algorithm in order to ensure P. knowlesi specificity.
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Figure 4.2. Flowchart summarising the experimental strategy used in the identification and validation of the P. knowlesi-specific candidates and sample sets used in this chapter. Test samples were obtained 
from a case community survey in Sabah, Malaysia (n=1957), Palawan, The Philippines (n=546) and from a hospital-based clinical trial in Sabah, Malaysia (n=97). The negative controls comprised of samples from an 
Easy Access Group (EAG) in Ethiopia (n=26) as P. vivax-positive P. knowlesi-negative samples and the malaria-naïve group were obtained from Public Health England (n=29).   
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In order to aid the design of each recombinant target, domain prediction software 
was used to help predict the sequence structure. Sites such as Gene3D 130 and 
SMART (http://smart.embl-heidelberg.de/) were employed to help obtain domain 
prediction information for each gene which helped with the design of truncated 
fragments (Figure 4.3). Although this work was done for all candidates, Figure 4.3 is 
a representative figure for PkSERA3 antigens 1 and 2, PkSSP2 and PkTSERA2 
antigen 1. 
 
Figure 4.3 Plasmodium knowlesi-specific recombinant antigen constructs. Schematic representations for each 
protein are shown with key features labelled. (a) PkSERA3 shows the location of the putative pro-enzyme and 
enzyme domains. The predicted subtilisin (SUB) 1 cleavage sites in relation to variable regions 1 and 2 and the 
cytoplasmic domain90. (b) PkSSP2/TRAP contains a von Willebrandt A domain (vWA), thrombospondin type (TSP) 
1 motif, a C-terminal transmembrane (TM) region and a cytoplasmic terminal domain (CTD). Putative T-cell and 
B-cell epitopes are highlighted with an asterix or black square, respectively131. (c) PkTSERA2 shows the lack of 
central enzyme domain due to truncation of the sequence90. Predicted secondary structures generated in I-
Tasser132,133 are shown above each scheme. Red boxes represent helices, blue arrows sheets and the black line 
coils. The position of recombinant proteins are highlighted below each scheme with the N- and C-terminal amino 
acid positions indicated. The overall length of each protein is referenced by the amino acid ruler above each 
secondary structure prediction. For all proteins SP refers to the signal peptide. 
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This information helped to avoid the unintended premature truncation of potential 
domains within the sequence. The hypothesis behind this approach was that 
premature truncation of putative domains could lead to suboptimal expression or 
difficulties in solubility with the recombinant construct. In addition, both signal 
peptides (SP) and any transmembrane (TM) regions were omitted from all of the 
final construct designs. The latter was done because a number of previous studies 
had suggested that the presence of SP and, or any TM regions could adversely 
affect the solubility and expression of the recombinant proteins114. 
To further characterise the recombinant sequences, Jameson-Wolf antigenic index 
was applied (Protean 4.0, DNAStar) to help identify potential antigenic regions. The 
predicted antigenic residues were targeted and, as shown in Figure 4.4, although 
based on a prediction, it is clear that the selected sequences for PkSERA3 antigens 
1 and 2 (Figure 4.4 B), PkSSP2 (Figure 4.4 C), PkTSERA2 antigens 1 and 2 
(Figure 4.4 D) and PKH_080030 (Figure 4.4 H) have a high probability of being 
antigenic, an important characteristic for a serological marker. Other than the 
SERAs, TRAP/SSP2 and MSP1 antigen, the remaining candidates for expression 
constructs come from gene families specific to P. knowlesi with, as yet, undefined 
functions.  
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Figure 4.4 Jameson-Wolf antigenicity predictions for P. knowlesi candidates. Figure shows antigenicity for the 
full gene, highlighting the selected candidates in black rectangles: (A) PkMSP1 showing PkMSP1 antigen 2; (B) 
PkSERA3 showing PkSERA3 antigens 1 and 2; (C) PkSSP2; (D) PkTSERA2 showing PkTSERA2 antigens 1 and 2; (E) 
PKH_021580; (F) PKH_031930 showing antigens 1 and 2; and (G) PKH_080030. The top and bottom scales 
indicate the amino acid number and the amino acid positions for the candidates within the gene, respectively. 
This figures represents 10 of the 18 antigen candidates originally selected. 
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Using the reference genome P. knowlesi H strain, maximum likelihood phylogenetic 
trees were assembled for the P. knowlesi orthologue protein candidates (AMA-1, 
MSP1, SSP2/TRAP, SERA3 and TSERA2), highlighting the relationship of each 
candidate between Plasmodium species (Figure 4.5).This was not done for the 
remaining candidates as these have been shown to be P. knowlesi specific gene 
candidates with no orthologues found in the other human Plasmodium spp.. 
Specifically, for PvAMA-1 (bootstrap value: 100%), PvMSP1 (bootstrap value: 100%) 
and PvMSP1-19 (bootstrap value: 87%), there is a strong relationship between 
different Plasmodium species, particularly between P. knowlesi and P. vivax (Figure 
4.5 A, B and C), highlighted further by corresponding near identical amino acid 
alignments (appendix IV Figure 1 and 2). 
Amino acid alignments were generated using available sequences for human-
pathogenic Plasmodium spp., which clearly highlight the level of sequence identity 
for both genes between P. knowlesi and P. vivax (appendix IV, Figure 1 and 2). 
Although the bootstrap value strongly supports the grouping of P. knowlesi with P. 
vivax for both SERA and TRAP/SSP2 (Figure 4.5 D and E; bootstrap value: 100%), 
the alignments for TRAP/SSP2 and the SERA antigens (PKNH_0413400 and 
PKNH_0413500) help identify regions specific for P. knowlesi (Figure 4.6). Based on 
these screens, any sequences showing high amino acid sequence identity to other 
Plasmodium spp., specifically P. ovale, P. malariae, P. falciparum and P. vivax, were 
re-edited to focus on P. knowlesi-specific regions only, where possible.
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Figure 4.5 Maximum likelihood phylogenetic analysis of the amino acid sequences of AMA1 (a), MSP1 (b), MSP1-19 (c), SERA3 (d), SSP2/TRAP (e) and TSERA2 (f) and gene sequences 
between P. knowlesi, P. falciparum, P. vivax, P. malariae and P. ovale/P. simiovale. Bootstrap values are given in percentages. 
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Figure 4.6 Amino acid sequences alignments for SERA3 and SSP2/TRAP gene sequences between P. knowlesi, 
P. falciparum, P. vivax, P. malariae and P. ovale/P. simiovale. P. knowlesi-specific sequences selected for 
development as constructs are highlighted in yellow. Asterisks indicate fully conserved residues, colons indicates 
strong residue conservation (>0.5, Gonnet PAM 250 matrix), period indicates weak residue conservation (=<0.5, 
Gonnet PAM 250 matrix). Blank spaces indicate no residue conservation. 
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A Reverse Transcriptase-PCR (RT-PCR) assay was performed to determine the 
transcriptional status of our selected candidates in mixed blood stage parasite 
samples. 
It would be ideal to use RNA extract from the different stages of the life cycle rather 
than a mixed stage sample, but P. knowlesi is known to have asynchronous 
cycles134, making it difficult to culture and collect samples from each cycle stage. At 
the time of this experiment, synchronised parasite samples were not available. The 
RT-PCR confirmed that MSP1, SERA3, TSERA2 and PKH_080030 were actively 
transcribed in the blood stage (Figure 4.7). 
 
Figure 4.7 P. knowlesi candidate gene transcriptional status in parasite mixed blood stage. Panel 1: MSP1; 
panel 2: SERA3; panel 3: TRAP/SSP2; panel 4: TSERA2; panel 5: PKH_021580; panel 6: PKH_031930; panel 7: 
PKH_080030; panel 8: CTRP; panel 9: CSP. g refers to genomic DNA, RT+ refers to presence of RT enzyme and RT- 
refers to absence of RT enzyme. Samples were run on a 1.2% agarose gel. The DNA ladder is indicated in bp 
(Hyperladder 1Kb, Bioline). 
 
By contrast, PKH_021580 and PKH_031930, along with TRAP/SSP2, which is a 
sporozoite protein, and the PkCTRP and PkCSP pre-erythrocityc stage controls, 
were negative by RT-PCR either due to the possibility of the candidate genes not 
being activated or simply due to the possibility of those candidates not being 
important in the blood stage of the parasite. In the absence of stage specific RNA 
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template, we could further speculate that the negative RT-PCR was due to the 
proteins being expressed during the liver stage or even within the mosquito vector.  
Thirteen of the 18 selected candidate sequences were successfully PCR amplified to 
be used in several cloning strategies followed by protein expression. The primary 
setback that arose with the remaining 5 candidates was the inability to amplify them 
and the reasons why these could not amplify were not clear. It was possible to 
exclude inappropriate temperatures as an issue due to the gradient PCR conditions 
running multiple temperatures simultaneously to determine the ideal amplification 
temperatures. We reviewed our primer design for these candidates and added 3-6 
nucleotides to the sequences. Three of the 5 candidates were successfully amplified 
with the remaining 2 candidates being excluded from our panel due to lack of time to 
troubleshoot the problem any further.  
Multiple strategies were employed in order to expand the cloning output in the least 
amount of time. Most of the candidates were successfully cloned using the SLIC 
cloning method. The Gibson and conventional cloning methods were applied to 
candidates that failed the SLIC cloning method after a series of troubleshooting 
steps such as changes in reagent concentrations, vector to insert ratios and 
incubation periods. Candidates were then transformed and positive transformants 
were identified by colony PCR as described in the methods (section 4.2.3.5). We 
determined that, although we had more setbacks using the SLIC method in obtaining 
any colonies, the conventional and SLIC methods produced more positive 
transformants than the Gibson method overall. Sixteen candidates were successfully 
cloned and transformed. By way of further validation, each protein construct was 
sequence verified by capillary sequencing to confirm each sequence and the 
position of the stop codons before expression. 
Figure 4.8 shows us the amplified P. knowlesi-specific PCR products for some of 
these candidates. All samples fall between 0.25 and 1kb in sizes. It was important 
not to exceed 1kb in sizes as the increase in size could potentially impact on the 
DEVELOPMENT OF PK SPECIES SPECIFIC REAGENTS TO CHARACTERISE ANTIBODY ISOTYPE PROFILES | LOU HERMAN  
 
97 | P a g e  
 
solubility of the final product114. The major issues found in this step were failures in 
sequencing or errors in the individual clone sequences. For all candidates that failed 
to be sequenced we repeated the sequencing step to exclude any assay errors. A 
number of candidates had problems due to the sequencing primers failing but it was 
not possible to troubleshoot this at that time. For candidates that showed errors in 
the clone sequences we repeated the cloning step in order to obtain clones with the 
appropriate sequences. It was found that some of our candidates had errors in the 
sequences due to the design of the original primers, therefore these were 
redesigned and cloned. Candidates PKH_140010, PKH_073420, PKH_000540, 
TSERA2 antigen 3 and two others not shown in the figure were excluded from the 
current panel since these did not pass the sequencing stage after a number of 
troubleshooting attempts and it was not possible to repeat cloning due to time 
constraints.  
 
Figure 4.8 Purified P. knowlesi-specific PCR amplified products. Lane 1: PkMSP1 ag2; lane 2: PkSERA3 ag1; lane 
3: PkSERA3 ag2; lane 4: PkSSP2; lane 5: PKH_140010; lane 6: PKH_031930 ag1; lane 7: PKH_031930 ag2; lane 8: 
PKH_021580; lane 9: PKH_073420; lane 10: PkTSERA2 ag1; lane 11: PkTSERA2 ag3; lane 12: PKH_000540; lane 
13: PKH_080030. M refers to the DNA ladder (Hyperladder 1kb plus, Bioline). Products were run on a 1% agarose 
gel. 
 
All the antigens were cloned into the pGEX-2T GST-tagged expression vector and 
expressed in BL21(DE3) E. coli expression cells (section 4.2.4.) as soluble products 
with final yields ranging from 11.9 – 20.5 mg/L (Figure 4.9; Table 4.3). The major 
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issue found at this step was having some of the candidates not being expressed in 
the allowed time frame (overnight expression). These were allowed to incubate for 
slightly longer periods of time in order to allow maximum cell growth with the least 
degradation. Candidates that failed to express with the extended time frame were 
transformed into new batches of expression cell lines in order to exclude cell 
degradation as the setback. All candidates that passed the sequencing stage were 
successfully expressed.  
Based on their predicted molecular masses (including the GST tag), SDS-PAGE 
analysis of the purified proteins clearly suggested multimerisation of the purified 
products (both monomer and dimer; Figure 4.9; Table 4.3).  Further analysis of the 
protein candidates was attempted by running Western blots using the hospital case 
samples135 in order to determine reactivity towards each recombinant, which was 
successfully observed. The Coomassie stained profile also illustrated that there is 
very little non-specific degradation of the recombinant proteins (Figure 4.9), 
suggesting that the proteins are stable under the conditions used. The protein sizes 
for each protein were larger than predicted, so called “gel shifting” when ran on SDS-
PAGE, which is not uncommon136-138. 
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Figure 4.9 SDS-PAGE of purified recombinants in reducing conditions. Lane 1: MSP1 ag2; Lane 2: SERA3 ag1; 
Lane 3: SERA3 ag2; Lane 4: SSP2; Lane 5: TSERA2 ag1; Lane 6: TSERA2 ag2; Lane 7: PKH_021580; Lane 8: 
PKH_031930 ag1; Lane 9: PKH_031930 ag2; Lane 10: PKH_080030. Band sizes are indicated on one side in kDa 
(Fermentas PageRuler Prestained Protein Ladder). Samples were ran under reducing conditions at approximately 
0.4 µg/ml per lane on a 4-20% gradient Tris-glycine gel (NuPAGE, BioRad) and stained with Coomassie Blue 
(BioSafe, BioRad). The arrows and asterisks indicate the protein monomers and aggregates, respectively. 
 
Although not fully explained for all proteins classes, evidence suggests that the 
presence of acidic residues, net hydropathy or protein aggregation can reduce the 
effectiveness of SDS in altering the charge, and therefore the migration of proteins 
through the gel139,140.  The fact that all 10 protein constructs exhibited signs of 
protein aggregation supports the suggestion that aggregation may affect protein 
migration on polyacrylamide gels. 
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Figure 4.10 SDS-PAGE of purified recombinants. Lane 1: MSP1 ag2; Lane 2: SERA3 ag1; Lane 3: SERA3 ag2; Lane 
4: SSP2; Lane 5: TSERA2 ag1; Lane 6: TSERA2 ag2; Lane 7: PKH_021580; Lane 8: PKH_031930 ag1; Lane 9: 
PKH_031930 ag2; Lane 10: PKH_080030. Band sizes are indicated on one side in kDa (Fermentas PageRuler 
Prestained Protein Ladder). Samples were ran under reducing conditions at approximately 0.4 µg /ml per lane on 
a 4-20% gradient Tris-glycine gel (NuPAGE, BioRad) and stained with Silver Stain (Thermo Scientific). 
 
The Silver stained profiles (Figure 4.10) only reinforce what was observed in the 
Coomassie stained gel, confirming that the expressed candidates are highly 
concentrated although some appear slightly degraded. Silver stain is a much more 
sensitive staining assay with a detection limit of under 1 ng141,142 (coomassie staining 
has a detection limit of approximately 100 ng). All products were successfully 
expressed but the profile of lanes 5 to 9 (TSERA2 antigen 1 and antigen 2, 
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PKH_02580, PKH_031930 antigens 1 and 2) suggests further engineering would be 
required to improve the expressed product.  
 
4.3.2. SINGLE-NUCLEOTIDE POLYMORPHISM (SNP) ANALYSIS IN P. KNOWLESI 
TARGET GENES 
P. knowlesi has recently been described as falling into three subpopulations in 
Malaysia, one from long-term laboratory isolates (cluster 1) and two associated with 
clinical human infections from separate macaque species reservoir hosts, the pig-
tailed (cluster 2) and long-tailed macaques (cluster 3)143. To establish a solid and 
reliable serological tool to be used in large population studies, ideally these tools 
should not be biased towards a single cluster, which would limit the value of these 
reagents. We characterised the existence of these SNPs associated with the 
different clusters for each selected P. knowlesi specific candidate, focussing on non-
synonymous (amino acid altering) positions within the P. knowlesi-specific truncated 
constructs. Table 4.9 summarises the synonymous and non-synonymous SNPs 
associated with the three clusters for each P. knowlesi candidate, suggesting that 
the majority of SNPs are found in sequence stretches not included in the candidate 
antigen areas (detailed SNP files in Appendix IV, table 1). The majority of non-
synonymous SNPs were found in regions not covered by the antigen design of all 
candidates. By omitting the majority of these cluster-specific SNPs we hoped to 
avoid segregation of detectable antibodies according to the defined clusters. The 
relevance of these genetic clusters in the context of immunity, and the potential 
relevance to host preferences is yet to be defined. Dr Jody Phelan’s input was 
obtained in order to compile this data.  
DEVELOPMENT OF PK SPECIES SPECIFIC REAGENTS TO CHARACTERISE ANTIBODY ISOTYPE PROFILES | LOU HERMAN  
 
102 | P a g e  
 
Table 4.9 Single-nucleotide polymorphism (SNP) frequencies of Malaysian clinical isolates sequences within P. knowlesi candidate genes. Full gene and candidate sequence SNPs are shown 
in total and for each of the three clusters. The type of SNPs are indicated.  
 
   cluster 1 cluster 2 cluster 3 Type 
Gene ID Candidate name Chromosome SNPs 
Lab 
Adapted 
n=8 
Pig-
tailed 
n=5 
Long-tailed 
n=32 
Non-
synonymous 
Synonymous 
Stop-
Gained 
PKNH_0728900 
Full gene   287 92 100 250 113 173 1 
MSP1_Ag 2 7 38 10 13 36 30 8 0 
PKNH_0413400 
Full gene   146 55 75 126 58 85 0 
SERA3 ag1 4 4 2 1 2 4 1 0 
SERA3 ag2 4 3 1 1 3 1 2 0 
PKNH_1265400 
Full gene   71 23 12 57 46 24 1 
SSP2 12 17 6 4 14 12 5 0 
PKNH_0216300 
Full gene   44 19 14 34 30 12 2 
PKH_021580 2 31 13 7 23 20 9 2 
PKNH_0321300 
Full gene   2 0 1 2 1 1 0 
PKH_031930 ag1 3 0 0 0 0 0 0 0 
PKH_031930 ag2 3 0 0 0 0 0 0 0 
PKNH_0413500 
Full gene   122 56 48 107 69 52 0 
TSERA2 ag1 4 39 21 16 36 17 22 0 
TSERA2 ag2 4 22 9 6 20 15 7 0 
PKNH_0800300 
Full gene   2 1 1 1 0 2 0 
PKH_080030 8 2 1 1 1 0 2 0 
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4.3.3. OPTIMISATION OF A 384-WELL ELISA METHOD ALONGSIDE 96-WELL 
STANDARD ELISA METHOD 
During the course of the project we were granted access to the Biomek robotic 
platform, which we attempted to re-task as a high throughput serological platform 
utilising the least reagent possible.  A sample set from Bioko, Equatorial Guinea, 
previously tested by 96-well ELISA on P. falciparum antigens (AMA-1 and MSP1-19) 
was selected for optimising this platform. For both PfAMA-1 and PfMSP1-19, 
inconsistencies were initially found between duplicate wells in the first run compared 
to the second run, where duplicate wells were shown to correlate with each other 
(Run 1: PfAMA-1 R2=0.1166 PfMSP1-19 R2=0.5524; Run 2: PfAMA-1 R2=0.9382 
PfMSP1-19 R2=0.8374; Figure 4.11 A, C, B and D, respectively, and Figure 4.12). In 
order to determine if results for both platforms could be comparable, comparisons 
were made between the 384-well and 96-well ELISAs, showing strong correlations in 
both runs (run 1: PfAMA-1 R2=0.328; PfMSP1-19 R2=0.8807; run 2: PfAMA-1 
R2=0.9257; PfMSP1-19 R2=0.8893; Figure 4.13), with the exception of PfAMA1 run 
1 (R2=0.328). Results showed a slight tendency to having higher OD values in the 
samples tested using 384-well ELISA compared to 96-well ELISA. Although 
promising, the preparation of reagents into the format required by the Biomek robotic 
platform proved to be more time consuming than a regular ELISA and the lack of 
expertise with the software reduced the possibility of further optimising the platform 
for our use.  In addition, two high throughput multiplex platforms were purchased by 
the group. The suspension bead array Luminex MAGPIX® reader (Luminex corp, 
USA) and two protein microarray platforms (Genepix® (Molecular Devices,USA) and 
the Araycam® (Grace Bio-Labs, USA)). 
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Figure 4.11 Reactivity differences between runs and duplicates using 384-well ELISA plates on the Biomek for PfAMA1 and PfMSP1-19. Data is plotted as raw OD values at 450 nm with R2 
values for the trendlines: PfAMA1 run 1 R2 =0.1166 (A); PfAMA1 run 2 R2 =0.9382 (B); PfMSP1-19 run 1 R2 =0.5524 (C); PfMSP1-19 run 2 R2 =0.8374 (D).
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Figure 4.12 Analysis of duplicate samples per Biomek 384-well ELISA run for PfAMA1 (run 1: A; and run 2: B) 
and PfMSP1-19 (run 1: C; and run 2: D). Data is plotted as raw OD values at 450 nm showing sample duplicates 
from well 1 (orange) and well 2 (blue) of each sample. 
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Figure 4.13 Comparisons between 96-well and 384-well ELISAs for PfAMA1 and PfMSP1-19. Data is plotted as 
raw OD values at 450 nm with R2 values for the trendlines indicated: PfAMA1 run 1 (blue) R2=0.328 and run 2 
(orange) R2=0.9257 (A); PfMSP1-19 run 1 (blue) R2=0.8807 and run 2 (orange) R2=0.8893 (B). 
 
4.3.4.  SERUM REACTIVITY TO P. KNOWLESI-SPECIFIC RECOMBINANT ANTIGENS 
In Sabah, Malaysia, serum samples were collected from Malaysian adults and 
children hospitalised with malaria infection at different time points from day of 
diagnosis (day 0), 7 and 28 days after treatment. The samples were down selected 
to identify 97 samples which the epidemiological data identified as being infected 
with P. knowlesi and were used for this experiment.  
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Hospital case samples were assayed by enzyme-linked immunosorbent assay 
(ELISA) using four antigens from the initial P. knowlesi-specific protein panel 
(SERA3 antigens 1 and 2, SSP2 and TSERA2 antigen 1) (chapter 3, section 3.1, 
Table 3.3) and a P. vivax control antigen (MSP1-19). Ethiopian P. vivax-positive, P. 
knowlesi-negative malaria endemic children’s sera (n=26)54 and adult UK malaria 
naïve sera (n=29) were used as a P. knowlesi-negative control panel. 
Reactivity towards PvMSP1-19 was seen in the P. knowlesi-negative malaria 
endemic control samples, due to previous exposure to P. vivax, but not in the 
malaria naïve control samples, which showed no reactivity to any of the antigens 
tested (Figure 4.14, top panel) (average OD values from PHE samples: PkSERA3 
ag1 OD=0.124; PkSERA3 ag2 OD=0.131; PkSSP2 OD=0.117; PkTSERA2 ag1 
OD=0.118). Detectable antibody reactivity to the P. knowlesi-specific antigens was 
not seen in the control group, with the exception of one weakly positive sample to 
PkSERA3 antigen 1 and another to PkSSP2 (Figure 4.14, first and third graphs from 
the top panel). 
 
DEVELOPMENT OF PK SPECIES SPECIFIC REAGENTS TO CHARACTERISE ANTIBODY ISOTYPE PROFILES | LOU HERMAN  
 
108 | P a g e  
 
 
Figure 4.14 Endemic and P. knowlesi-negative sera reactivity to Plasmodium knowlesi-specific antigens. 
Scatter plots showing sera reactivity to: P. vivax MSP1-19 with P. knowlesi SERA3 ag1 (column 1), SERA3 ag2 
(column 2), SSP2/TRAP (column 3) and TSERA2 ag1 (column 4) antigens. Sera samples from P. knowlesi negative 
controls n = 55 (row 1; PHE UK malaria naïve (blue), Ethiopian children (red)) and Malaysian hospital case sera 
samples from days 0 (n = 92), 7 (n = 72) and 28 (n = 77) of diagnosis (rows 2±4, respectively). The red line in each 
graph represent the cut off values for the respective P. knowlesi antigen and was calculated based on Public 
Health England negative control sera samples (average ODs ± (3xSD)): The vertical cut off line is based on 
PvMSP1-19 = 0.501. The horizontal cut off line for the P. knowlesi antigens were based on the following values: 
SERA3 ag1 = 0.292; SERA3 ag2 = 0.366; SSP2/TRAP = 0.322 and TSERA2 ag1 = 0.208. 
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From all three time points, day 7 showed the highest antibody reactivity to all four P. 
knowlesi antigens (Figure 4.14, Figure 4.15 and Figure 4.16) with PkSERA3 antigen 2 
showing the highest prevalence, 63.8% (46/72), in comparison to PkSERA3 antigen 
1 (18.1%, 13/72), PkSSP2 (33.3%, 45/72) and PkTSERA2 antigen 1 (43.1%, 31/72) 
(Figure 4.14, columns 1, 3 and 4). 
 
Figure 4.15 Serial fold increase in antibody reactivity for each antigen following treatment of knowlesi 
malaria. (a) SERA3 ag1, (b) SERA3 ag2, (c) SSP2/TRAP and (d) TSERA2 ag1. Asterisks indicate level of significance, 
ns denotes non-significant values (p0.0001; p0.001; p0.01; p0.05 and p>0.05 ns; Wilcoxon signed rank tests). 
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Figure 4.16 Plasmodium knowlesi antigen reactivity to Malaysian hospital case serum samples and negative 
control serum samples. Dot plot of Malaysian hospital case serum samples from days 0 (n = 92), 7 (n = 72) and 
28 (n = 77) of PCR diagnosis and P. knowlesi-negative control serum samples (Ethiopian Pv-positive n = 26; PHE 
malaria naïve n = 29). Antibody reactivity to the P. knowlesi-specific antigens (a) SERA3 ag1, (b) SERA3 ag2, (c) 
SSP2/TRAP and (d) TSERA2 ag1 are shown.  
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Compared to controls, the PkSERA3 antigen 2 showed a higher prevalence at all 
time-points (p<0.001) (Figure 4.14 and 4.15 B). Antibody responses measured at 
day 7 and 28 to PkSERA3 antigen 2 demonstrated a significant increase when 
compared to day 0 (p<0.001 for both comparisons), with fold changes as high as 50 
observed for some samples (Figure 4.15 B). In comparison, the fold changes 
observed in serum responses to the PkTSERA2 antigen 1 (day 7 and 28; p=<0.001 
and p=0.005 respectively), PkSERA3 antigen 1 (day 7; p=0.008), and PkSSP2 (day 
7 and 28; p=0.001 and p=0.013), although statistically significant, had comparatively 
lower fold changes with a maximum of 15 (Figure 4.15 A, C and D). 
4.3.5. IDENTIFICATION OF P. KNOWLESI EXPOSED INDIVIDUALS 
To assess the predictive ability of responses to these antigens to identify P. knowlesi 
exposed individuals, we used boosted regression tree analysis, an ensemble 
modelling method combining aspects of machine learning and statistical analysis 
shown to have strong predictive performance and reliable identification of variable 
importance126. Similar data-adaptive statistical models are increasingly being used 
for classification and identification of patterns in large datasets and have previously 
been applied to identify predictive antigens21. Although the samples size is small, 
boosted regression trees have been used for classification with similarly small 
training data sets126. To further compensate for the small dataset, we fitted 100 
models of random samples of equal numbers of seropositive and seronegative 
samples within this training dataset and cross-validated these model predictions. Out 
of the 100 models fitted for randomly sampled equal numbers of exposed and 
unexposed individuals, the median classification accuracy was 88.9% (IQR: 86.1-
91.3%), calculated as the cross-validated area under the receiver operator curve 
(AUC). Relative variable importance was calculated for all models. PkSERA3 
antigen 2 contributed most to the models (median relative variable importance: 
50.4% (IQR 43.3- 61.4%)), followed by PkTSERA2 antigen 1, PkSSP2 and 
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PkSERA3 antigen 1 (Figure 4.17). This part of the data analysis was performed by 
Kim Fornace. 
 
 
Figure 4.17 Relative variable importance of responses to each antigen from 100 boosted regression tree 
models predicting P. knowlesi seropositivity. Median values for the relative variable importance and 
interquartile ranges are shown for all antigens tested: PkSERA3 ag 1 (4.8%; IQR 2.5±7.8%); PkSERA3 ag 2 (50.4%; 
IQR 43.3±61.4%); PkSSP2/TRAP (6.5%; IQR 3.7±11.8%) and TSERA ag 1 (34.2%; IQR 26.2±41.8%). Figure from 
published source1. 
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4.3.6. COMMUNITY SURVEY SAMPLES DEMOGRAPHIC 
Surveys and sample collection occurred from October 2014 to January 2015 in 
Kudat (n=1162) and Pulau Banggi (n=795) in Sabah, Malaysia and in September 
2014 in Palawan (n=546), Philippines, by a team led by Kim Fornace. A total of 
῀2503 individuals were samples for this study. A similar proportion of men and 
women were samples with ages ranging between 3 months and 99 years (median 
age was 24 years) and household engagement in some agricultural activities was 
reported by the majority of individuals (74%; 1846/2503). Forest coverage around 
houses (within 1 Km) were 39% in Matunggong, 55% in Bacungan and 82% in 
Limbuak, with Matunggong being the most fragmented2.  
4.3.7. P. KNOWLESI EXPOSURE ASSOCIATION TO AGE AND GENDER IN A SMALL 
COMMUNITY SURVEY 
To determine exposure to P. knowlesi in the sampled regions, PkSERA3 antigen 2 
was selected, alongside P. vivax and P. falciparum AMA-1 and MSP1-19, as it was 
previously shown to be the P. knowlesi antigen showing most reactivity to clinical 
blood samples from exposed individuals1. Only one P. knowlesi antigen was 
selected at this occasion due to the limited volume of blood samples, limiting the 
ELISA method to only testing 5 antigens.  
Exposure to P. knowlesi varied between the regions studied, with the highest 
antibody prevalence of 11.7% (93/795) detected in Pulau Banggi, Malaysia, followed 
by 6.8% (79/1162) in Kudat, Malaysia, and finally 1.1% (6/546) in Palawan, The 
Philippines, the region with the lowest seroprevalence from this study (Figure 4.18). 
For P. falciparum and P. vivax antigens, exposure was higher than for P. knowlesi in 
all study sites, with Matunggong, Kudat, at 16.9% (196/1162) and 6.9% (80/1162), 
Limbuak, Pulau Banggi, at 13.5% (107/795) and 16.7% (133/795), and Bacungan, 
Palawan, at 10.4% (61/587) and 9.7% (57/587), respectively.
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Figure 4.18 Sera reactivity to PkSERA3 
antigen 2 in endemic populations of 
Malaysia and The Philippines. Scatter 
plots showing sera reactivity to P. 
knowlesi SERA3 ag2 in Kudat (A), Pulau 
Banggi (B) and Palawan (C). The red 
lines in each graph represent the cut 
off values for the P. knowlesi antigen, 
which was calculated based on Public 
Health England negative control sera 
samples (average ODs ± (5xSD)) and 
PvMSP1-19 (average ODs: ± (3xSD)): 
The vertical cut off line for Malaysia 
(Kudat (A) and P. Banggi (B)) is based 
on PkSERA3 ag2=0.192 and the 
horizontal cut off line is based on 
PvMSP1-19=0.141. The vertical cut off 
line for The Philippines (Palawan (C)) is 
based on PkSERA3 ag2=0.422 and the 
horizontal cut off line is based on 
PvMSP1-19=0.301.
1 
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From all samples surveyed, 7.1% (178/2503) of the total population were 
seropositive for P. knowlesi, 16.1% (364/2266) for both P. falciparum antigens and 
12.6% (270/2141) for both P. vivax antigens. Results for all antigens were not 
available for all individuals due to non-systematic errors in sample labelling and 
insufficient sample volume. 
There was no significant difference observed in reactivity to P. knowlesi between 
men and women (Figure 4.19), and there was no significant association between 
gender and seropositivity to P. knowlesi, with a similar proportion of men and women 
seropositive to P. knowlesi (7.1% (88/178); 7.2% (90/178) respectively; OR (odds 
ratio): 0.99, 95% CI: 0.71±1.37, p=0.95). For all sites, antibody reactivity to 
PkSERA3 antigen 2 was detected in 4.2% (39/921) of individuals under 15 years of 
age and in 9.4% (25/265) of individuals over 60 years (Figure 4.20), though the 
highest reactivity was found in individuals between 45-60 years (11.6%; 43/370). For 
P. falciparum and P. vivax antigens, antibody reactivity was detected in 3.5% 
(29/821) and 2.9% (23/792) of individuals under 15 years and in 32.9% (78/237) and 
28.1% (64/228) of individuals over 60 years, respectively. For all antigens tested, 
seropositivity was associated with an increase in age, despite seroreactivity being 
detected in the youngest age groups. Agricultural work was found to be positively 
associated with P. knowlesi seropositivity as well as age and region. Of individuals 
under 15 years, the youngest were most likely to react to P. knowlesi than to the 
non-zoonotic malaria species. 
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Figure 4.20 Sera 
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4.4. DISCUSSION 
P. knowlesi is a naturally occurring infection of long-tailed and pig-tailed macaques, 
historically associated with forested areas of Southeast Asia8. Increased 
deforestation of their natural habitat is thought to have led to increased interaction 
between macaques and the human population in endemic areas144. Changes in 
village level forest cover and historical forest loss has been associated with an 
increase in P. knowlesi clinical cases in Sabah30, with malaria caused by P. knowlesi 
increasingly reported in Southeast Asia12. Conversely, there has also been a steady 
decline in the prevalence of P. falciparum and P. vivax infections in the same 
region145.  
The recent efforts of the malaria community towards achieving malaria elimination 
means that tools to help monitor the impact and effectiveness of intervention 
strategies are an urgent requirement146. The development of species-specific tools 
for P. knowlesi would allow accurate assessment of the levels and geographical 
limits of infection with this zoonotic species147. There is an urgent need to develop a 
comprehensive discovery strategy to help identify P. knowlesi unique antigenic 
markers of exposure in order to further characterise this organism and develop 
stronger and better identification methods.  
Currently, there are no specifically designed biomarkers for the serosurveillance of 
P. knowlesi infections. Recombinant proteins are available [PkCSP148, PkAMA1149, 
PkDBP150, PkSPATR58, PkLDH151, Pk1-Cys peroxiredoxin152, Pk knowpains153, 
PkMSP1-4299, PkMSP1-33100, PkMSP1-19101, Pk tryptophan-rich antigens 
(PkTrags)154, PkMSP3155 and PkSBP1156, but are limited in number and are 
generally not species-specific. As a result, their utility as serological diagnostic tools 
is generally secondary to their original design.  The reported level of amino acid 
sequence conservation to other Plasmodium spp. in some currently available P. 
knowlesi proteins is > 60% across large stretches of continuous sequence. Such 
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reagents could not be specific to P. knowlesi99,102,157,158 and would be unable to 
reliably discriminate between antibody responses to different parasite species in co-
endemic settings. 
We have successfully developed a panel of 10 P. knowlesi-specific recombinant 
antigens using an in silico approach. Although this project was successful, the 
development pipeline of this panel of antigens suffered challenges at every major 
step of the process. Recombinant protein development and expression requires a lot 
of time and effort. There were difficulties in the candidate amplification step, with 
some candidate sequences having to be altered slightly in order to amplify, others 
requiring primer design to be reviewed and others simply being excluded from the 
panel entirely. Three different cloning methods were applied in order to maximise the 
cloning output. This decision was taken due to the inefficiency of the SLIC method. 
Multiple troubleshooting attempts were made including changing vector to insert 
ratios, changes in individual reagent concentrations, using new batches of reagents 
and cells as well as changing incubation periods. At the time it was not possible to 
determine the reasons for the failed cloning attempts, therefore alternative cloning 
methods were sought after, the Gibson and the conventional methods. With more 
time, we would have liked to determine the causes of the inefficient cloning using the 
SLIC method and better compare this method to the others used in terms of number 
of transformants obtained, number of successfully cloned transformants and value 
for money in reagents per method. Another limitation was found during the antigen 
expression phase, with some candidates failing to be expressed and others 
expressing very little. By extending the expression time of some of the candidates it 
was possible to overcome this difficulty but this is a factor that would need to be 
reassessed more closely for individual candidates. Determining the optimal 
expression conditions for individual antigen candidates would have required more 
time and resources than was available. In future, it would be beneficial to determine 
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what conditions to express individual antigen candidates or groups of candidates in 
order to obtain substantial amounts with the least protein degradation possible. 
High levels of amino acid identity (83%) between PvMSP1-19 and PkMSP1-19, 
meant we were unable to use these reagents to dissect the species-specific immune 
responses due to the inevitable cross-reactive antibody responses. This is consistent 
with a proportion (48.9% (45/92)) of the confirmed P. knowlesi-exposed clinical 
samples in this study reacting with PvMSP1-19 at day 0, although it is unknown 
whether these participants had previously been exposed to P. vivax. However, this 
limitation simply reflects the paucity of available serological reagents for use in 
assessing exposure to infection, a deficit this study aims to address. The data 
presented here not only show us that we have successfully developed P. knowlesi 
tools to determine exposure in endemic populations, but also that specific tools for P. 
vivax and P. falciparum need to be developed for population studies where these 
three are co-endemic. One of the imitations of the assays using clinical and 
community samples was the lack of appropriate negative control serum samples, 
ideally endemic individuals that had never been infected with any of the malaria 
species. The lack of species-specific control antigens for P. falciparum and P. vivax 
was also a limitation in this study, as this would have proved helpful in determining 
the specificity of the P. knowlesi reagents as well as determining whether the 
individuals tested had prior exposure to these other species or not. Although the 
small number of clinical case samples do not give sufficient statistical power to 
assess either the duration of antibody responses to the panel of antigens or 
population-level exposure, the P. knowlesi clinical case samples represent a unique 
dataset with which to validate the immunogenicity of our antigen panel.  
The use of the boosted regression tree model was able to discriminate between P. 
knowlesi exposed and unexposed individuals for the purposes of classification of 
seropositivity rather than to assess individual-level risk factors. While this clinical 
dataset is sufficient for classification as exposed or unexposed, it is not sufficiently 
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large enough to stratify by age, gender or previously reported malaria status. In 
order for us to assess these types of risk factors, we first need to apply an approach 
(using known negatives, mixture or probability models) to classify antibody 
responses as seropositive or seronegative and then assess risk factors within the 
population, which we discuss later on. 
The panel of reagents developed for this study focussed on immunologically relevant 
orthologous targets previously described in P. falciparum. The serine repeat antigen 
(SERA) family had previously attracted attention as a source of both drug and 
vaccine candidates74. In P. falciparum, SERA 5 is the most abundant 
parasitophorous vacuole protein and is essential to blood stage growth of the 
parasite80, with antibodies against this antigen thought to inhibit parasite growth81. 
Although possessing a papain-like enzymatic domain, recent evidence suggests that 
the protein plays a non-enzymatic role80. SERA 3 has also been shown to be a 
highly immunogenic antigen with an important, although not essential role in the 
erythrocytic cycle84 and has also been implicated as having a role in liver stage 
merozoite release in P. berghei85. Similarly, evidence for the sporozoite surface 
protein 2 (SSP2) suggested an immunogenic antigen involved in protection from 
disease in mice73. Although we were unable to confirm active transcription of SSP2 
due to the lack of available material, we were able to validate active transcription of 
both the SERA3 and TSERA2 candidate genes. Collectively, the evidence provided 
by studies on Plasmodium supports the design of seroepidemiology tools based on 
these targets. Despite the targeted approach used in designing the recombinant 
constructs, the SERA3 antigen 2 construct was by far the most promising candidate. 
The differences in the performances of the antigens could be due to a number of 
factors: (1) variation in the inherent immunogenicity of the regions selected, (2) 
variations in the expression status of the P. knowlesi antigens compared to P. 
falciparum or (3) the loss of immunoreactive epitopes due to the truncation of the 
protein and potential loss of conformational epitopes.  
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There are a number of potential limitations of the serology study. The small sample 
size of the clinical samples used prevented detailed analysis of the samples, such as 
monitoring the impact of factors such as age, on the profile of reactivity to the 
reagents under test. In addition, the lack of repeated samples per individual (i.e. 
longitudinal samples) prevented us from investigating the longevity of antibody 
responses to each target, across individuals and age groups. The availability of 
supporting biological information on P. knowlesi, such as functional data, 
transcriptional or RNA seq data would have helped with the rational selection of 
additional candidates for further study and the design recombinant tools. This is the 
first study to describe the development a panel of P. knowlesi-specific serological 
tools using freely available in silico software. We have demonstrated the importance 
of targeting species-specific reagents at the amino acid level and highlighted the 
potential of such proteins as serosurveillance tools. Not only have we developed a 
novel panel of P. knowlesi species specific recombinant antigens, but we have been 
able to measure specific immune responses to these reagents and described the 
change in antibody profile following treatment. 
We tried optimising the Biomek robotic arm for the ELISA protocol as a high 
throughput serological platform to overcome the lack of reagents, as it would use the 
least reagent possible and test a higher number of samples per assay. Samples 
previously tested on a standard ELISA were used and rerun with the same antigens 
using the Biomek at least twice. We did not proceed to using this platform as an 
alternative as at first the results did not seem to correlate between platforms for the 
same reagents. The first and second runs did not seem to correlate very well, 
particularly for PfAMA-1. It is possible that there was a problem during run 1 using 
the Biomek where samples showed poor reactivity to the P. falciparum antigens and 
duplicates did not correlate. Maybe the samples, the secondary antibody or the TMB 
substrate were not properly mixed by the robotic pipetting arm, or the washing steps 
were not properly performed, potentially due to a blockage in the pipetting arm. More 
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runs would need to be done to determine if it was human error or a true difference 
between runs generally. More runs would need to be compared using different 
samples to determine if it was an issue with just that run or if there genuinely are 
different results for every re-run of the same samples and reagents. The preparation 
of reagents into the format required proved to be more time consuming and the lack 
of expertise with the software reduced the possibility of further optimising the 
platform for our use. Instead, we focused on using the standard ELISA protocol 
instead with the selected P. knowlesi antigens. 
The expanded panel of P. knowlesi antigens was developed and successfully 
expressed but were not run on the ELISA platform. Further analysis of these 
antigens is found in the next chapters, where we employ high throughput serology 
approaches such as the protein microarray to help identify additional important 
targets of immunity21,159.  
As such, we have already demonstrated the utility of the SERA3 antigen 2 reagents 
as a potential seroepidemiological tool and further validation of the SERA3 antigen 2 
at the population level has been performed.  Based on the clinical samples results, 
the PkSERA 3 antigen 2 recombinant was used to survey ~2500 samples across 
three site; Limbuak, Pulau Banggi and Matunggung, Kudat, Sabah, Malaysia and 
Bacungan, Palawan, the Philippines2. One of the key elements from this study using 
this reagent was the indication of community level patterns of exposure, with higher 
levels of exposure among individuals over 60 years of age2. P. knowlesi exposure 
was identified in children under 5 in all sites, which suggests transmission was 
recent or ongoing, although at a low level, and it was found to increase with age. 
Clinical P. knowlesi is commonly reported in adult men10,160, however, it was shown 
that men and women had similar antibody reactivity to P. knowlesi antigens in all 
sites. The main limitations of this study are the non-randomised population sampling 
approach and limited geographical scale. The results presented here highlight the 
utility of serological techniques to identify differences in transmission intensity in 
DEVELOPMENT OF PK SPECIES SPECIFIC REAGENTS TO CHARACTERISE ANTIBODY ISOTYPE PROFILES | LOU HERMAN  
 
124 | P a g e  
 
settings where the sensitivity of parasite prevalence surveys is limited by the scarcity 
of infected individuals and suboptimal diagnostics.  
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Chapter 5 : HIGH THROUGHPUT SEROLOGICAL SCREENING OF 
MALAYSIAN HOSPITAL CASE SAMPLES AND COMMUNITY 
SURVEY SAMPLES USING THE MULTIPLEX BEAD ASSAY   
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5.1. INTRODUCTION 
Serological methods have been especially developed over the years to detect 
antibodies towards Plasmodium spp. proteins, identifying infection and determining 
disease exposure over time1-7 and are now widely accepted. Routinely, the 
measurement of exposure to malaria in endemic populations is carried out using a 
small number of well characterised plasmodium antigens8-11. New tools are needed 
for close monitoring of malaria infection as it moves towards elimination in certain 
areas because submicroscopic infections are missed by routine microscopy 
diagnosis12-14, which can give false reassurance of elimination. Appropriate P. 
knowlesi detection tools in serology have long been overdue and, as discussed in 
chapter 4, we have now developed and made available a panel of P. knowlesi 
specific antigenic markers of exposure for further characterisation of this organism 
and the human host immune response to it15. Novel proteins are being identified at 
an increasing rate16-23 and developing a platform appropriate to screen such a large 
number of targets has become essential in order to obtain a better understanding of 
host-pathogen interactions and antibody-mediated immunity towards pathogens, in 
this case, malaria. Antibody-based detection assays such as ELISA and Western 
blot for example, in general, require large quantities of reagents and serum samples, 
the latter being the most difficult to overcome in particular settings where samples 
are finite, and these platforms can only look at very few antigens at a time. There 
has been a technological shift towards multiplex platforms in the current market in 
order to meet this need of detecting multiple targets in a single sample. 
Cytometric Bead Assay, also known as multiplex bead assay (MBA)24-26 or bead 
suspension assay, is one assay that can be used as a multiplex platform for malaria 
serology. The MBA is a flow cytometry application that uses microspheres (beads) 
that are uniquely identified by fluorescent dyes and differentiated based on specific 
spectral addresses which can be recognized by wavelength differences27,28. 
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Internally dyed or different sized29 microspheres are distinguished by light scatter 
characteristics and are also detected by phycoerythrin(PE)-labelled anti-human 
antibodies, therefore different bead sets can be measured alongside immunoassay 
signals30. These microspheres can be coupled to a multitude of different reagents 
(Figure 5.1). 
 
Figure 5.1 Multiplex bead assay range of applications.  Beads can be covalently coupled to: (a) Protein; (b) 
monoclonal or polyclonal antibodies; (c) viruses, (d) bacterial cell wall components; (e) DNA from virus/bacteria; 
and (f) chemicals/drugs. Coupled beads can then be detected using phycoerythrin-labelled detection agents 
such as fluorescent antibodies or streptavidin. Image from a published source30. 
 
In this case, beads can be coupled to recombinant malarial protein antigens, 
combined to screen multiple antigens on a small amount of plasma, and then 
individually identified by their specific spectral address (Figure 5.2). This technology 
is a sound replacement to the ELISA method when testing multiple targets on small 
amounts of serum and it has been reported to have a better reproducibility, better 
and larger dynamic range and to give comparable results to the ELISA platform31-35. 
Some of the advantages to replacing the ELISA platform with a bead-based assay 
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are the high throughput aspect of this platform, the need for fewer reagents and 
reduced sample volume and the ability to analyse a target in the context of multiple 
others, all under the same experimental conditions36. With this technology it is 
possible to quantify up to 500 analytes in a single well per sample using as little as 5 
µl of serum37,38. With this platform being increasingly used, it is now an affordable 
mid-high throughput multiplexing platform. 
 
Figure 5.2 Schematic representation of a sandwich-based Luminex assay. Targets are measured by the Luminex 
xMAP technology using light-emitting diodes (LEDs) or lasers. Typically up to 30 targets can be measured 
simultaneously. The coupled beads are dispensed into an assay plate before sample addition, then a detection 
antibody is added. The beads are then individually excited by the appropriate laser (top panels), in the case of 
the LX200 and FLEXMAP 3D instruments, or the different LEDs which are then detected by the CCD imager 
(bottom panels), in the case of MAGPIX instrument, and results saved. Figure from ThermoFisher Scientific 
(https://tinyurl.com/yauzl9c7). 
 
This technology can be used in multiple ways, for example in vaccine development39 
or pathogen characterisation40-42 (Figure 5.1). It has been developed for detecting 
antibodies towards multiple pathogens causing diseases such as Meningitis31, 
Tetanus33, Diphtheria33, Influenza33, Toxoplasmosis43-45, and now, Malaria46-50 as 
well, a field where this method is gradually taking ground. Not only can the MBA 
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platform be used in immunoassays measuring antibodies41,47,51 and cytokines52-54, 
but also in nucleic acid assays55-58, making it a versatile high throughput technology. 
This chapter describes the analysis of serum samples from Malaysian clinical cases 
used in the previous chapter on the MBA platform using P. knowlesi-specific 
recombinant antigens.   
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5.2. METHODS 
5.2.1. Coupling of recombinant proteins to MicroPlex microspheres for 
multiplex bead assay analysis 
The antigen coupling protocol was modified from a method previously described by 
Ondigo et. al.59. The appropriate antigen concentrations were determined and 
optimised by a coupling titration assay, where the antigens were coupled to beads in 
a range of concentrations (i.e. 0.015, 0.12, 0.94, 7.5, 60 and 480 μg/ml) and the 
results plotted to determine the ideal coupling concentration per antigen. Tom Hall 
helped to perform this part of the experiment. Briefly, for coupling a whole 
MicroPlex® bead stock (1 ml of beads at 12.5x106/ml concentration), beads were 
both vortexed and sonicated for 60 seconds to homogenise the suspension and 
avoid clumps of beads, placed on a magnetic rack before being washed with 500 μl 
mili-Q water and, after being removed from the magnetic rack, resuspended in 400 
μl 100 mM monobasic Sodium Phosphate buffer (Sigma-Aldrich), pH 6.2 (activation 
buffer). To activate the beads for chemical coupling of the antigen, 50 μl of 50 mg/ml 
Sulfo-NHS (N-Hydroxysulfosuccinimide sodium salt) (Sigma-Aldrich) and 50 μl 50 
mg/ml EDC (N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride) (Sigma-
Aldrich) were added sequentially, vortexing after each addition. The bead 
suspensions were incubated at RT and vortexed moderately for 10 seconds at both 
10 and 20 minutes during the incubation period. The activated beads were briefly 
spun in a minifuge to pellet beads, placed in a magnetic rack for 1 minute and the 
supernatant removed. Beads were washed three times in 500 μl 1x PBS/T (Oxoid) to 
remove the activation buffer. After the final wash, the activated beads were coated 
with antigen by resuspension in 1 ml of the relevant antigen previously diluted in 1x 
PBS solution, at the appropriate concentration. They were then incubated at RT for 2 
hours away from light on a tube rotator. After incubation, the beads were centrifuged; 
the supernatant removed, and washed three times with 500 μl Buffer A (1x PBS, 
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0.5% BSA, 0.05%Tween, 0.02% sodium azide). After the final wash, coupled beads 
were pelleted and resuspended in 1000 μl Buffer A with 0.02% Pefabloc (Sigma-
Aldrich) (storage buffer) and counted on a haemocytometer (NanoEnTek) to 
determine the percentage bead recovery. Coated beads were stored at 4ºC until 
required.  
5.2.2. Measuring total IgG responses to antigen coupled microsphere beads 
using the MagPix (Luminex) suspension bead array   
Antigen coupled bead stocks were combined and diluted into buffer A to make a 20 
microspheres/μl solution. 50 μl of the microsphere mixture was transferred to each 
well of a 96-well Bioplex pro microtiter plate (Bio-Rad); this resulted in 1000 
beads/region/well. Each bead set has a specific spectral address making it possible 
to track each coupled antigen despite using a single secondary antibody reagent. 
The beads were washed once by magnetically pelleting the beads, vigorously 
dispensing the waste liquid into a sink and adding 100 μl of PBS/T. The previous 
day, serum samples and controls were diluted 1/400 in buffer B (0.1% casein, 0.5% 
PVA (Poly(vinyl alcohol)), 0.5% PVP (Polyvinylpyrrolidone) and E. coli extract at 
15.25 μg/ml in buffer A, with the liquid plastic solutions of PVA and PVP used to 
prevent non-specific binding to the beads), 50 μl were added to the plate containing 
beads in singlet for serum samples and in duplicate for controls, and incubated for 1 
hour and 30 minutes at RT in the dark on a microplate shaker set to 700 rpm. 
The P. knowlesi-negative control samples used were based on a hyper-immune 
endemic Tanzanian pool (P. falciparum)60, lyophilised WHO Reference Reagent for 
anti-malaria human serum (NIBSC, UK; 10/198 (P. falciparum)), lyophilised non 
WHO reference material for anti-malaria human plasma (NIBSC, UK; 72/096 (P. 
vivax)) and the malaria naïve negative control samples used were a pool of Public 
Health England (PHE; LSHTM ethics approval #11684) serum samples. Plates were 
washed three times using 100 μl of 1x PBS/T as described above and 50 μl of goat 
anti-human IgG (gamma- chain specific, F(ab`)2 fragment-R-phycoerythrin (Jackson 
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immunoResearch) secondary antibody diluted 1/200 in buffer A was added to each 
well. The plates were incubated for 1 hour and 30 minutes as above. Plates were 
washed three times as previously, 50 μl of buffer A was added to all wells and the 
plates were incubated for 30 minutes at RT in the dark on a microplate shaker set to 
700 rpm. Plates were washed once using 100 μl of 1x PBS/T, the beads were 
resuspended in 100 μl of 1x PBS and analysed on the MAGPIX® reader (Luminex 
corp, USA). The results were expressed as median fluorescent intensity (MFI).  
5.2.3. STATISTICAL ANALYSIS 
Final net median fluorescent intensity (MFI) was obtained by subtracting background 
MFI values, reducing background reactivity. Cut off values were defined separately 
for each antigen, Plasmodium spp. and relevant study.  Although 37 bead sets were 
used to screen these samples, only up to 5 bead sets were analysed for the purpose 
of this chapter: two antigens from the P. knowlesi panel (PkSERA3 antigen 2 and 
PkSSP2 as these were the most reactive candidates from the panel at the time) 
alongside the relevant control antigens (PvMSP1-19, PvAMA1 and PfMSP1-19). For 
the hospital-based clinical treatment trial samples, seropositivity cut offs were 
calculated based on Public Health England negative control sera samples (average 
MFI ± (3xSD)). The seropositivity cut offs were based on the following values: 
PkSERA3 ag2=4318.31; PkSSP2/TRAP=2126.35 and PvMSP1-19=729.5. To define 
seropositive individuals in the Sabah cross sectional survey, mixture models were fit 
for normalised MFI. Cut off values to define antigen seropositivity for P. vivax and P. 
falciparum were defined as the mean MFI of the seronegative population plus 3 
standard deviations. For a more parsimonious cut off value for P. knowlesi, 
seropositivity cut offs were defined as the mean MFI of the seronegative population 
plus 5 standard deviations. The seropositivity cut offs were based on the following 
values: PkSERA3 ag2=892.93; PkSSP2=929.35; PvMSP1-19=602.05, 
PvAMA1=147.8 and PfMSP1-19=466.9. Risk factors associated with P. knowlesi 
seropositivity were evaluated using multivariate logistic regression. Analysis and 
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graphic representation of serological data was carried out using PRISM (GraphPad 
PRISM 7) and STATA/IC 14.2 (StataCorp. 2015. Stata Statistical Software: Release 
14. College Station, TX: StataCorp LP.). 
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5.3. RESULTS 
5.3.1. CLINICAL SAMPLE SERUM REACTIVITY TO P. KNOWLESI-SPECIFIC RECOMBINANT 
ANTIGENS USING THE CYTOMETRIC BEAD ASSAY PLATFORM 
The Luminex assay used the full set of Malaysian serum and bloodspot samples 
collected from adults and children hospitalised with malaria at different time-points 
(day 0, 7 and 28, as well as 1 and 2 year follow up; Table 3.1; chapter 3, section 3.3) 
post-treatment, as described above but including P. vivax (n=36), P. falciparum 
(n=16) and P. malariae (n=1) as well as P. knowlesi (n=110) diagnosed individuals. 
The experimental strategy for this chapter is outlined in Table 5.1, showing the 
identification of the target sequences of interest and, highlighted in green, the test 
samples used. 
All samples were assayed using the full Luminex bead panel (37 bead sets), 
including two antigens from the panel of P. knowlesi-specific proteins (PkSERA3 
antigen 2 and PkSSP2) (Table 4.3; chapter 4, section 4.2.1.) alongside PvMSP1-19 
as a control antigen. For the purpose of this thesis, we only analysed the P. knowlesi 
antigens alongside relevant control antigens. Although we only show preliminary 
analysis of this here using only the P. knowlesi antigens, the full panel was included 
for the full epidemiological analysis of the Sabah cross sectional survey (unpublished 
data). The 2 year follow up analysis was not included here due to a very low number 
of samples being available (n=3). 
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Figure 5.3 Flowchart summarising the experimental strategy used in the identification and validation of the P. knowlesi-specific candidates and sample sets used in this chapter. Test 
samples were obtained from a cross sectional survey (n=10,118) and from a hospital-based clinical treatment trial (n=164), both in Sabah, Malaysia. The negative controls comprised of 
samples from an Easy Access Group (EAG) in Ethiopia as P. vivax-positive P. knowlesi-negative samples (n=40) and the malaria-naïve group were obtained from Public Health England (n=18). 
Cross sectional survey samples and the clinical samples were tested on the Luminex cytometric bead assay platform alongside the P. knowlesi-negative controls. Highlighted in green are the 
sections relevant to this chapter.
DEVELOPMENT OF PK SPECIES SPECIFIC REAGENTS TO CHARACTERISE ANTIBODY ISOTYPE PROFILES | LOU HERMAN 
 
146 | P a g e  
 
Similar to the ELISA results, day 7 showed the highest antibody reactivity in P. 
knowlesi diagnosed individuals to both antigens with PkSERA3 antigen 2 showing 
the highest prevalence, 57.9% (44/76) (Table 5.1; Figure 5.4). P. falciparum 
diagnosed individuals showed the highest prevalence for PkSERA3 antigen 2 at day 
0, 66.7% (10/15). P. vivax diagnosed individuals showed the highest prevalence for 
PkSERA3 antigen 2 at day 7, 100% (30/30) and appeared to track with the P. 
knowlesi diagnosed individuals. Because these were clinical samples from regions 
where both P. vivax and P. falciparum are also endemic alongside P. knowlesi, there 
is no way of guaranteeing that these individuals had not been previously infected 
with other Plasmodium spp., therefore we may see P. knowlesi antigen reactivity in 
individuals diagnosed with non-P. knowlesi species. Although there were fewer 
samples, individuals that were followed up 1 year later showed much lower reactivity 
towards the P. knowlesi antigens compared to the previous time points (Table 5.1; 
Figure 5.4). From all individuals tested, independently of diagnostic status, 
PkSERA3 antigen 2 showed the highest prevalence at day 7, with 66.7% (80/120) of 
individuals above the cut off value (Table 5.1; Figure 5.4). Detectable antibody 
reactivity to the P. knowlesi-specific antigens was largely absent in the Ethiopian 
samples to both P. knowlesi antigens, with 82.5% (33/40) and 77.5% (31/40) of 
individuals non-reactive to PkSSP2 and PkSERA3 antigen 2, respectively (Figure 
5.4).
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Table 5.1 Hospital case sample seropositivity by day, antigen tested and diagnostic status. 
Data is presented as number of people seropositive and percentages in parenthesis. Seropositivity was calculated based on Public Health England negative control sera samples (average net 
MFI ± (3xSD)). Seropositivity (pos) cut offs for the P. knowlesi antigens (ags) were based on the following values: PkSERA3 ag2=4318.31 and PkSSP2/TRAP=2126.35. 
         
  Day 0 Day 7 Day 28 Year 1 
 n=154 n=120 n=120 n=46 
 Pk n=102 Pk n=76 Pk n=80 Pk n=37 
 Pf n=15 Pf n=14 Pf n=13 Pf n=3 
 Pv n=35 Pv n=30 Pv n=27 Pv n=5 
  SSP2/TRAP SERA3 ag2 SSP2/TRAP SERA3 ag2 SSP2/TRAP SERA3 ag2 SSP2/TRAP SERA3 ag2 
Total pos (%) 47 (30.52) 69 (44.81) 74 (61.67) 80 (66.67) 48 (40) 69 (57.5) 3 (6.52) 4 (8.7) 
Pk diagnosed (%) 24 (23.53) 32 (31.37) 43 (56.58) 44 (57.89) 31 (38.75) 40 (50) 1 (2.7) 3 (8.11) 
Pf diagnosed (%) 9 (60) 10 (66.67) 10 (71.43)  6 (42.86) 5 (38.46) 5 (38.46) 1 (33.33) 0 (0) 
Pv diagnosed (%) 14 (40) 27 (77.14) 21 (70) 30 (100) 12 (44.44) 24 (88.89) 1 (20) 1 (20) 
Total Pk ag pos (%) 84 (54.54) 103 (85.83) 90 (75) 6 (13.04) 
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Figure 5.4 Endemic and P. knowlesi-negative sera reactivity to Plasmodium knowlesi-specific antigens. Scatter 
plots showing sera reactivity to: P. vivax MSP1-19 with P. knowlesi SERA3 ag2 (column 1) and SSP2/TRAP 
(column 2) antigens. Sera samples from P. knowlesi negative controls n=58 (row 1; PHE UK malaria naïve (grey 
squares), Ethiopian children (black triangles)) and Malaysian hospital case sera samples from days 0 (Pk n=102; 
Pv n=35; Pf n=15), 7 (Pk n=76; Pv n=30; Pf n=14), 28 (Pk n=80; Pv n=27; Pf n=13) and year 1 (Pk n=37; Pv n=5; Pf 
n=3) of diagnosis (rows 2±5, respectively). Results were divided by diagnostic status of individuals with P. 
knowlesi diagnosed samples represented as grey circles, P. falciparum as black circles and P. vivax as clear 
circles. The vertical red line in each graph represents the cut off values for seropositivity to the respective P. 
knowlesi antigen and was calculated based on Public Health England negative control sera samples (average MFI 
± (3xSD)). The horizontal cut off line for the P. vivax antigen is based on PvMSP1-19=729.5. The vertical cut off 
line for the P. knowlesi antigens were based on the following values: PkSERA3 ag2=4318.31 and 
PkSSP2/TRAP=2126.35. 
 
Since these samples had been previously tested using the ELISA method, we used 
this opportunity to compare the results between the two platforms to evaluate 
reproducibility and sensitivity. We compared only the samples that had been tested 
on both platforms (total n=144; P. knowlesi n=97; P. vivax n=31; P. falciparum 
n=16). The Luminex platform showed more sensitivity compared to the ELISA 
platform, especially PkSSP2 reactivity (Figure 5.5). Luminex as the more sensitive 
assay might explain what is seen in the P. knowlesi-negative controls reactivity 
towards the P. knowlesi antigens (Figure 5.5). 
A small number of the total samples tested on the Luminex platform that were 
collected as serum samples were also collected as blood spot samples (n=26), 
making it possible to compare the different types of samples in terms of reactivity. 
The serum samples clearly showed stronger reactivity profiles compared to the BS 
samples (Figure 5.6). The BS samples had been collected on different, thinner, filter 
paper instead of the usual thicker type (3MM, Whatman, UK), as described 
previously (chapter 2, section 2.7.4.), which likely explains why these were so poor 
in comparison to serum. The technique is reliable when samples are collected in the 
appropriate manner as previously described by Corran et. al.61. Figure 5.7 is an 
example of this analysis using a higher number of samples. 
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Figure 5.5 Analysis of endemic and P. knowlesi-negative sera reactivity to Plasmodium knowlesi-specific 
antigens using the Luminex and ELISA platforms. Scatter plots show sera reactivity between the Luminex (y axis 
as net MFI) and ELISA (x axis as OD (450 nm)) platforms towards: PvMSP1-19 (column 1), PkSERA3 ag2 (column 
2) and PkSSP2/TRAP (column 3) antigens. Sera samples plotted were from P. knowlesi negative controls n=40 
(row 1; Ethiopian children shown as black triangles) and from Malaysian hospital case sera samples from days 0 
(Pk n=92; Pv n=31; Pf n=14), 7 (Pk n=72; Pv n=28; Pf n=14) and 28 (Pk n=77; Pv n=27; Pf n=13) of diagnosis (rows 
2±4, respectively). Results were divided by diagnostic status of individuals with P. knowlesi diagnosed samples 
represented as grey circles, P. falciparum as black circles and P. vivax as clear circles. Trendline values for R2  are 
indicated on each plot. 
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Figure 5.6 Analysis of bloodspot and serum sample reactivity differences to Plasmodium knowlesi-specific antigens. Scatter plots show sera reactivity between bloodspot (y axis as net MFI) 
and serum (x axis as net MFI) samples towards: PvMSP1-19 (column 1), PkSERA3 ag2 (column 2) and PkSSP2/TRAP (column 3) antigens. Sera samples plotted were from Malaysian hospital 
case samples from day 0 (Pk n=24; Pv n=1; Pf n=1) of diagnosis. 
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Figure 5.7 Example analysis of bloodspot and serum sample reactivity differences to a Plasmodium-specific 
antigen. Scatter plots show sera reactivity between bloodspot (x axis as net MFI) and serum (y axis as net MFI) 
samples towards a plasmodium antigen. This plot was used with the permission of Lotus van Den Hoogen as an 
example comparing bloodspots and serum for a larger sample set. 
 
5.3.2. SABAH COMMUNITY CROSS SECTIONAL SURVEY REACTIVITY TO P. KNOWLESI-
SPECIFIC RECOMBINANT ANTIGENS USING THE CYTOMETRIC BEAD ASSAY 
PLATFORM  
As with the clinical samples, the Luminex assay was used to screen community 
samples from a cross sectional survey in Sabah, Malaysia (n=10,118; Figure 5.3). 
The median age of participants was 25 years (age range 2 months - 105 years) and 
similar proportions of men and women were sampled. Reactivity was seen towards 
both P. knowlesi antigens included in the 37-strong antigen panel, PkSERA3 antigen 
2 and PkSSP2 (Figure 5.8).  
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Figure 5.8 Sera reactivity to PkSERA3 antigen 2 and PkSSP2 in the endemic population of Sabah, Malaysia. 
Scatter plots showing population (n=10,118) sera reactivity to P. vivax MSP1-19 with P. knowlesi SERA3 ag2 (A) 
and SSP2 (B). The red lines in each graph represent the cut off values for the P. knowlesi and P. vivax antigens 
and were calculated based on the negative population (P. knowlesi: average net MFI ± (5xSD); P. vivax: average 
net MFI ± (5xSD)): The vertical cut off lines are based on PkSERA3 ag2=892.93 and PkSSP2=929.35. The 
horizontal cut off line is based on PvMSP1-19=602.05. 
 
PkAMA1 had been excluded from our P. knowlesi antigen panel due to high amino 
acid sequence homology with P. vivax AMA1 (85%; Table 3.1; chapter 3, section 
3.1), therefore we did not clone nor express this antigen. However, Dr Bart Faber 
(Biomedical Primate Research Centre (BPRC), The Netherlands) kindly donated 
PkAMA1 antigen for use in the Luminex panel. We used this opportunity to look at 
the reactivity correlations between PkAMA1 and PvAMA1, which showed evidence 
of some correlation (R2= 0.5650; Figure 5.9). From all samples surveyed, 31% 
(3139/10125) of the total population were seropositive for P. knowlesi SERA3 
antigen 2, 12.7% (1286/10124) for SSP2 and 23.09% (2330/10092) for P. vivax 
MSP1-19 (Figure 5.8). For both P. knowlesi antigens combined, 37.8% 
(3,827/10,125) of the population were seropositive.
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Figure 5.9 Sera reactivity to 
PkSERA3 antigen 2, PkSSP2 
and PkAMA1 in the 
endemic population of 
Sabah, Malaysia. Scatter 
plots showing population 
(n=10,118) sera reactivity to 
P. vivax AMA1 with P. 
knowlesi SERA3 ag2 (A), 
SSP2 (B) and AMA1 (C). The 
red lines in each graph 
represent the cut off values 
for the P. knowlesi and P. 
vivax antigens and were 
calculated based on the 
negative population (P. 
knowlesi: average net MFI ± 
(5xSD); P. vivax: average net 
MFI ± (5xSD)): The vertical 
and horizontal cut off lines 
are based on PkSERA3 
ag2=892.93; PkSSP2=929.35 
and PkAMA1=2104.63. The 
horizontal cut off line is 
based on PvAMA1=147.8.
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A similar proportion of men and women seropositive to any P. knowlesi antigen 
(47.24% (1,808/3,827); 52.65% (2,015/3,827) respectively; Figure 5.10). There was 
no significant association between sex and P. knowlesi malaria seropositivity (OR 
(odds ratio): 1.00, 95% CI: 0.92±1.09, p=0.92). 
 
Figure 5.10 Sera reactivity in men and women to PkSERA3 antigen 2 and PkSSP2 in the endemic population of 
Sabah, Malaysia. Plots showing population (n=10,118) sera reactivity in men and women to P. knowlesi SERA3 
ag2 (A) and SSP2 (B). Samples without sex information were labelled as not applicable (N/A). The red lines in 
each graph represent the cut off values for the P. knowlesi antigens and were calculated based on the negative 
population (average net MFI ± (5xSD)): The horizontal cut off lines are based on PkSERA3 ag2=892.93 and 
PkSSP2=929.35. Risk factors were determined by multivariate logistic regression using STATA. 
 
Antibody reactivity to PkSERA3 antigen 2 was detected in 2.3% (72/3,128) of 
individuals under 5 years of age and 23.27% (728/3,128) in individuals aged over 55 
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years (Figure 5.11 A), though the highest reactivity was found in individuals between 
30-54 (36.22%; 1,133/3,128). Antibody reactivity to PkSSP2 was detected in 2.73% 
(35/1,284) of individuals under 5 years of age and 27.10% (348/1,284) in individuals 
aged over 55 years (Figure 5.11 B), though the highest reactivity was found in 
individuals between 30-54 (37.69%; 484/1,284). Age was found to be associated 
with P. knowlesi malaria seropositivity (p<0.0001). 
 
Figure 5.11 Sera reactivity by age groups in the endemic population of Sabah, Malaysia. Plots showing 
population (n=10,118) sera reactivity to PkSERA3 ag2 (A), PkSSP2 (B), PvMSP1-19 (C) and PfMSP1-19 (D). The red 
lines in each graph represent the cut off values for the P. knowlesi antigens and were calculated based on the 
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negative population (average net MFI ± (5xSD)): The horizontal cut off lines are based on PkSERA3 ag2=892.93 
and PkSSP2=929.35. Risk factors were determined by multivariate logistic regression using STATA. 
 
Of the population that had responded positively to having slept in the forest, 29.41% 
(10/34) and 20% (4/20) were seropositive to P. knowlesi SERA3 antigen 2 and 
SSP2, respectively (Figure 5.12 A and B). P. vivax MSP1-19 had 41.38 % (12/29) 
people responding yes and P. falciparum 28.21% (11/39; Figure 5.12 C and D, 
respectively). It was not possible to determine associations with seropositivity due to 
the low number of individuals reporting (n=80). People were also questioned about 
having seen macaques or not during their daily routine. A significant association was 
observed between seeing macaques and P. knowlesi seropositivity (P<0.0001). 
 
Figure 5.12 Sera reactivity in the endemic population of Sabah, Malaysia, by questionnaire responses towards 
having slept in the forest or not. Plots show sera reactivity to PkSERA3 ag2 (A), PkSSP2 (B), PvMSP1-19 (C) and 
PfMSP1-19 (D). Individuals questioned reported not having slept in the forest (N) or having slept in the forest (Y). 
The red lines in each graph represent the cut off values for the P. knowlesi, P. vivax and P. falciparum antigens 
and were calculated based on the negative population (P. knowlesi: average net MFI ± (5xSD); P. vivax and P. 
falciparum: average net MFI ± (5xSD)): The horizontal cut off lines are based on PkSERA3 ag2=892.93; 
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PkSSP2=929.35; PvMSP1-19=602.05 and PfMSP1-19=466.9. Risk factors were determined by multivariate logistic 
regression using STATA. 
 
5.4. DISCUSSION 
The results presented here provide important insights in the use of mid-high 
throughput technology in P. knowlesi serology. We have shown for the first time 
proof of principle that multiplexing of P. knowlesi antigens can be used for 
serological assessment of human samples on a MBA platform. 
We found that PkSERA3 antigen 2 was the most highly reactive antigen, which 
agreed with ELISA results. This was observed in both clinical and community 
samples. Here, we describe the kinetics of what is potentially a short-term marker of 
exposure, which would be useful to determine recent infection in the population. The 
development of such tools would help to answer questions relating to population 
exposure and our understanding of the geographical boundaries of infection. 
Protein-based approaches have been developed in order to determine the presence 
and functionality of proteins using high throughout platforms62-64. 
Interest in high throughput multiplex technology is rapidly increasing, particularly in 
the serology field. With the help of MBA technology we can now detect multiple 
targets simultaneously in a single sample while utilising the least reagent possible.  
This will enable us to analyse targets in the context of multiple other targets, giving 
us a better overview of how these might affect how the immune system responds to 
pathogens. 
From the full panel of P. knowlesi antigens, only two were selected for the MBA 
alongside 35 other antigens from other malaria species and pathogens, as these 
had shown the most promising results by ELISA (Chapter 4). There were difficulties 
in optimising the remaining P. knowlesi antigens for use on the MBA platform due to 
insufficient controls. 
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The MBA platform was shown to be more sensitive than the ELISA (Figure 5.5) in 
detecting antibody reactivity towards Plasmodium spp. antigens, with more samples 
showing higher reactivity on the MBA than the ELISA. This indicates that the MBA 
could potentially be a better platform to analyse samples from areas where 
submicroscopic malaria can be missed. Although the data presented here fits with 
the geographic distribution of P. knowlesi, the P. knowlesi-specific antigens SERA3 
antigen 2 and SSP2 showed some level of cross-reactivity in the control samples 
from Ethiopian school children, although reasonably low (Figure 5.4). This had not 
been observed on the ELISA platform, which again indicates the higher sensitivity of 
the MBA platform. One of the reasons for this could be due to the less stringent cut 
off (mean+[3xSD]) used for the analysis of the MBA results, as was done for the 
initial ELISA analysis (mean+[3xSD])15. A more stringent analysis (mean+[5xSD]) 
could be applied due to the lack of prior data on P. knowlesi reactivity analysis, as 
was done on the small community survey study65. It is possible that mimetopes are 
prevalent in the Ethiopian sample set and that serum antibodies specific to these 
mimetopes are reacting to the P. knowlesi recombinant antigens. Mimetopes are 
peptide sequences that mimic the immunological response from an antigen’s 
epitope, although not sequence homologous.  In order to verify this, it would be 
necessary to dissect the antigens where we see this reactivity by creating 
overlapping short sequences, or tiled epitopes, and screening each of these against 
the specific reactive individuals, identifying the epitope potentially eliciting this 
response. Another reason could be that the low homology that was found between 
the sequences of these candidate antigens and P. vivax (identities: SERA3 antigen 
1 23/58 (40%); SSP2 fragment 40/93 (43%)) is in fact enough to cause some cross-
reactivity to be seen in a P. knowlesi non-endemic setting (Table 4.1, chapter 4, 
section 4.2.1). A larger number of a more diverse non-endemic sample set would be 
needed to better understand what was observed here. The MBA data has shown 
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that specific tools for P. vivax and P. falciparum need to be developed for population 
studies where these are co-endemic with, in this case, P. knowlesi, as this would 
have helped in ensuring specificity. The lack of appropriate endemic negative 
controls was a limitation to the clinical study. 
In the large Sabah community survey P. knowlesi seroprevalence was higher than P. 
vivax seroprevalence. P. knowlesi risk was associated with an increase in age as 
well as having seen macaques during an individual’s normal routine. Although a 
preliminary analysis was presented in this chapter, extensive epidemiological 
analysis of this cross-sectional survey is needed to identify ecological and 
behavioural risk factors across a broader geographic scale. 
ELISA data has previously shown that IgG reactivity towards PkSERA3 ag2 
decreases slightly by day 28 (reference15 and chapter 4), as was shown by MBA 
analysis, with barely any reactivity by 1 year post-diagnosis (Figure 5.4). For a more 
in-depth analysis of antigens across time, more time points would be required to be 
collected and analysed for each individual in order to have a better idea of the 
antigen kinetics and the potential associations with protection for instance. Studies 
have shown that IgG antibodies against P. falciparum antigens are important for the 
development of clinical immunity66,67, something that could potentially be seen for P. 
knowlesi infections in endemic populations. Larger sample sets from endemic 
regions would need to be screened for isotype reactivity in order to determine if 
these or other correlations exist for P. knowlesi as well. There has been much 
interest in recent years in trying to establish whether serological markers after 
challenge can be useful predictors of protection particularly in the field of 
vaccinology68. The relationship between antibody titres and protection is currently 
not quite clear. 
In future, it will be necessary to determine bead stability for each antigen under 
different transport and storage conditions and antigen-specific kinetics in different 
endemic settings will also need to be considered when using this platform. Standard 
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methods to determine seropositive cut off thresholds for novel antigens will also 
need to be established, ensuring reproducibility and comparability.  
Here we have shown the application of high throughput MBA technology in the 
serological screening of P. knowlesi endemic populations, both at the clinical and the 
community level. The application of this method in epidemiological analysis will not 
only reduce the need of high sample volumes when it is hard to obtain, but will also 
enable the measurement of all analytes deemed important in a single assay, 
reducing time and costs.  
This only marks the beginning of what these advancements will enable us to do, 
such as screening for reactivity patterns towards drug treatments and vaccines, 
potentially making it possible to produce personalised drugs, vaccines and 
treatments targeted towards certain populations or subsets, specific age groups, 
genders.  
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Chapter 6 : HIGH THROUGHPUT SEROLOGICAL PROFILING OF 
ANTIBODY ISOTYPES IN MALAYSIAN HOSPITAL CASE 
SAMPLES USING A BESPOKE PROTEIN MICROARRAY 
PLATFORM    
DEVELOPMENT OF PK SPECIES SPECIFIC REAGENTS TO CHARACTERISE ANTIBODY ISOTYPE PROFILES | LOU HERMAN 
 
168 | P a g e  
 
6.1. INTRODUCTION 
Over the years, the detection of antibodies towards Plasmodium spp. has been 
performed using especially developed serological methods in order to determine 
disease exposure over time1-7. These methods are currently widely accepted, 
however, focus has been on P. falciparum and P. vivax parasites, mainly looking at 
total IgG antibodies4,7-12.  Currently there is a lack of data regarding IgM and IgA 
isotype responses in malaria research, particularly for P. knowlesi. Antibody and 
isotype data is important to characterise the human host immune response towards 
malarial infection and to make important associations of risk and protection. 
IgG antibody responses to malaria infection have been extensively studied by a 
multitude of research groups5,13-17, establishing that reactivity towards this isotype is 
associated with protection against malaria. In a longitudinal clinical and 
parasitological study in Myanmar, protection against clinical P. falciparum malaria 
infection was found to correlate with the level of IgG3 responses elicited by PfMSP3 
and PfGLURP (Glutamate Rich Protein), whilst IgG4 antibodies increased in number 
with every malaria attack13, with an attack being defined as elevated temperature 
with high parasitemia compared to asymptomatic individuals and separated by >72 
hours. Similar results had been seen in Senegal14, Burkina Faso17 and more recently 
in Ghana15,16, suggesting that IgG subclass responses to PfGLURP potentially 
promote a moderate development of protection in endemic areas in Asia and Africa. 
It was demonstrated by Osier et. al.5 that high levels of naturally acquired IgG 
antibodies to P. falciparum AMA1, MSP1 block 2, MSP2 and MSP3 antigens in 
Kenyan children were related to the decreased probability of developing malaria5. 
Osier et. al.5 also showed that malaria risk was inversely associated with a high 
number of antigen targets recognised by antibodies. It has also been possible to 
determine recent and historic exposure6,7,18 to malaria through the measurement of 
IgG reactivity, as well as transmission intensity9,19-22 and age associations2,22,23 such 
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as the increase of antibody responses with age6. The measurement of antibodies 
can be used as proxies for these other measurements, acting as biomarkers of 
malaria exposure. 
Although less extensively studied, IgM was also found to be associated with clinical 
immunity to malaria infection. Using standardised Afro-Immuno Assay (AIA) network 
ELISA procedures17,24, it was found that IgM and IgG antibody responses to 
PfMSP1-19 and PfMSP3 were associated with protection to malaria in Ghanaian 
children24. Similar IgG responses were seen in children from Burkina Faso which 
were associated with reduced risk of malaria as well as age, indicating cumulative 
exposure over time17. The AIA network is a project that has developed 
immunoassays which ensure that the reagents, protocols and statistical methods 
used to assess associations with protection are the same, making these types of 
studies more comparable17,24. Studies have also looked at IgM response differences 
between different ethnic groups in Mali, enabling distinction of these groups from 
one another based on these responses25,26. IgM responses were significantly higher 
in the Fulani people compared to the Dogon25,26. It was suggested that host genetic 
polymorphisms yielding stronger IgM responses in certain ethnic groups was the 
result of selective pressure due to malaria. Antibody isotype and subclass responses 
to malaria infection were shown to be genetically regulated, with some isotypes 
shown to have higher heritability than others in children27, making it possible to 
eventually identify the genes responsible for up or downregulating certain isotypes. 
Overall, IgG is regarded as one of the most important isotypes when it comes to 
protective immunity towards malaria infection, but recently IgM has shown increasing 
significance and interest.    
In contrast to IgG and IgM, IgA is one of the least studied isotypes in the field of 
malaria, with most information coming from malaria-caused nephropathy cases28,29. 
One of the complications in P. falciparum infections is acute renal failure30, with 
glomerulopathy being a less common form of renal failure29,31. The most common 
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form of glomerulonephritis is IgA nephropathy, associated with glomerular IgA1 
subclass deposits32,33, suggested to be caused by aberrantly glycosylated polymeric 
IgA1 complexes34. 
There have been few non-nephropathy related studies. One study showed that IgA 
responses appear to follow IgM and IgG responses35. Another looked at PfMSP1-19-
specific recombinant IgA activity in vitro and in vivo, showing that these recognised 
parasites in infected RBC in vitro, although protection was not observed in human 
FcαRI transgenic mice36 (specific cell surface receptor which binds to Fc region of 
specific antibodies). A similar study showed that IgG1 was protective in human 
FcγRI transgenic mice after challenge with lethal doses of PfMSP1-19-transgenic P. 
berghei, demonstrating the importance of such receptors in triggering protection37. A 
separate study had observed that IgA1, IgA2, IgG2 and IgG4 could not activate 
antibody-dependant cellular inhibition of P. falciparum, with only IgG1 and IgG3 
showing this ability38. It was also observed that IgA-associated immune complexes 
appeared to be protective in children with cerebral malaria39. IgA serum levels 
towards a P. falciparum antigen extract were found to increase with age in 
seropositive individuals from an endemic population, and it was shown to inhibit P. 
falciparum growth in vitro40. Very little is known about the importance and activity of 
IgA antibodies in malaria; contradicting data have been published on this topic. It is 
important to measure and interpret the levels of these different components and their 
relationships to one another as these are the foundations of a good understanding of 
the immune system in different health states. These can help monitor the course of 
certain infectious diseases in order to characterise the immune response towards 
the disease and the outcome of various treatments. 
Routinely, the measurement of exposure to malaria in endemic populations is carried 
out using a small number of well characterised plasmodium antigens20,21,41,42, though 
until now, there have not been any species-specific antigens for P. knowlesi. With 
the newly available P. knowlesi antigens we have developed, it will be possible to 
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further characterise this organism and the human host response to it43. Novel 
proteins are being identified at an increasing rate44-51 and developing a platform 
appropriate to screen multiple targets has become essential in order to obtain a 
better understanding of host-pathogen interactions and antibody-mediated immunity 
towards pathogens. As mentioned in the previous chapter, there are several 
antibody-based detection assays but most require large quantities of reagents. 
There has been a technological shift towards multiplex platforms in the current 
market in order to meet this need of detecting multiple targets in a single sample. 
Much like the Multiplex Bead Assay (MBA) discussed in the previous chapter, 
protein microarrays make it possible to test thousands of different analytes from 
different pathogens in a single assay10,52,53. In addition to being able to screen 
multiple targets per sample (e.g. antigens) like the MBA, it has the ability to multiplex 
the biomarkers being measured per spot (e.g. different antibody isotypes)54. This can 
enable us to further characterise how multiple infections shape the immune 
response as well as potentially determine how different pathogen combinations 
shape the immune response. 
A microarray is the miniaturisation of an assay onto a slide/chip, also called a planar 
array and these were originally developed for high-throughput measuring of DNA 
and RNA expression55,56. Because it is not possible to learn about the functionality of 
proteins purely based on gene transcription and expression levels57, particularly 
since the presence of a protein cannot always be inferred directly from gene 
transcription, protein-based approaches have been developed for use on the 
microarray platform55,56. 
Protein microarray assays can be divided into three categories: 1) analytical, 2) 
functional and 3) reverse-phase protein microarrays (RPPM; Figure 6.1; reviewed 
in58). 
Briefly, an analytical protein microarray consists of immobilising a capture antibody 
on a chip which, when used in an assay, captures protein from the serum or protein 
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solution being tested59,60 (Figure 6.1). This is detected using a reporter or detection 
antibody, much like a sandwich ELISA61, and has been successfully used to detect 
protein levels of carcinoma cells after treatment62. 
A functional microarray consists of immobilising purified full-length functional 
proteins on a chip in order to study biochemical properties of proteins when these 
interact with DNA, lipids, drugs, peptides and other proteins, as well as enzyme-
substrate relationships (Figure 6.1)61,63. A functional microarray was first used by 
Zhu et. al. where substrate specificity of protein kinases was determined in yeast64. 
Finally, a RPPM, related to analytical microarrays, consists of immobilising small 
amounts of tissue or cell lysates on a chip58,60,65 (Figure 6.1). Antibodies against the 
target proteins are used to probe the array and can be detected using for example 
fluorescently tagged secondary antibodies. Although the lack of commercially 
available specific antibodies may limit the application of this method, we have 
chosen this method for the next two chapters and have used the few reagents that 
are available. 
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Figure 6.1 Protein microarray categories. (A) Analytical protein microarrays immobilise antibodies on a chip and 
capture targeted proteins in solution which can then be detected using fluorophore tags or labelled reporter 
antibodies. (B) Functional protein microarrays immobilise full-length functional proteins which can interact with 
other proteins, small molecules, nucleic acid and even enzyme-substrate relationships. These are used to study 
biochemical interactions. (C) Reverse Phase Protein Microarrays (RPPM) immobilise tissue or cell lysates and can 
detect antibody presence. Figure from a published source58. Copyright © 2013 John Wiley & Sons, Inc.  
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Malaria prevalence has previously been assessed using protein microarrays. Baum 
et. al. assessed the epidemiology of asymptomatic and submicroscopic Plasmodium 
spp. in Thailand, concluding that transmission is still ongoing although a lot of it goes 
undetected by traditional methods of detection66,67. Similarly, Uplekar et. al. looked at 
prevalence in India identifying antigens associated with asymptomatic malaria68. 
A principle benefit of large-scale proteomic approaches using microarray is that they 
can capture antibody isotype and subclass reactivity patterns towards a multitude of 
antigens. In some instances, these have been used to distinguish symptomatic from 
asymptomatic disease patterns in atopic diseases such as asthma and eczema by 
measuring IgE reactivity profiles69; and to identify markers of host immunity to 
malaria by measuring IgG reactivity. A microarray immunoassay was developed 
using recombinant antigens from P. falciparum blood-stage vaccine candidates and 
tested on serum from Gambian children70. It was reported that protection against 
clinical malaria was significantly associated with serum IgG reactivity towards 
combined antigen recognition whilst single antigen reactivity did not correlate with 
immune status70. In a separate study a protein microarray was used to identify 
biomarkers that accurately determined recent malaria exposure7.   
This chapter describes the analysis of serum samples from Malaysian clinical cases 
on the RPPM protein microarray platform using the expanded panel of P. knowlesi-
specific recombinant antigens. More specifically, we dissect the antigen reactivity 
seen towards three different immunoglobulin isotypes: IgM, IgG and IgA.  
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6.2. METHODS 
6.2.1. PRINTING OF RECOMBINANT PROTEINS ON MICROARRAY SLIDES 
The selected purified and PBS-dialysed recombinant antigens were printed onto 
nitrocellulose-coated slides (ONCYTE® AVID, Grace Bio-Labs, USA) using the 
Arrayjet Marathon Classic printer (Arrayjet, UK). A total of 194 antigens and controls 
were printed within each array, including the full P. knowlesi panel of antigens. 
Reference spots (0.4 mg/ml) were included as fiducial markers to help the GenePix® 
software (GenePix Pro 7.2.29.002) and ArrayCam® Multiplex Microarray Imaging 
System (Grace Bio-Labs, USA) correctly assign the data extraction grid to each 
array during the imaging process of the arrays. A standard control curve of each 
purified immunoglobulin in a serial dilution (200; 100; 50; 25; 12.5; and 6.25 µg/ml) 
and blanks were also included on the array. The material selected to be reference 
spots was chosen on the basis that it would fluoresce independently of sample 
reactivity, in this case, purified human IgG (Sigma-Aldrich) as per standard protocol. 
The serial dilution immunoglobulin control curves of purified human IgG, IgM, IgA 
(I4506, I8260, I4036 respectively; Sigma-Aldrich), IgE and IgD (ab91022, ab65866 
respectively; Abcam) were used to verify that the secondary antibodies were binding 
with the correct specificity as well as to derive an estimate of antibody binding in test 
samples. Blanks spots were one part glycerol printing buffer (1x PBS-T and 60% 
glycerol bidistilled) and one part 1x PBS and these were used to control for non-
specific binding and background reactivity.  
The array layout is prepared as a .csv file in MS Excel as described in appendix VI. 
The layout is inputted to the Command Centre for Marathon v1.4.2 software 
(Arrayjet) in order to generate a 384-well plate map file, indicating a specific loading 
pattern of antigen to obtain the desired printed layout. The recombinant antigens 
were diluted to 0.2 mg/ml (where stock antigen concentration allowed) in 1x PBS in 
order to print spots at 0.1 mg/ml (or half stock concentration, where required) on the 
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array. These were prepared in a 384-microwell plate with glycerol printing buffer (1x 
PBS-T and 60% glycerol bidistilled) to a final well volume of 20 µl following the plate 
map prepared previously, mixing thoroughly by pipetting and finally centrifuging the 
plate down at 1800 x g for 5 minutes to eliminate any bubbles. A septa (Applied 
Biosystems) was fitted to the plate in order to prevent evaporative loss from the 
diluted protein samples. 
The inside of the printer is wiped clean from any dust and contaminants before 
starting the printing process and both the printer and atmospheric controller turned 
on to allow conditions inside the printer to equilibrate. Once a series of system 
checks are performed, printing parameters determined (as per appendix VI) and 
blank slides are loaded into the printer, the microplate is loaded for printing to 
commence. In this instance, the recombinant antigen spots were printed in singlets. 
The slides remain in the printer for at least 6 hours after printing with the 
atmospheric controller still on before being stored in slide boxes at 4°C in a vacuum 
desiccator. Tate Oulton performed this part of the experiment. 
6.2.2. CONJUGATION OF SECONDARY ANTIBODY TO FLUORESCENT MARKERS FOR 
TWO DIFFERENT MICROARRAY SCANNERS TO EXPAND PANEL OF AVAILABLE 
DETECTION REAGENTS 
As described in the following sections, two different microarray scanner machines 
were used to test human and macaque serum samples for immunoglobulin 
antibodies against the full microarray panel of recombinant antigens (P. falciparum 
(AMA1, MSP1-19, etc.), P. vivax (AMA1, MSP1-19, etc.) and P. knowlesi (MSP1 
antigen 2, SERA3 antigens 1 and 2, SSP2, TSERA2 antigens 1 and 2, 
PKH_021580, PKH_031930 antigens 1 and 2 and PKH_080030). 
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6.2.2.1. Antibody isotypes compatible with ARRAYCAM® microarray 
scanner 
Quantum dots, or Qdots®, are tools used as fluorescent probes in the field of biology 
due to their improved optical stability, greater fluorescence brightness, and narrow 
emission bands compared to molecular dyes71. Qdots® are nanocrystals that, 
according to the size of the crystal, emit light at different wavelengths. These 
nanocrystals are made of semiconductor materials. Bound Qdot® reagents are 
excited by a diode laser within the imager and fluorescent images are captured in 
high resolution using a digital camera. Compared to organic dyes, Qdots® are 
brighter and much more stable to photobleaching71. A single Qdot® has the 
fluorescent intensity of approximately 20 rhodamine molecules71. Qdot® technology 
enables multiplex detection of reactivity on a single array using colour discrimination. 
Individual band pass filters are used to collect the signal, in this case, from the 
800nm, 655nm, and 585nm channels (Figure 6.2). 
 
Figure 6.2 Fluorescence SpectraViewer simulation image for Qdot® 585, 655 and 800. The image shows the 
relative intensity percentages for the different fluorophore emission plots, shown in solid lines, and excitation 
plots, shown as dashed lines (Qdot 585 yellow, Qdot 655 red, Qdot 800 mauve). This image was generated using 
the ThermoFisher Scientific online SpectraViewer simulator https://bit.ly/2uuXBmZ. 
   
Based on previously published data54, anti-immunoglobulin antibodies (affinity-
purified goat anti-Human IgG Qdot® 800 (catalog number 110610), goat anti-Human 
IgM Qdot® 655 (catalog number 110630) and goat anti-Human IgA Qdot® 585 
(catalog number 110620), Grace Bio-Labs, USA) were selected for their availability 
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and compatibility to the ArrayCam® Multiplex Microarray Imaging System (Grace 
Bio-Labs, USA). These did not require conjugation steps and were ready to use 
reagents. 
6.2.2.2. Conjugation of antibody isotypes compatible with GenePix 
microarray scanner 
Anti-immunoglobulin antibodies were conjugated to fluorescent dyes chosen for their 
compatibility to the GenePix® 4000B microarray scanner (Molecular Devices, USA) 
as described below. As the protein microarray has yet to be fully explored, currently 
there are very few appropriately labelled reagents available. We therefore obtained 
labelling kits and reagents tailored to the experiments we wanted to perform. 
An Alexa Fluor™ 532 antibody labelling kit was used to label α-human/macaque IgG 
(0.5-1 mg/ml stock; #555784 BD Sciences), α-human IgD (1 mg/ml stock; #2030-01 
2B Scientific) and α-monkey IgA (1 mg/ml stock; #617-101-006 2B Scientific), which 
were all verified as Non-Human Primate (NHP) approved reagents by the NHP 
Reagent Resource (http://www.nhpreagents.org). Conjugations were performed as 
per manufacturer’s instructions. Briefly, the antibodies were diluted to 1 mg/ml and 
1M sodium bicarbonate buffer was added at 1/10th of the volume of the diluted 
antibodies, then 100 µl was transferred to the vial of reactive dye and gently inverted 
to dissolve the dye. The solution was incubated at RT for 1 hour and gently inverted 
every 10 minutes to increase labelling efficiency. During the incubation time, the kit 
purification columns were prepared. This step ensures the removal of unbound dye 
from the dye-conjugated protein. The columns have two frits inserted at the bottom 
before adding purification resin. The resin must be stirred before being added to the 
column and, once added up to 1 ml, it must be allowed to settle by gravity before 
more resin is added to a total of approximately 1.5 ml. The column buffer is allowed 
to drain from the column by gravity before being centrifuged at 1100 x g for 3 
minutes. Once this is done, the antibody-dye reaction is loaded dropwise onto the 
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spin column and allowed to absorb into the resin bed before being centrifuged into a 
collection tube at 1100 x g for 5 minutes. 
An Alexa Fluor™ 633 Protein labelling kit was used to label Goat α-human IgG 
(H+L) Cross-Adsorbed Secondary Antibody (2 mg/ml stock; # A-21091 
ThermoFisher Scientific),α-human IgE (1 mg lyophilised stock rehydrated in 2mM 
glacial acetic acid; 01-10-04 Insight) and α-human IgM (2 mg/ml stock; # 054900 
ThermoFisher Scientific), which were also all verified as NHP approved reagents by 
the NHP Reagent Resource (http://www.nhpreagents.org). Conjugations were 
performed as per manufacturer’s instructions. Briefly, the antibodies were diluted to 
2 mg/ml in 1x PBS and 50 µl of 1M sodium bicarbonate buffer was added to 500 µl 
of the diluted antibodies, then the solution was transferred to the vial of reactive dye, 
gently inverted to dissolve the dye and incubated at RT for 1 hour. The kit 
purification columns were prepared as instructed before adding purification resin. 
The resin must be properly stirred and added to the column until the resin is 
approximately 3 cm from the top of the column, allowing the excess buffer to drain 
away. The reaction mix is loaded onto the column and allowed to enter the resin 
before being rinsed with 100 µl of elution buffer, taking care not to disturb the resin 
bed. As the solution is run through the column, two coloured bands become visible, 
indicating the separation of incorporated dye and unincorporated dye. The first 
coloured band contains dye-incorporated protein, which should be collected. Elution 
buffer is added as necessary and retained in fractions for approximately 30 minutes 
in order to elute as much labelled protein as possible. 
The protein concentration and the degree of labelling for each antibody isotype was 
determined as per manufacturer’s instructions. Briefly, absorbance was measured 
using the NanoDrop® Spectrophotometer ND-1000 (ThermoFisher Scientific) at 280 
nm and 530 nm for samples labelled with Alexa Fluor™ 532nm and at 632 nm for 
samples labelled with Alexa Fluor™ 633 nm. The following formulas were used to 
determine protein concentration for label 532 nm and for label 633 nm: ([A280-
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(A530*0.09)]*5df)/2,030,000 and ([A280-(A632*0.55)]*5df)/2,030,000 respectively. The 
following formulas were used to determine the degree of labelling for label 532 nm 
and for label 633 nm: (A530*5df)/(810,000*protein concentration) and 
(A632*5df)/(1,000,000*protein concentration) respectively. The labelled protein was 
stored at 4°C in the dark and for longer storage, at -20°C in small aliquots. 
6.2.3. TITRATION OF THE DIFFERENT SECONDARY ANTIBODIES  
In order to run the experiment, it was necessary to determine the optimal working 
concentrations of the reagents in order to obtain realistic and comparable results. 
The serum sample dilution was selected based on the established in house protocol 
developed by Tate Oulton, which indicates that 1/400 dilution is ideal. A series of 
secondary antibody dilutions were run in order to determine the ideal working 
dilutions for both the Genepix® (Molecular Devices,USA) and the Araycam® (Grace 
Bio-Labs, USA) experiments. The dilutions were 1/125, 1/250, 1/500 and 1/1000 for 
the Genepix and 1/100, 1/200, 1/400, 1/800 and 1/1000 for the Arraycam. The rest 
of the experiment was conducted as described below and part of it was performed 
by Tate Oulton.  
6.2.4. PROCESSING OF SERUM SAMPLES ON MICROARRAY SLIDES 
The human and macaque serum samples were diluted the previous day at 1/400 in 
array 0.25x blocking buffer (Arrayit 1x Blockit buffer in 1x PBS). The array slides 
were securely placed into a hybridisation cassette (HC) (Arrayit), 100 μl of array 
blocking buffer was added to each array and these were left to incubate at RT for 1 
hour on a rotary platform at 100 rpm after properly sealing the HC. The slides were 
washed three times with 200 μl 1x PBS/T (1x PBS and 0.01% Tween 20) array wash 
buffer before 100 μl of diluted human or macaque samples were added to each 
array and incubated at RT for 1 hour as described earlier.  The slides were washed 
three times as previously described and 100 μl of diluted secondary antibody 
(secondary antibodies conjugated to Qdots® at 1/200 dilution) in array blocking 
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buffer was added to each array, then incubated in the dark at RT for 1 hour as 
described earlier. The microarray slides were then washed three times with 200 μl 
1x PBS/T array wash buffer and once with 200 μl mili-Q water before being 
centrifuged at 1800 x g for 5 minutes in 50 ml tubes. It was ensured that slides were 
properly dried before being stored in slide boxes at 4°C in a vacuum desiccator for 
later scanning. The slides were scanned by Tate Oulton using GenePix 4000B 
microarray scanner (Molecular Devices, USA) or ArrayCam (Grace Bio-Labs, USA) 
as appropriate, and the results expressed as median fluorescent intensity (MFI).  
6.2.5. DATA PROCESSING 
All microarray data was processed using R scripts written by Dr. Nuno Sepulveda, 
Dr. William Stone and Dr. Katherine Glass (these scripts were run on RStudio, 
Version 1.1.453 – © 2009-2018 RStudio, Inc.). Briefly, background corrections were 
made using the normexp method from the limma package72 with offset = 50. Targets 
which were printed immediately following ‘high intensity spots’ (e.g. top standard, 
reference spots) were excluded, due to a potential carryover effect during printing. 
Buffer spots were used to quality check the printing process, allowing the 
identification of deviant slides, pads and samples and excluding samples with buffer 
means greater than the total buffer mean plus three standard deviations. Data was 
normalised as a ratio of signal for each spot to the mean buffer signal within each 
sample (Target MFI/ Buffer MFI) and log transformed (base 2). GST signal was 
subtracted from the normalised data for GST-tagged targets before being analysed. 
Negative normalised values (values below buffer mean) were set to zero. 
Seropositivity cutoffs were calculated independently for each sample as the mean 
MFI of the buffer spots plus three standard deviations. More information on the 
different statistical analyses performed on the different data sets is found the 
respective chapters. 
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6.2.6. STATISTICAL ANALYSIS 
For the hospital samples, scatter plot matrices and correlation plots were created 
using STATA/IC 14.2 (StataCorp. 2015. Stata Statistical Software: Release 14. 
College Station, TX: StataCorp LP.) and RStudio (Version 1.1.453 – © 2009-2018 
RStudio, Inc.), showing the presence or absence of collinearity between P. knowlesi 
recombinant antigens. Dot plots, bar graphs and heat maps were created using 
PRISM (GraphPad PRISM 7). Statistically significant differences in antibody 
responses between time points per antigen were determined using Friedman’s test 
followed by Dunn’s post hoc test using PRISM (*P<0.05; **P<0.01; ***P<0.001). The 
same test was applied to the antigen breadth data but no statistical significances 
were recorded. 
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6.3. RESULTS 
6.3.1. P. knowlesi-specific recombinant antigen serum reactivity towards a 
subset of Malaysian clinical samples using the ArrayCam protein 
microarray scanner 
In the previous chapter we used the MBA to analyse reactivity towards multiple P. 
knowlesi antigens in clinical and community samples, looking at IgG responses. In 
this chapter we apply a similar methodology on the protein microarray platform 
which, unlike the MBA, can detect multiple antibody isotypes in a single assay. 
The experimental strategy for this chapter is outlined in Figure 6.3, showing the 
identification of the target sequences of interest and, highlighted in green, the test 
samples used on the protein microarray platform. The protein microarray assay used 
a subset of the Malaysian serum samples collected from adults and children 
hospitalised with malaria at different time-points (day 0, 7 and 28; Table 3.1; chapter 
3, section 3.3) post-treatment diagnosed as P. knowlesi (n=12), P. vivax (n=1) or P. 
falciparum (n=1).  
This work was attempted for the GenePix microarray scanner and, although it was 
possible to produce custom-made reagents for this platform, the optimisation of such 
reagents proved to be time consuming and the reagent signals were found to cross-
react. Cross-reactivity was observed between the different antibodies, which could 
potentially lead to epitope conflict further down the line. An alternative route to 
analysing isotype profiles on microarray was pursued, using Qdot® fluorescent 
probes and the ArrayCam scanner. Qdot® fluorescent probes bound to secondary 
anti-immunoglobulin antibodies IgM, IgG and IgA were procured (Grace Bio-Labs, 
USA) to be used on the ArrayCam microarray imaging system (Grace Bio Labs, 
Oregon, USA) as these had already been previously optimised54. Qdot® probes are 
a relatively new reagent which are brighter and much more stable to photobleaching 
than other organic dyes71,73,74.  
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Figure 6.3 Flowchart summarising the experimental strategy used in the identification and validation of the P. knowlesi-specific candidates and sample sets used in this chapter. Test 
samples were obtained from a hospital-based clinical treatment trial in Sabah, Malaysia (n=164), and were collected at different time points post-diagnosis and treatment (day 0, 7 and 28). A 
subset of the clinical samples (n=14) were tested on the protein microarray platform. Highlighted in green are the sections relevant to this chapter.
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Qdot® probes are a relatively new reagent which are brighter and much more stable 
to photobleaching than other organic dyes71,73,74. These can be excited with a wider 
range of wavelengths than organic dyes and have narrower emission spectra, 
enabling the use of multiple Qdot® probes in a single reading75. Each of the 3 
antibodies are bound to a specific Qdot® fluorescent probe that is excited by a diode 
laser at a specific wavelength (IgM 655 nm, IgG 800 nm and IgA 585 nm; Figure 
6.2), making it possible to determine reactivity towards all 3 isotypes in a single run. 
For continuity, only samples that had data recorded for all three time points (day 0, 
day 7 and day 28 after diagnosis and treatment) were selected from the Malaysian 
clinical samples for analysis. A total of 14 individuals with all three time points from 
the clinical samples were selected to be tested using the microarray platform, with 
12 of the individuals having been PCR diagnosed with P. knowlesi, 1 with P. vivax 
and 1 with P. falciparum. One of the samples from day 0 (CCK069) was not tested in 
this assay as it was originally collected as a bloodspot instead of serum sample, as a 
result the material was not sufficiently concentrated to be able to achieve the 
appropriate concentration for this assay. However, the other time points for this 
individual (days 7 and 28) were tested and analysed. Originally 1 year follow up 
samples were to be included in this analysis but these were also excluded due to 
insufficient sample volume for use on the microarray platform at the appropriate 
dilution. These samples were probed for reactivity towards the full panel of P. 
knowlesi recombinant antigens. Figure 6.4 is a representative figure showing the 
different fluorescence captured within the same sector of a slide measuring all three 
isotypes simultaneously at their respective wavelengths. 
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Figure 6.4 Protein microarray example slide showing fluorescent reactivity within the same slide sector 
towards the different isotype wavelengths. (A) Anti-human IgM  is seen at 655 nm, (B) anti-human IgG is seen 
at 800 nm and (C) anti-human IgA is seen at 585 nm on the ArrayCam slide scanner for the same serum sample. 
 
For the following sections, different graphical analyses were applied to the data. 
Figure 6.5 to Figure 6.7 show overall serum reactivity correlation matrices towards all 
P. knowlesi antigens at days 0, 7 and 28 after diagnosis and treatment for each of 
the immunoglobulins (IgM; IgG and IgA; Figure 6.5Figure 6.6Figure 6.7, 
respectively). 
Reactivity towards IgM occurs primarily at day 0 (Figure 6.8; appendix VII, Figure 1 
A), with the highest reactivity seen towards PkSERA3 antigen 2. Very little 
collinearity of responses were observed between the different P. knowlesi-specific 
antigens towards IgM at any time point, with only TSERA2 antigens and 
PKH_031930 antigens showing significant correlations. The only antigens to show a 
significant negative correlation were SSP2 and PKH_021580 at day 7 (Figure 6.5 B; 
r=-0.62). 
In Figure 6.6, which shows IgG reactivity correlations, the PkTSERA2 antigens show 
significant collinearity with the PKH_031930 antigens, particularly on day 7. 
PKH_031930 antigen 1 and 2 show a significant and strong response collinearity at 
all time points, which is not surprising as these are fragments within the same gene 
sequence. Similarly to IgM, the strongest reactivity is seen towards PkSERA3 
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antigen 2, however this is seen at day 28 (Figure 6.8; appendix VII, Figure 2 C). 
Antigen PkTSERA2 antigen 1 also showed strong reactivity towards IgG at day 28 
after diagnosis and treatment (Figure 6.8). 
IgA was the isotype to show the least collinearity between antigens (Figure 6.7). 
Reactivity towards IgA appears to be the weakest of all three antibody isotypes, 
however, PkSERA3 antigen 2 still seems to be the P. knowlesi-specific antigen to 
show strongest reactivity (Figure 6.8; appendix VII, Figure 3).  
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Figure 6.5 Correlation plots 
showing IgM isotype reactivity 
towards P. knowlesi-specific 
antigens in Malaysian clinical 
samples at days 0, 7 and 28 after 
diagnosis and treatment (n=12). 
Plots indicate positive or 
negative associations. The upper 
diagonal half shows the 
correlation by colour and circle 
size. The lower diagonal half 
shows the correlation values. The 
data is sorted from highest to 
lowest correlation. Correlation is 
shown as highest in dark blue 
and large circles to very low or 
no reactivity in red and smaller 
circles. Asterisks signify 
significant difference in 
correlation between antigens 
using Pearson’s correlation test 
using p=0.05. 
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Figure 6.6 Correlation plots 
showing IgG isotype reactivity 
towards P. knowlesi-specific 
antigens in Malaysian clinical 
samples at days 0, 7 and 28 after 
diagnosis and treatment (n=12). 
Plots indicate positive or 
negative associations. The upper 
diagonal half shows the 
correlation by colour and circle 
size. The lower diagonal half 
shows the correlation values. The 
data is sorted from highest to 
lowest correlation. Correlation is 
shown as highest in dark blue 
and large circles to very low or 
no reactivity in red and smaller 
circles. Asterisks signify 
significant difference in 
correlation between antigens 
using Pearson’s correlation test 
using p=0.05.  
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Figure 6.7 Correlation plots 
showing IgA isotype reactivity 
towards P. knowlesi-specific 
antigens in Malaysian clinical 
samples at days 0, 7 and 28 after 
diagnosis and treatment (n=12). 
Plots indicate positive or 
negative associations. The upper 
diagonal half shows the 
correlation by colour and circle 
size. The lower diagonal half 
shows the correlation values. The 
data is sorted from highest to 
lowest correlation. Correlation is 
shown as highest in dark blue 
and large circles to very low or 
no reactivity in red and smaller 
circles. Asterisks signify 
significant difference in 
correlation between antigens 
using Pearson’s correlation test 
using p=0.05. 
DEVELOPMENT OF PK SPECIES SPECIFIC REAGENTS TO CHARACTERISE ANTIBODY ISOTYPE PROFILES | LOU HERMAN 
 
191 | P a g e  
 
6.3.2. Isotype reactivity profiles to each P. knowlesi-specific antigen 
Much like the results obtained from the ELISA analysis of these same samples 
(chapter 4, section 4.2.5.), It was clear that for these Malaysian clinical samples 
PkSERA3 antigen 2 showed the strongest reactivity towards all isotypes, followed by 
PkTSERA2 antigen 1 for IgM and IgG (Figure 6.8Figure 6.9).  
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Figure 6.8 Heat map of IgM, IgG and IgA reactivity towards P. knowlesi-specific antigens at days 0, 7 and 28 
after diagnosis and treatment of Malaysian clinical samples (n=12). The colour scale represents the antigen 
reactivity geometric mean log2 MFI ratio.  Reactivity is shown as highest in dark blue to very low or no reactivity 
in white. 
 
 It was observed that P. knowlesi-specific antigen reactivity towards anti-IgM 
antibody showed a decreasing trend over time for all antigens without exception, 
with PkSERA3 antigen 2, PkSSP2 and PkTSERA2 antigen 1 showing a significant 
decrease (P<0.001, P<0.05 and P<0.05, respectively; Figure 6.9 A).  
Unlike IgM, there is an increasing trend in reactivity towards IgG across time for all 
antigens with a peak in reactivity at day 7 and the occasional decrease by day 28, 
with PkSSP2 showing a significant increase at day 7 (P<0.05; Figure 6.9 B). Only 4 
antigens indicated an increasing trend in reactivity towards IgG across time, peaking 
at day 28 (PkSERA3 antigen 2, PkTSERA2 antigens 1 and 2 and PKH_031930 
antigen 1; Figure 6.9). 
The isotype to show the least reactivity of all three was IgA, with irregular peaks and 
falls across time for the different P. knowlesi-specific antigens (Figure 6.9 C). As 
mentioned previously, the highest responding antigen was PkSERA3 antigen 2, and 
unlike for the other isotypes, followed by PkMSP1 antigen 2, which showed reversed 
reactivity towards IgM across time (Figure 6.8; Figure 6.9 A and C).
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Figure 6.9 Tukey box and whisker plots of Immunoglobulin isotype reactivity to the P. knowlesi-specific 
antigens for the Malaysian clinical sera (n=12). Reactivity to each time point is grouped by antigen: day 0 
(white), 7 (light blue) and 28 (dark blue).  The data is plotted for (A) IgM, (B) IgG and (C) IgA. The median is based 
on Log2 of the MFI ratio for each antigen and the box indicates values for the lower and upper quartile. The 
error bars shown are the lower and upper quartiles ±1.5xIQR. Level of significance between day 0 and the other 
days are indicated by asterisks, level of significance between day 7 and 28 are indicated by a line with asterisks, 
non-significant values were not plotted (*P<0.05; **P<0.01; ***P<0.001; Friedman test with Dunn post hoc 
comparisons of reactivity in the three time points).  
 
6.3.3. Breadth of antibody response towards P. knowlesi antigens in clinical 
samples 
In the following section we determine the number of individuals reactive to a specific 
antigen and the number of antigens eliciting an antibody response in a single person 
(breadth of response per isotype). PkSERA3 antigen 2 was the antigen to elicit the 
most IgM, IgG and IgA reactivity (Figure 6.10). For IgM, this was followed by 
PkTSERA2 antigens 1 and 2 (Figure 6.10 A). Independently of time points, the 
majority of individuals tested showed IgG reactivity towards PkSERA3 antigen 2, 
followed by PkTSERA2 antigen 2 and PKH_031930 antigen 1 (Figure 6.10 B). For 
PkSERA3 antigen 2, 10 out of 12 individuals were reactive to this antigen at day 28. 
IgG was the isotype with most seropositive antigens independently of time point. IgA 
reactivity towards PkSERA3 antigen 2 was highest at day 7 (Figure 6.10 C).  
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Figure 6.10 Total number of seropositive individuals per P. knowlesi antigen for IgM, IgG and IgA at each time 
point. Malaysian clinical serum samples (n=12) were used to screen a panel of antigens using the protein 
microarray platform. Cut offs were calculated based on each sample array buffer spots, identifying cut offs per 
individual tested. Graph shows the number of seropositive people for each antigen at days 0 (white), 7 (blue) 
and 28 (purple). 
 
Figure 6.11 shows the number of antigens each individual showed reactivity towards 
each isotype across the different time points. Antigen breadth eliciting an IgM 
response was mostly scattered at day 0, with every individual reacting to a different 
number of antigens (Figure 6.11 A). At day 7 most individuals showed reactivity 
towards 3 antigens, which went down to 1 antigen by day 28 (Figure 6.11 A). For 
IgG, the highest number of antigens seen per person was during day 7 post-
diagnosis and treatment, where all 10 antigens elicited reactivity in at least one 
individual (Figure 6.11 B). IgA showed the lowest antigen breadth, although a higher 
antigen breadth was seen for some individuals later in time (Figure 6.11 C). 
 
  
Figure 6.11 Number of seropositive P. knowlesi antigens for each individual across the different time points 
for IgM, IgG and IgA. Malaysian clinical serum samples (n=12) were used to screen a panel of antigens using the 
protein microarray platform. Figure represents the number of reactive antigens detected by a single person at a 
specific time point. The violin plots are proportional to the number of people. The different time points are 
indicated as follows: day 0 (red), day 7 (green) and day 28 (blue). Differences in antibody responses between 
time points per antigen were determined using Friedman’s test followed by Dunn’s post hoc test using PRISM. 
Non-significant results were not plotted. 
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6.4. DISCUSSION 
The results presented here not only have shown the usefulness of high throughput 
technology in serology, but also how this technology can be used to measure 
multiple components of the immune response simultaneously. We have shown proof 
of principle that multiplexing of P. knowlesi antigens can be used for serological 
assessment of human samples using the protein microarray platform. Additionally, 
responses to IgM, IgG, and IgA were measured simultaneously on the microarray 
platform for a subset of P. knowlesi infected endemic samples. 
We found that PkSERA3 antigen 2 was the most highly reactive antigen, which 
agreed with ELISA and Multiplex Bead Assay (MBA) results. This was observed in 
clinical samples, and responses were both time and isotype specific. We have 
described the kinetics of a potentially short-term marker of P. knowlesi exposure, 
which would be useful to determine recent infection in the population. It might be 
possible to infer that IgMhigh, IgGlow reactivity could be indicative of very recent 
exposure, while an IgMlow, IgGhigh response could indicate an older infection. The 
differing isotype profiles in infections may be related to disease progression and 
severity – further work is need in this area. 
The large scale analysis of genes, gene expression and function has long existed76-
79. Although it is possible to determine gene function by measuring levels of mRNA 
transcription80, gene function is more accurately measured by the activity of the 
translated proteins these encode. However, there are limitations to the 
transcriptomic approaches that can be overcome by proteomic tools. For example, 
levels of mRNA do not always reflect translation into proteins and protein levels57 
and it is not possible to measure post-translational modifications in mRNA. For 
instance, a lack of mRNA may lead to the false assumption that the protein is not 
present, particularly stable proteins that do not require constant replenishment by de 
novo synthesis. Protein-based approaches have been developed in order to 
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determine the presence and functionality of proteins using high throughout 
platforms55,56,81. 
Detecting multiple targets in a single sample and analysing these in the context of 
multiple others as well as the host immune system has long been pursued. This is 
now possible with MBA and protein microarray technology, which not only enable 
multiplexing, but also have a low sample requirement, making it possible to screen 
thousands of samples for thousands of targets.  
IgG reactivity towards PkSERA3 ag2 was previously shown by ELISA to decrease 
slightly by day 28 (reference43 and chapter 4), as was shown by MBA analysis, with 
barely any reactivity by 1 year post-diagnosis (Error! Reference source not 
found.). In this chapter, the protein microarray data shows an increasing trend in 
IgG reactivity to this antigen (Figure 6.9 B). Although not statistically significant, this 
could potentially be due to a smaller sample size used for the protein microarray 
analysis (n=12) and in future, larger sample sets would be used for this type of 
analysis. Unfortunately, the reason for a smaller sample set was that not enough 
samples had all time points available. For a more in-depth analysis of antigens 
across time, more time points would be required to be collected and analysed for 
each individual in order to have a better idea of the antigen kinetics and the potential 
associations with protection for instance. Studies have shown that IgG antibodies 
against P. falciparum antigens are important for the development of clinical 
immunity23,82, something that could potentially be seen for P. knowlesi infections in 
endemic populations. Further optimisation of the assay analysis would be required 
and larger sample sets from endemic regions would need to be screened for isotype 
reactivity in order to determine any correlations. It would also be necessary to 
develop the assay in a way that would make it possible to directly compare the 
different isotype reactivity with one another.  
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There has been much interest in trying to establish whether serological markers can 
be used as predictors of protection in the field of vaccinology83,84, however, the 
relationship between antibody titres and protection is currently not quite clear. 
Associations were made between time after diagnosis and antibody isotype increase 
(IgG) or decrease (IgM), although only the decrease in IgM across time was 
statistically significant. The data presented here is consistent with previously 
published data showing that IgM antibody expression happens as an early response 
to malaria infections, followed by IgG expression85. The increase and decrease of 
IgG and IgM respectively occur within 30 days of diagnosis and in the data 
presented here, seem to cross at day 7. The overall lower IgA response can 
potentially be a result of first time infection, a theory which was previously indicated 
in mice86, although not translatable to this study as the isotype profiling was done on 
a small subset of human samples. The high IgA response towards PkMSP1 ag2 is 
reminiscent of a study where PfMSP1-19-specific recombinant IgA was able to 
recognise parasites in infected RBC36. Reversed IgM responses were observed 
towards PkMSP1 ag2 (Figure 6.8, Figure 6.9 A and C). Biswas et. al. published 
similar results  where a negative correlation was seen between IgA and IgM 
positivity looking at reactivity towards soluble extract from cultured P. falciparum, 
potentially indicating a class switch from IgM to IgA40. A similar observation between 
IgM and IgA was seen with PKH_031930 ag1 (Figure 6.8, Figure 6.9 A and C). This 
would require further investigation as IgA has not been studied extensively in malaria 
research. 
One of the limitations of protein microarray is the commercial unavailability of 
specific tagged antibodies, making it more difficult to procure specific reagents and 
coupling these in-house. Not only is this more time-consuming, it also reduces the 
comparability of results between research groups. Providing specific tools for 
antibody profiling are made readily available, it would be possible to screen samples 
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not only for isotype reactivity, but also for subclass reactivity in a high throughput 
manner, making it possible to dissect malaria exposed and unexposed populations 
through reactivity patterns, as has been done for asthmatic patients69. Here we have 
shown the application of high throughput protein microarray technology in the 
serological screening of P. knowlesi endemic populations, at the clinical level, not 
only looking at reactivity towards different antigens but also looking at individual 
isotype reactivity to those antigens. The simultaneous measurement of analytes and 
biomarkers in a single individual makes it possible to determine the relationships 
these have with one another and how these might shape immunity, or lack thereof, 
towards particular pathogens or a group of them.  
This only marks the beginning of what these advancements will enable us to do, 
such as screening for reactivity patterns towards drug treatments and vaccines, 
potentially making it possible to produce personalised drugs, vaccines and 
treatments targeted towards certain populations or subsets, specific age groups, 
genders.  
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Chapter 7 : GENERAL DISCUSSION 
For many years, microscopy has been the gold standard in identification of 
Plasmodium spp. infection. However, in distinguishing between species within this 
genus, it is limited when they have a similar morphological appearance1-6. There is 
therefore an urgent need for new techniques that can achieve greater sensitivity, 
specificity and depth of analysis. We have successfully developed a panel of ten P. 
knowlesi recombinant antigens. The results presented here provide important 
insights in the use of high throughput technology in serology and aid understanding 
of antibody isotype responses towards P. knowlesi infection in an endemic setting. 
We have shown for the first time proof of principle that multiplexing of P. knowlesi 
antigens can be used for serological assessment of human samples using the 
Multiplex bead Assay (MBA) and the protein microarray platforms. Two of these 
antigens have already been used as serosurveillance tools in two community 
surveys in Sabah, Malaysia, using the high throughput MBA technology. 
Interest in high throughput multiplex technology is rapidly increasing, particularly in 
the serology field. Modern advances in multiplexing technology have made it 
possible for us to not only quantitatively assess reactivity towards multiple targets at 
once, but also to simultaneously measure the qualitative host response to antigen 
exposure in the form of antibody isotypes and subclasses7. Detecting multiple 
targets in a single sample and analysing these in the context of multiple others as 
well as the host immune system has long been pursued. This is now possible with 
MBA and protein microarray technology, which not only enable multiplexing, but also 
have a low sample requirement, making it possible to screen thousands of samples 
for thousands of targets.  
Between the 1970s and 1980s, it was determined that Eukaryotic DNA could be 
replicated and transcribed in Escherichia coli8 and this was followed by the 
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development of the PCR method9, discoveries which enabled the development of 
recombinant gene expression technologies. Currently, genomic, proteomic and 
transcriptomic datasets are widely available, making it possible to use sequence-
based approaches to develop recombinant antigens. 
With these advances it is now possible to express specific genes of interest from a 
number of different organisms and many different expression platforms have since 
been developed10-14. These include yeast expression systems10,15,16, insect cell lines 
combined with recombinant viruses13, mammalian cell lines17-19, bacterial expression 
systems12,20 and cell-free systems21,22, just to name a few, each with their 
advantages and disadvantages. Recombinant proteins are an important part of drug 
discovery23, vaccine research12,24 and now serology25,26 as well. The development of 
recombinant antigens is an arduous task in itself, as reported in a number of 
reviews27,28, and this project was no different.  One of the major setbacks in 
developing these antigens was during the cloning phase of the production pipeline, 
with some candidate clones incorporating errors or producing low yields while other 
candidates refused to clone and transform after a series of troubleshooting attempts. 
In future, due to our large and increasing number of candidates, we would outsource 
the cloning stage of our development pipeline in order to reduce the time spent on 
this phase. By reducing the time spent on cloning troubleshooting, more time would 
be available to focus on the development and characterisation of antigens, ensuring 
specificity. Alternatively, we would consider applying a wider range of cloning 
techniques and determine the most suitable method for the project. We could 
potentially outsource the expression of our antigens as well, not only ensuring that 
they do express but also in order to obtain similar yields for each antigen and try to 
reduce variability between batches.  
Developing recombinant antigens is one thing, determining their usefulness is 
another, and this varies with the field it will be intended for. In our case, we would 
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eventually like to determine whether any of these P. knowlesi recombinant antigens 
or antigen combinations could be useful predictors of protection, for instance. 
There have been many studies indicating associations between specific malarial 
antigen reactivity and protection. Evidence for the Sporozoite Surface Protein 2 
(SSP2) suggested an immunogenic antigen involved in protection from disease in 
mice29 and in human vaccine studies30,31. Antibodies targeting antigen Merozoite 
Surface Protein 1-19 (MSP1-19), shown to be highly immunogenic in both P. 
falciparum32 and P. vivax33, appeared to be associated with protection34-37. 
Antibodies against PfSERA5 are thought to inhibit parasite growth 38,39 and to induce 
protection against blood stage in vivo infection40. On the other hand, it has also been 
shown that, rather than a single antigen, a panel of 19 different P. falciparum 
antigens were shown to be a potential signature associated with sporozoite-induced 
protective immunity in volunteers immunised with radiation attenuated P. falciparum 
sporozoites41. Other studies have shown similar outputs42,43. However, in the P. 
knowlesi field, there have not been many in depth studies such as these, and most 
were in macaque studies44-48. It is imperative that we not only develop new antigens, 
but also that we study their individual effects as well as their combined effects on the 
host immune system. Antigen recognition profiles using the protein microarray 
platform for instance, can not only be used to determine correlations with protection 
to disease but also with clinical disease stage classification41,49, susceptibility41 or in 
vitro virus neutralising activity50 for example, all of which can determine antigens 
which might be associated with protection. The advantage of using high throughput 
technology is largely the high throughput serum analyses it enables, making it 
possible to screen thousands of samples for thousands of targets. It is important that 
we develop new antigens but we must be aware of the limitations which exist in 
antigen discovery, for instance that expression and folding of the recombinant 
proteins might be different from the native structure. Another point to be aware of is 
that an antigen might elicit a cellular immune response rather than a humoral 
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response, which means analyses of responses towards new antigens should not be 
restricted to antibody reactivity. Determining T cell targets can be more challenging 
than determining antibody targets but several approaches have been developed to 
tackle this, such as epitope-prediction algorithms51 and high throughput cellular 
assays52. Cell-free in vitro transcription translation (IVTT) strategies have been used 
to identify targets of cellular immunity for influenza, cytomegalovirus and Epstein 
Barr virus in humans53 and Plasmodium spp. in mice53, measuring T cell activation. 
These cell-free systems are a successful alternative to producing proteins from 
complex organisms, such as Plasmodium spp., which have shown difficulties in cell-
based systems54,55. In future, alternative approaches such as this would be 
considered in order to produce P. knowlesi recombinant antigens which had proven 
difficult to produce. 
Given enough time, we would have liked to further expand our panel of P. knowlesi 
recombinant antigens and characterise them. We would have also liked to determine 
the ideal storage conditions for the individual antigens by performing an accelerated 
stability testing study. This would determine how stable the individual antigens are to 
specific conditions and how long they are stable for. Lasting high MFI values would 
be the ideal output for every antigen in all conditions. 
As previously discussed in this thesis, the presence or absence of antibodies can be 
used to infer exposure to infection, in this case, P. knowlesi malaria. We have 
successfully tested Malaysian clinical samples against our panel of recombinant 
antigens using the MBA platform and not only found similar results to the ELISA, but 
we were able to confirm that the MBA platform is more sensitive than the ELISA. 
Because the MBA platform is more sensitive, we observed some level of cross-
reactivity in the MBA analysis of the clinical samples. In hindsight it would have been 
ideal to have developed a number of species-specific antigens for both P. vivax and 
P. falciparum to test alongside the P. knowlesi antigens to be used as true control 
antigens in the assessment of cross reactivity. 
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After testing the clinical samples, for the first time, we examined sera at the 
community level using our panel of recombinant P. knowlesi antigens. Prior to this 
study it has only been possible to assess the presence of P. knowlesi in Malaysia 
from clinical research. Not only does this underestimate the presence of P. knowlesi 
at the community level, but as discussed, it is difficult to attribute the symptoms of 
malaria to a specific species. We were able to demonstrate surprisingly high levels 
of exposure to the parasite (PkSERA3 antigen 2: 31% (3139/10125) seropositive), 
and from an early age. Seropositivity was detected in children under 5 years and 
became more frequent with increase in age. This indicates that P. knowlesi malaria 
is being actively transmitted within those populations and has the potential to worsen 
if left unchecked. Although there was no statistically significant association between 
seropositivity and sleeping in the forest, a reasonably high number of people who did 
sleep in forests were seropositive to P. knowlesi (PkSERA3 antigen 2, 29.41% 
(10/34); PkSSP2, 20% (4/20)) and seeing macaques was associated with 
seropositivity (p<0.0001). Other studies have shown that occupations connected to 
forestry and farming led to higher parasitemias5. Not only is human behaviour 
connected to acquiring P. knowlesi infection but potentially macaque behaviour as 
well56. With the ever increasing rates of deforestation in Malaysia4,56, humans and 
wild macaques are brought closer together, which could increase the risk of infection 
in humans56. This increase in risk of P. knowlesi infection could compromise malaria 
elimination strategies in several countries if not attended to as soon as possible, 
especially because it is zoonotic. Malaria elimination strategies have not taken into 
account the existence of animal reservoirs besides the insect vector, because until 
recently, the human disease was thought to be caused purely by an obligate human 
parasite. With the zoonotic P. knowlesi recently being classified as the fifth human 
malaria parasite57, this story has changed, and now we must remember the original 
host to this organism, macaques. Current malaria control strategies include the use 
of antimalarial drugs combined with the use of bed nets and insecticides58, and now 
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a recently licensed vaccine against malaria exists, although with modest efficacy59. 
There are many challenges when it comes to the eradication of malaria due to the 
incorporation of multiple approaches, interventions, disciplines and organisations all 
leading to malaria surveillance, transmission interruption, and treatment 
programs58,60. One of the challenges of elimination for instance is P. vivax, which 
unlike P. falciparum, has a dormant liver-stage (hypnozoite) which can relapse many 
months or even years after the initial infection61,62. Rapid diagnostic tests (RDTs), 
routinely used for malaria diagnosis by many health facilities, detecting P. falciparum 
histidine-rich protein 2 and 3 (Pfhrp2 and Pfhrp3) have failed to detect malaria 
parasites in various countries63-67, due to a deletion of the gene encoding those 
proteins65,66. P. knowlesi elimination faces similar challenges purely because of the 
existence of the macaque animal reservoir68. 
The work presented here has potential applications for other emerging Plasmodium 
species. P. knowlesi is not the only monkey malaria parasite to make itself known as 
infecting humans. P. cynomolgi has recently been found to naturally infects humans 
as well, although it is not as common69. P. cynomolgi is morphologically similar to P. 
vivax1, therefore diagnosis of this parasite could be as difficult as it is for P. knowlesi. 
There has been much interest in recent years in trying to establish whether 
serological markers after challenge can be useful predictors of protection particularly 
in the field of vaccinology70. There have been high-profile studies such as in the 
development of the MVA85A vaccine, that have shown that we do not yet fully 
understand this field, particularly across different species71,72. It is becoming clear, 
however, that the quality of an immune response is at least as important as its 
magnitude, for instance the avidity of the response and the antigen or antigens it is 
directed towards. 
As it stands, we find it necessary to further develop our current panel of P. knowlesi 
antigens and to expand the number of antigens currently on it in order to better 
dissect the epidemiology of P. knowlesi in Southeast Asia. In future projects we 
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would like to use the next generation sequenced genome73 to further develop and 
increase the current P. knowlesi panel of recombinant antigens. We would also aim 
to raise polyclonal antibodies to each antigen in order to localise them on the 
parasite and further characterise their function in the parasite. Large panels of 
antigens have previously been used to successfully determine reactivity patterns in 
small and large groups of individuals42,74 and learning about the intricacies of these 
antigens could help us understand these patterns as well. 
Here we have described a novel panel of antigens and show the potential these 
antigens have in determining patterns of reactivity towards P. knowlesi infection in 
humans. Based on this, it will be possible to determine antibody patterns associated 
with protection and risk. Establishing associations between seropositive individuals 
and specific activities, occupations and/or geographic locations will enable the 
design of highly tailored interventions with the purpose of reducing the risk of 
infection and disease, leading to the eradication of P. knowlesi malaria in those 
areas. Once we have established the existence of associations and appropriate 
management strategies are put in place, it will be possible to achieve the goal of 
eradicating malaria in Southeast Asia.  
DEVELOPMENT OF PK SPECIES SPECIFIC REAGENTS TO CHARACTERISE ANTIBODY ISOTYPE PROFILES | LOU HERMAN 
 
214 | P a g e  
 
 
 
 
 
THE END  
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APPENDIX I: PUBLICATION 
RESEARCH ARTICLE 
Identification and validation of a novel panel of Plasmodium knowlesi biomarkers of 
serological exposure 
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APPENDIX II: PUBLICATION 
RESEARCH ARTICLE 
Exposure and infection to Plasmodium knowlesi in case study communities in 
Northern Sabah, Malaysia and Palawan, The Philippines 
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APPENDIX III: PROTOCOL 
Blood spot sample preparation standard operating protocol (SOP) 
1. OVERVIEW  
This SOP describes the processes and preparation of filter paper blood samples for 
the measurement of total IgG by ELISA.  
 
2. SAFETY  
Adhere to local safety regulations. Wear appropriate personal protective equipment.  
 
3. MATERIALS  
Equipment:  
a)  96 deep-well plates (Costar 0.5ml V well bottom assay block)  
b)  96 cap sealing mats (Thermo scientific)  
c)  8 or 12-channel 300 µl Pipette  
d)  Tweezers  
e)  Leather hole puncher (3 mm is ideal) 
f)  Protective nitrile gloves  
g)  Plate shaker  
 
Documents:  
Deep-well Plate Plan  
 
Reagents:  
All reagents should be stored according to the instructions supplied with them and 
disposed of at the expiry date recorded on the product.  
a)  Sodium Azide, BDH  
b)  Tween20, Sigma  
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c)  NaH2PO4 (Sodium dihydrogen orthophosphate), VWR International Ltd  
d)  Na2HPO4 (di-sodium hydrogen orthophosphate), VWR International Ltd  
e)  NaCl (Sodium chloride), Fisher scientific  
4. PREPARATION OF BUFFER SOLUTIONS  
All buffer solutions should be clearly labelled with:  
 * Reagent name  
 * Expiry date  
 * Preparation date  
 * Name of person who prepared the buffer 
Reagents should be stored under appropriate conditions. See Table 1 for details on 
preparation and storage.      
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Table 1: Buffer solutions - preparation 
Buffer solution Reagent/chemical Amount/Volume 
Phosphate buffered saline (PBS) 10X 
pH 7.2  
 
NaH2PO4 5.7 g 
Na2HPO4 16.7 g 
NaCl 85 g 
Distilled water Make up to 1 L 
Store at room temperature, dispose of after one month 
PBS/Tween (0.05%)  
 
PBS 10X 100 ml 
Tween 20 0.5 ml 
Distilled water 900 ml 
Make up as needed daily, dispose of unused solution at the end of each day  
Reconstitution buffer 
 
Sodium Azide 1 g 
PBS/Tween 1 L 
Store at room temperature, dispose of after 6 months (or earlier if solution becomes 
cloudy) 
NB: Sodium Azide is Poisonous. Adhere to appropriate safety regulations for handling 
and disposal. 
NB: Fully dissolve the reagent/chemical prior to use 
 
5. PREPARATION OF BLOODSPOTS 
5.1.  Label a 96 deep-well with the study ID, date, dilution 1/200 and label all deep wells 
with an unique ID, usually label deep well sequentially DW1, DW2, DW3, DW4 etc.  
5.2.  Use a paper template to record the location of the sample (Deep-well Plate Plan; 
example at the end of the document), indicating which  bloodspots occupy which 
well 
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Figure 1: How to label a deep well plate. 
 
5.3.  Add samples in the direction of 1A-H, 2A-H, 3A-H etc 
5.4.  Use all wells except leave columns 11 & 12 empty (this will become  clear why 
at a later date), as indicated in Figure 1. 
5.5.  Using the hole punch, cut a bloodspot disc from the middle of the filter paper sample 
(See Figure 2). It helps to have the hole of the  punch facing up so you can see your 
positioning, especially when the spots are small (Figure 2b).  
 
 
  
Figure  2. Example of location to cut the bloodspot from the filter paper sample. (A) 
Example of a cut spot. (B) Showing the suggested positioning of the hole punch over the 
spot 
LE
A
V
E 
EM
P
TY
 
A                                                           B 
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5.6.  Tap the blood spot out onto the work bench (ensuring it is cleaned 
 beforehand) (Figure 3a), use tweezers to pick up the bloodspot disc  and place in 
the well (Figure 3b). Record the sample identity number  (ID) on the plate plan. 
 
  
 
Figure 3: Handling blood spot discs once cut. (A) Tap the disc onto the work bench and then 
(B) pick up disc using tweezers and transfer to the deep well plate.    
 
5.7. If handling large numbers of papers, stack in lots of 8 (1 column per 
stack)  after cutting (Figure 4), and repackage at the end of the plate. This 
 increases processing speed and makes it easier to keep track of where 
 you are at (matching number of papers TO number of discs in deep well 
 plate AND id’s entered into plan). 
 
 
Figure 4: Place processed papers in piles of 8 to easily keep track of where 
you are up to. 
 A                                                                                             B 
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5.8.  Depending on paper filter type & size of the spot cutter, will determine 
 the amount of reconstitution buffer required. Optimal should be a 3 mm 
 diameter bloodspot cutter. See Table 2 for details.  
 
5.9.  Add the appropriate amount of the Reconstitution buffer (prepared in 
 step 4), to the wells containing bloodspots  
 
Table 2 –Filter paper reconstitution based on size of cutter  
Spot diameter (mm)  Amount of blood (μl)  Volume to reconstitute (μl) 
1.0  0.2  20  
1.5  0.5  50  
2.0  0.9  90  
2.5  1.4  140  
3.0  2.1  200  
3.5  2.8  280  
4.0  3.7  360  
4.5  4.7  460  
5.0  5.8  570  
5.5  7.0  690  
6.0  8.3  820  
*based on serum dilution equivalent to 1/200 dilution using 3MM (Whatman) filterpaper 
 
5.10.  Place a sealing mat on the deep-well plate. Ensure it is tightly sealed  
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5.11.  Place on plate shaker to rock gently overnight (5 - 10 revs/minute)  
 
5.12.  Next day inspect the plate: the circles of filter paper should appear white 
 and the solution pink/red in all cases.  
 
5.13.  Reject samples where the circle is still red and the solution pale (Figure 
3).  
 
                           
Figure 5: Bloodspot elution showing good (pink/red solution and white spot) 
and bad elutions (spot remains red and solution shows little colour). 
 
5.14.  Plates stored, sealed, at 4°C for up to 1 month or 1 year at - 20°C. 
5.12.  Type up written plate plans into an Excel spreadsheet. This allows for 
samples IDs to be easily merged with the processed data. 
 
 
 
Good                    Bad 
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                                                                  STUDY NAME: 
  DATE:                                                      DEEP WELL ID:                                                                          NAME: 
 1 2 3 4 5 6 7 8 9 10 
A           
B           
C           
D           
E           
F           
G           
H           
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APPENDIX IV: CHAPTER 4 SUPPLEMENTARY DATA 
Supplementary figures for chapter 4: Identification and validation of a novel panel of 
Plasmodium knowlesi serological biomarkers of exposure, and their subsequent use 
in the measurement of exposure and infection in Malaysia and The Philippines.  
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Figure 1 Amino acid sequences alignments for AMA1 gene sequence between P. knowlesi, P. falciparum, P. 
vivax, P. malariae and P. ovale/P. simiovale. Asterisks indicate fully conserved residues, colons indicates strong 
residue conservation (>0.5, Gonnet PAM 250 matrix), period indicates weak residue conservation (=<0.5, Gonnet 
PAM 250 matrix). Blank spaces indicate no residue conservation  
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Figure 2 Amino acid sequences alignments for MSP1 gene sequence between P. knowlesi, P. falciparum, P. 
vivax, P. malariae and P. ovale/P. simiovale. Sequence for PkMSP1-19 is highlighted in yellow. Asterisks indicate 
fully conserved residues, colons indicates strong residue conservation (>0.5, Gonnet PAM 250 matrix), period 
indicates weak residue conservation (=<0.5, Gonnet PAM 250 matrix). Blank spaces indicate no residue 
conservation.  
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Figure 3 Amino acid sequences alignments for SERA3 gene sequence between P. knowlesi, P. falciparum, P. 
vivax, P. malariae and P. ovale/P. simiovale. P. knowlesi-specific sequences selected for development as 
constructs are highlighted in yellow (SERA3 fragment 1 and fragment 2). Asterisks indicate fully conserved 
residues, colons indicates strong residue conservation (>0.5, Gonnet PAM 250 matrix), period indicates weak 
residue conservation (=<0.5, Gonnet PAM 250 matrix). Blank spaces indicate no residue conservation.  
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Figure 4 Amino acid sequences alignments for SSP2/TRAP gene sequence between P. knowlesi, P. falciparum, 
P. vivax, P. malariae and P. ovale/P. simiovale. P. knowlesi-specific sequence selected for development as 
constructs is highlighted in yellow. Asterisks indicate fully conserved residues, colons indicates strong residue 
conservation (>0.5, Gonnet PAM 250 matrix), period indicates weak residue conservation (=<0.5, Gonnet PAM 
250 matrixBlank spaces indicate no residue conservation.  
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Figure 5 Amino acid sequences alignments for TSERA2 gene sequence between P. knowlesi, P. falciparum, P. 
vivax, P. malariae and P. ovale/P. simiovale. P. knowlesi-specific sequences selected for development as 
constructs (TSERA2 fragment 1 and 2) are highlighted in yellow. Asterisks indicate fully conserved residues, 
colons indicates strong residue conservation (>0.5, Gonnet PAM 250 matrix), period indicates weak residue 
conservation (=<0.5, Gonnet PAM 250 matrix). Blank spaces indicate no residue conservation. 
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Table 1 Single-nucleotide polymorphism frequencies of Malaysian clinical isolates sequences within P. 
knowlesi candidate genes. 
Gene Chromosme 
Geno
me 
Posit
ion 
Refer
ence 
Allele 
Gen
e 
Posit
ion 
Num
ber 
Sam
ples 
Cluster 
1 
Cluster 
2 Cluster 3  Type 
PKH_08
0030 
ordered_PKN
H_08_v2 
1366
9 A 186 19 
cluster
1:3/8 
cluster
2:0/5 
cluster3:
16/32 
synonymous
_variant 
PKH_08
0030 
ordered_PKN
H_08_v2 
1371
4 C 231 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
synonymous
_variant 
PKH_03
1240 
ordered_PKN
H_03_v2 
2116
8 G 819 40 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
32/32 
synonymous
_variant 
PKH_03
1240 
ordered_PKN
H_03_v2 
2117
7 A 810 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
missense_va
riant 
PKH_03
1240 
ordered_PKN
H_03_v2 
2118
5 G 802 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_03
1240 
ordered_PKN
H_03_v2 
2119
0 A 797 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
missense_va
riant 
PKH_03
1240 
ordered_PKN
H_03_v2 
2120
1 A 786 39 
cluster
1:7/8 
cluster
2:0/5 
cluster3:
32/32 
synonymous
_variant 
PKH_03
1240 
ordered_PKN
H_03_v2 
2121
9 A 768 4 
cluster
1:3/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_03
1240 
ordered_PKN
H_03_v2 
2127
3 T 714 10 
cluster
1:2/8 
cluster
2:0/5 
cluster3:
8/32 
synonymous
_variant 
PKH_03
1240 
ordered_PKN
H_03_v2 
2128
8 G 699 27 
cluster
1:3/8 
cluster
2:0/5 
cluster3:
24/32 
synonymous
_variant 
PKH_03
1240 
ordered_PKN
H_03_v2 
2132
1 G 666 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
synonymous
_variant 
PKH_03
1240 
ordered_PKN
H_03_v2 
2179
3 T 194 14 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
14/32 
missense_va
riant 
PKH_03
1240 
ordered_PKN
H_03_v2 
2232
2 A 67 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_03
1240 
ordered_PKN
H_03_v2 
2234
1 C 48 3 
cluster
1:3/8 
cluster
2:0/5 
cluster3:
0/32 
missense_va
riant 
PKH_03
1240 
ordered_PKN
H_03_v2 
2234
8 T 41 40 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
32/32 
missense_va
riant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8715
4 C 269 2 
cluster
1:2/8 
cluster
2:0/5 
cluster3:
0/32 
missense_va
riant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8726
6 A 381 26 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
26/32 
synonymous
_variant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8729
3 T 408 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8733
2 A 447 32 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
32/32 
synonymous
_variant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8733
4 C 449 2 
cluster
1:2/8 
cluster
2:0/5 
cluster3:
0/32 
missense_va
riant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8735
6 A 471 8 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
0/32 
synonymous
_variant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8739
3 C 508 8 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
0/32 
missense_va
riant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8739
9 A 514 32 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
32/32 
missense_va
riant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8740
8 A 523 32 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
32/32 
missense_va
riant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8741
9 C 534 8 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
0/32 
synonymous
_variant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8742
0 A 535 40 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
32/32 
missense_va
riant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8743
6 C 551 40 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
32/32 
missense_va
riant 
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PKH_14
0010 
ordered_PKN
H_14_v2 
8744
3 A 558 8 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
0/32 
missense_va
riant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8745
7 T 572 40 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
32/32 
missense_va
riant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8746
4 T 579 32 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
32/32 
missense_va
riant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8747
1 A 586 32 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
32/32 
missense_va
riant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8747
3 A 588 32 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
32/32 
missense_va
riant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8748
2 C 597 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8748
5 G 600 40 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
32/32 
synonymous
_variant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8748
8 A 603 32 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
32/32 
synonymous
_variant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8749
5 A 610 37 
cluster
1:5/8 
cluster
2:0/5 
cluster3:
32/32 
missense_va
riant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8751
2 A 627 35 
cluster
1:3/8 
cluster
2:0/5 
cluster3:
32/32 
synonymous
_variant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8754
1 G 656 8 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
0/32 
missense_va
riant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8755
2 T 667 8 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
0/32 
missense_va
riant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8756
6 A 681 8 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
0/32 
synonymous
_variant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8757
9 A 694 8 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
0/32 
missense_va
riant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8758
8 A 703 8 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
0/32 
missense_va
riant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8763
8 T 753 43 
cluster
1:8/8 
cluster
2:3/5 
cluster3:
32/32 
synonymous
_variant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8764
4 C 759 10 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
0/32 
missense_va
riant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8767
1 G 786 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8767
9 A 794 31 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
31/32 
missense_va
riant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8768
5 A 800 8 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
0/32 
missense_va
riant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8769
9 A 814 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8775
7 G 872 4 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
4/32 
missense_va
riant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8776
7 A 882 26 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
26/32 
synonymous
_variant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8777
0 A 885 10 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
0/32 
missense_va
riant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8777
3 T 888 32 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
32/32 
synonymous
_variant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8781
1 G 926 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
missense_va
riant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8781
3 T 928 10 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
0/32 
missense_va
riant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8782
3 G 938 10 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
0/32 
missense_va
riant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8784
4 A 959 10 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
0/32 
missense_va
riant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8785
0 A 965 8 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
0/32 
missense_va
riant 
PKH_14
0010 
ordered_PKN
H_14_v2 
8785
4 T 969 8 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
0/32 
synonymous
_variant 
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PKH_04
1230 
ordered_PKN
H_04_v2 
5908
52 C 36 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 NA 
PKH_04
1230 
ordered_PKN
H_04_v2 
5908
56 A 40 21 
cluster
1:1/8 
cluster
2:0/5 
cluster3:
20/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5911
98 G 382 5 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
5/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5912
01 G 385 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5912
09 G 393 1 
cluster
1:1/8 
cluster
2:0/5 
cluster3:
0/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5912
10 C 394 13 
cluster
1:5/8 
cluster
2:0/5 
cluster3:
8/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5912
28 C 412 4 
cluster
1:0/8 
cluster
2:2/5 
cluster3:
2/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5912
51 C 435 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5912
69 G 453 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5912
84 G 468 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5913
11 G 495 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5913
29 A 513 39 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
31/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5913
38 C 522 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5913
41 G 525 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5913
47 C 531 3 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
3/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5913
51 G 535 9 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
9/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5913
54 G 538 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5913
66 T 550 42 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
32/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5913
89 G 573 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5914
16 T 600 24 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
24/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5914
23 C 607 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5914
26 G 610 27 
cluster
1:8/8 
cluster
2:1/5 
cluster3:
18/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5914
33 A 617 29 
cluster
1:8/8 
cluster
2:1/5 
cluster3:
20/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5914
40 G 624 10 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
10/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5914
44 A 628 42 
cluster
1:8/8 
cluster
2:3/5 
cluster3:
31/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5914
47 G 631 2 
cluster
1:0/8 
cluster
2:2/5 
cluster3:
0/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5914
53 C 637 9 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
8/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5914
56 A 640 9 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
8/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5914
64 G 648 8 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
8/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5914
83 C 667 29 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
19/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5914
85 G 669 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
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PKH_04
1230 
ordered_PKN
H_04_v2 
5914
91 T 675 29 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
19/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5914
94 C 678 6 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
6/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5914
98 T 682 8 
cluster
1:0/8 
cluster
2:2/5 
cluster3:
6/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5915
00 A 684 16 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
6/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5915
22 C 706 1 
cluster
1:1/8 
cluster
2:0/5 
cluster3:
0/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5915
32 G 716 25 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
15/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5918
05 A 726 23 
cluster
1:1/8 
cluster
2:2/5 
cluster3:
20/32 NA 
PKH_04
1230 
ordered_PKN
H_04_v2 
5918
12 G 733 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5918
15 C 736 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5918
41 C 762 5 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
4/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5918
98 A 819 42 
cluster
1:8/8 
cluster
2:3/5 
cluster3:
31/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5919
07 A 828 43 
cluster
1:8/8 
cluster
2:3/5 
cluster3:
32/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5919
13 A 834 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5919
43 T 864 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5919
46 G 867 15 
cluster
1:0/8 
cluster
2:2/5 
cluster3:
13/32 NA 
PKH_04
1230 
ordered_PKN
H_04_v2 
5921
71 C 888 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5922
13 C 930 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5922
43 A 960 2 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
1/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5922
61 T 978 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5922
64 C 981 1 
cluster
1:1/8 
cluster
2:0/5 
cluster3:
0/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5922
70 C 987 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5922
92 G 1009 9 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
9/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5923
18 C 1035 6 
cluster
1:0/8 
cluster
2:2/5 
cluster3:
4/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5923
24 C 1041 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5923
38 G 1055 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5923
39 C 1056 3 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
2/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5923
64 A 1081 41 
cluster
1:7/8 
cluster
2:2/5 
cluster3:
32/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5923
77 A 1094 41 
cluster
1:7/8 
cluster
2:2/5 
cluster3:
32/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5923
81 A 1098 1 
cluster
1:1/8 
cluster
2:0/5 
cluster3:
0/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5923
93 A 1110 2 
cluster
1:2/8 
cluster
2:0/5 
cluster3:
0/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5923
95 G 1112 8 
cluster
1:0/8 
cluster
2:2/5 
cluster3:
6/32 
missense_va
riant 
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PKH_04
1230 
ordered_PKN
H_04_v2 
5924
20 T 1137 5 
cluster
1:0/8 
cluster
2:2/5 
cluster3:
3/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5924
34 T 1151 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5924
36 G 1153 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5924
39 G 1156 19 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
19/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5924
61 G 1178 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5924
64 A 1181 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5924
71 C 1188 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5924
84 A 1201 3 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
3/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5924
85 A 1202 9 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
8/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5924
92 T 1209 21 
cluster
1:7/8 
cluster
2:3/5 
cluster3:
11/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5924
93 A 1210 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5925
07 G 1224 43 
cluster
1:8/8 
cluster
2:3/5 
cluster3:
32/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5925
08 G 1225 43 
cluster
1:8/8 
cluster
2:3/5 
cluster3:
32/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5925
14 C 1231 34 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
24/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5925
19 A 1236 37 
cluster
1:8/8 
cluster
2:3/5 
cluster3:
26/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5925
22 G 1239 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5925
27 C 1244 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5925
37 T 1254 36 
cluster
1:8/8 
cluster
2:3/5 
cluster3:
25/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5925
69 A 1286 9 
cluster
1:4/8 
cluster
2:2/5 
cluster3:
3/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5925
74 C 1291 22 
cluster
1:5/8 
cluster
2:3/5 
cluster3:
14/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5925
77 G 1294 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5925
87 A 1304 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5925
94 C 1311 31 
cluster
1:8/8 
cluster
2:3/5 
cluster3:
20/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5925
97 G 1314 12 
cluster
1:1/8 
cluster
2:1/5 
cluster3:
10/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5926
21 C 1338 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5926
42 T 1359 28 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
18/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5926
52 A 1369 39 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
29/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5926
69 G 1386 40 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
30/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5926
70 C 1387 7 
cluster
1:5/8 
cluster
2:0/5 
cluster3:
2/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5927
14 C 1431 3 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
2/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5927
20 C 1437 34 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
24/32 
synonymous
_variant 
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PKH_04
1230 
ordered_PKN
H_04_v2 
5927
26 A 1443 33 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
23/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5927
32 A 1449 41 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
31/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5927
35 T 1452 33 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
23/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5927
38 G 1455 33 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
23/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5927
59 C 1476 30 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
20/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5927
63 C 1480 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5927
71 G 1488 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5928
12 C 1529 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5928
18 C 1535 4 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
4/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5928
20 T 1537 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5928
25 C 1542 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5929
06 A 1623 41 
cluster
1:8/8 
cluster
2:1/5 
cluster3:
32/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5929
09 G 1626 15 
cluster
1:1/8 
cluster
2:0/5 
cluster3:
14/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5930
35 C 1752 7 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
7/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5930
71 A 1788 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5931
26 T 1843 9 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
9/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5931
55 G 1872 40 
cluster
1:8/8 
cluster
2:1/5 
cluster3:
31/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5932
63 A 1980 5 
cluster
1:4/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5933
32 A 2049 4 
cluster
1:2/8 
cluster
2:0/5 
cluster3:
2/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5933
84 C 2101 3 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
3/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5935
36 C 2253 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5935
69 T 2286 9 
cluster
1:0/8 
cluster
2:2/5 
cluster3:
7/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5936
11 C 2328 20 
cluster
1:6/8 
cluster
2:0/5 
cluster3:
14/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5936
14 G 2331 26 
cluster
1:6/8 
cluster
2:0/5 
cluster3:
20/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5936
41 A 2358 34 
cluster
1:7/8 
cluster
2:1/5 
cluster3:
26/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5936
47 A 2364 25 
cluster
1:1/8 
cluster
2:1/5 
cluster3:
23/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5936
49 C 2366 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5936
50 G 2367 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5936
56 C 2373 3 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
2/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5936
77 C 2394 3 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
2/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5936
86 G 2403 3 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
3/32 
synonymous
_variant 
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PKH_04
1230 
ordered_PKN
H_04_v2 
5937
01 T 2418 7 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
6/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5937
07 C 2424 29 
cluster
1:7/8 
cluster
2:0/5 
cluster3:
22/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5937
14 T 2431 12 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
11/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5937
28 A 2445 4 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
4/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5937
34 T 2451 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5937
36 G 2453 3 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
3/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5937
44 G 2461 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5942
40 A 2957 12 
cluster
1:2/8 
cluster
2:2/5 
cluster3:
8/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5942
59 G 2976 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5942
77 C 2994 3 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
3/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5942
83 T 3000 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5942
89 C 3006 27 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
26/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5942
92 T 3009 28 
cluster
1:1/8 
cluster
2:1/5 
cluster3:
26/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5942
93 T 3010 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5943
25 G 3042 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5943
37 G 3054 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5943
41 C 3058 10 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
0/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5943
70 C 3087 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5944
34 C 3151 2 
cluster
1:0/8 
cluster
2:2/5 
cluster3:
0/32 
missense_va
riant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5944
72 C 3189 5 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
4/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5944
81 G 3198 43 
cluster
1:8/8 
cluster
2:3/5 
cluster3:
32/32 
synonymous
_variant 
PKH_04
1230 
ordered_PKN
H_04_v2 
5945
11 C 3228 3 
cluster
1:0/8 
cluster
2:2/5 
cluster3:
1/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5956
18 C 13 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5956
27 A 22 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5958
68 C 39 24 
cluster
1:7/8 
cluster
2:2/5 
cluster3:
15/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5958
69 G 40 18 
cluster
1:1/8 
cluster
2:0/5 
cluster3:
17/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5958
77 G 48 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5958
82 G 53 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5958
92 A 63 17 
cluster
1:5/8 
cluster
2:0/5 
cluster3:
12/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5958
98 G 69 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5959
05 G 76 39 
cluster
1:7/8 
cluster
2:2/5 
cluster3:
30/32 
missense_va
riant 
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PKH_04
1240 
ordered_PKN
H_04_v2 
5959
12 A 83 22 
cluster
1:5/8 
cluster
2:1/5 
cluster3:
16/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5959
22 G 93 29 
cluster
1:5/8 
cluster
2:2/5 
cluster3:
22/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5959
25 T 96 22 
cluster
1:5/8 
cluster
2:1/5 
cluster3:
16/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5959
63 C 134 5 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
5/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5959
68 G 139 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5960
54 A 225 11 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
11/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5960
76 G 247 12 
cluster
1:2/8 
cluster
2:1/5 
cluster3:
9/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5960
78 T 249 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5960
83 A 254 13 
cluster
1:2/8 
cluster
2:1/5 
cluster3:
10/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5960
97 G 268 25 
cluster
1:2/8 
cluster
2:0/5 
cluster3:
23/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5960
98 C 269 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5961
09 G 280 27 
cluster
1:3/8 
cluster
2:1/5 
cluster3:
23/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5961
11 C 282 9 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
9/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5961
22 A 293 33 
cluster
1:3/8 
cluster
2:1/5 
cluster3:
29/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5961
31 C 302 33 
cluster
1:8/8 
cluster
2:1/5 
cluster3:
24/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5961
33 A 304 43 
cluster
1:8/8 
cluster
2:3/5 
cluster3:
32/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5961
35 T 306 42 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
32/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5961
47 C 318 1 
cluster
1:1/8 
cluster
2:0/5 
cluster3:
0/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5961
49 G 320 9 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
8/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5961
59 G 330 34 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
24/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5961
65 A 336 29 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
19/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5961
89 A 360 24 
cluster
1:8/8 
cluster
2:1/5 
cluster3:
15/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5962
07 G 378 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5962
58 T 429 29 
cluster
1:7/8 
cluster
2:0/5 
cluster3:
22/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5962
70 C 441 6 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
6/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5962
73 G 444 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5962
76 C 447 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5962
79 T 450 13 
cluster
1:2/8 
cluster
2:0/5 
cluster3:
11/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5963
08 A 479 3 
cluster
1:0/8 
cluster
2:3/5 
cluster3:
0/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5963
43 A 514 14 
cluster
1:2/8 
cluster
2:3/5 
cluster3:
9/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5963
47 A 518 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
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PKH_04
1240 
ordered_PKN
H_04_v2 
5963
50 A 521 14 
cluster
1:2/8 
cluster
2:3/5 
cluster3:
9/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5963
52 A 523 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5963
59 A 530 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5963
64 C 535 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5963
93 G 564 3 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
3/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5964
11 C 582 12 
cluster
1:4/8 
cluster
2:0/5 
cluster3:
8/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5964
38 C 609 4 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
4/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5964
50 G 621 19 
cluster
1:6/8 
cluster
2:0/5 
cluster3:
13/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5967
01 G 657 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5967
25 T 681 4 
cluster
1:3/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5967
40 G 696 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5967
61 A 717 43 
cluster
1:8/8 
cluster
2:3/5 
cluster3:
32/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5967
76 C 732 39 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
31/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5969
97 C 801 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5970
00 C 804 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5970
24 A 828 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5970
29 A 833 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5970
39 A 843 2 
cluster
1:0/8 
cluster
2:2/5 
cluster3:
0/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5970
48 T 852 5 
cluster
1:0/8 
cluster
2:2/5 
cluster3:
3/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5970
72 C 876 32 
cluster
1:3/8 
cluster
2:2/5 
cluster3:
27/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5970
86 A 890 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5970
90 C 894 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5971
53 C 957 11 
cluster
1:6/8 
cluster
2:0/5 
cluster3:
5/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5971
57 C 961 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5971
62 T 966 4 
cluster
1:4/8 
cluster
2:0/5 
cluster3:
0/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5971
71 C 975 5 
cluster
1:0/8 
cluster
2:3/5 
cluster3:
2/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5971
73 G 977 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5971
74 C 978 4 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
4/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5971
90 A 994 43 
cluster
1:8/8 
cluster
2:3/5 
cluster3:
32/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5971
92 C 996 3 
cluster
1:0/8 
cluster
2:3/5 
cluster3:
0/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5972
05 G 1009 17 
cluster
1:2/8 
cluster
2:0/5 
cluster3:
15/32 
missense_va
riant 
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PKH_04
1240 
ordered_PKN
H_04_v2 
5972
06 G 1010 2 
cluster
1:1/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5972
31 T 1035 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5972
38 C 1042 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5972
40 C 1044 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5972
46 C 1050 10 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
10/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5972
47 G 1051 3 
cluster
1:3/8 
cluster
2:0/5 
cluster3:
0/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5972
52 A 1056 22 
cluster
1:3/8 
cluster
2:0/5 
cluster3:
19/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5972
55 G 1059 5 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
4/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5972
63 A 1067 9 
cluster
1:3/8 
cluster
2:0/5 
cluster3:
6/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5972
65 G 1069 8 
cluster
1:2/8 
cluster
2:0/5 
cluster3:
6/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5972
71 G 1075 6 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
6/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5972
84 A 1088 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5972
90 T 1094 25 
cluster
1:5/8 
cluster
2:1/5 
cluster3:
19/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5972
93 C 1097 10 
cluster
1:3/8 
cluster
2:1/5 
cluster3:
6/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5972
97 G 1101 3 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
3/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5973
01 G 1105 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5973
04 G 1108 15 
cluster
1:2/8 
cluster
2:2/5 
cluster3:
11/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5973
05 C 1109 11 
cluster
1:4/8 
cluster
2:1/5 
cluster3:
6/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5973
13 G 1117 30 
cluster
1:8/8 
cluster
2:3/5 
cluster3:
19/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5973
19 C 1123 20 
cluster
1:2/8 
cluster
2:2/5 
cluster3:
16/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5973
23 T 1127 8 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
8/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5973
29 C 1133 3 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
3/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5973
40 G 1144 34 
cluster
1:8/8 
cluster
2:3/5 
cluster3:
23/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5973
42 A 1146 3 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
3/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5973
43 G 1147 15 
cluster
1:0/8 
cluster
2:2/5 
cluster3:
13/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5973
47 G 1151 3 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
3/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5973
52 G 1156 5 
cluster
1:0/8 
cluster
2:2/5 
cluster3:
3/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5973
91 A 1195 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5974
01 A 1205 27 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
17/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5974
06 G 1210 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5974
19 G 1223 32 
cluster
1:8/8 
cluster
2:1/5 
cluster3:
23/32 
missense_va
riant 
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PKH_04
1240 
ordered_PKN
H_04_v2 
5974
53 A 1257 2 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
1/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5974
59 G 1263 9 
cluster
1:4/8 
cluster
2:0/5 
cluster3:
5/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5974
66 C 1270 13 
cluster
1:6/8 
cluster
2:1/5 
cluster3:
6/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5974
68 G 1272 1 
cluster
1:1/8 
cluster
2:0/5 
cluster3:
0/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5974
87 A 1291 15 
cluster
1:7/8 
cluster
2:1/5 
cluster3:
7/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5974
94 G 1298 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5975
05 C 1309 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5975
07 C 1311 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5975
11 C 1315 14 
cluster
1:7/8 
cluster
2:0/5 
cluster3:
7/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5975
15 C 1319 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5975
20 G 1324 43 
cluster
1:8/8 
cluster
2:3/5 
cluster3:
32/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5975
24 G 1328 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5975
82 G 1386 1 
cluster
1:1/8 
cluster
2:0/5 
cluster3:
0/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5975
85 T 1389 6 
cluster
1:0/8 
cluster
2:3/5 
cluster3:
3/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5976
04 G 1408 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5976
09 C 1413 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5977
29 T 1533 2 
cluster
1:2/8 
cluster
2:0/5 
cluster3:
0/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5977
35 C 1539 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5977
56 G 1560 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
synonymous
_variant 
PKH_04
1240 
ordered_PKN
H_04_v2 
5977
76 A 1580 3 
cluster
1:3/8 
cluster
2:0/5 
cluster3:
0/32 NA 
PKH_02
1580 
ordered_PKN
H_02_v2 
7634
08 A 623 34 
cluster
1:5/8 
cluster
2:1/5 
cluster3:
28/32 
missense_va
riant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7634
19 A 612 42 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
32/32 
missense_va
riant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7634
23 A 608 42 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
32/32 
missense_va
riant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7634
24 C 607 42 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
32/32 
missense_va
riant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7634
25 A 606 42 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
32/32 
synonymous
_variant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7634
68 A 563 2 
cluster
1:1/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7634
98 A 533 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7635
00 A 531 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
synonymous
_variant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7635
05 G 526 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7635
08 G 523 3 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
3/32 
missense_va
riant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7635
10 C 521 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
missense_va
riant 
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PKH_02
1580 
ordered_PKN
H_02_v2 
7635
24 C 507 7 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
7/32 
synonymous
_variant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7635
38 C 493 18 
cluster
1:2/8 
cluster
2:0/5 
cluster3:
16/32 stop_gained 
PKH_02
1580 
ordered_PKN
H_02_v2 
7635
52 G 479 41 
cluster
1:8/8 
cluster
2:1/5 
cluster3:
32/32 
missense_va
riant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7635
71 G 460 1 
cluster
1:1/8 
cluster
2:0/5 
cluster3:
0/32 
missense_va
riant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7635
78 A 453 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
synonymous
_variant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7635
92 A 439 41 
cluster
1:8/8 
cluster
2:1/5 
cluster3:
32/32 
missense_va
riant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7636
14 A 417 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7636
72 G 359 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
missense_va
riant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7636
80 A 351 4 
cluster
1:4/8 
cluster
2:0/5 
cluster3:
0/32 
synonymous
_variant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7637
16 A 315 41 
cluster
1:8/8 
cluster
2:1/5 
cluster3:
32/32 
synonymous
_variant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7637
43 T 288 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
synonymous
_variant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7637
53 G 278 5 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
5/32 
missense_va
riant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7637
55 C 276 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
synonymous
_variant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7637
61 T 270 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7637
88 G 243 3 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
3/32 
synonymous
_variant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7637
98 C 233 28 
cluster
1:2/8 
cluster
2:0/5 
cluster3:
26/32 
missense_va
riant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7638
01 A 230 28 
cluster
1:2/8 
cluster
2:0/5 
cluster3:
26/32 
missense_va
riant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7638
02 G 229 4 
cluster
1:4/8 
cluster
2:0/5 
cluster3:
0/32 
missense_va
riant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7638
04 G 227 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7638
27 T 204 22 
cluster
1:2/8 
cluster
2:0/5 
cluster3:
20/32 
synonymous
_variant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7638
43 C 188 3 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
3/32 
missense_va
riant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7638
49 T 182 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7638
55 C 176 4 
cluster
1:4/8 
cluster
2:0/5 
cluster3:
0/32 
missense_va
riant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7638
59 T 172 24 
cluster
1:3/8 
cluster
2:0/5 
cluster3:
21/32 
missense_va
riant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7638
71 G 160 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7638
77 A 154 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
missense_va
riant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7639
07 C 124 3 
cluster
1:1/8 
cluster
2:0/5 
cluster3:
2/32 
missense_va
riant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7640
62 G 93 5 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
5/32 
synonymous
_variant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7640
63 C 92 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
missense_va
riant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7640
84 G 71 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 stop_gained 
PKH_02
1580 
ordered_PKN
H_02_v2 
7640
87 G 68 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
missense_va
riant 
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PKH_02
1580 
ordered_PKN
H_02_v2 
7641
12 G 43 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
missense_va
riant 
PKH_02
1580 
ordered_PKN
H_02_v2 
7641
48 C 7 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_03
1930 
ordered_PKN
H_03_v2 
9767
82 A 636 8 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
7/32 
synonymous
_variant 
PKH_03
1930 
ordered_PKN
H_03_v2 
9770
48 A 370 4 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
4/32 
missense_va
riant 
PKH_14
2200 
ordered_PKN
H_14_v2 
1060
699 G 33 9 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
9/32 
synonymous
_variant 
PKH_14
2200 
ordered_PKN
H_14_v2 
1060
700 A 34 3 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
3/32 
missense_va
riant 
PKH_14
2200 
ordered_PKN
H_14_v2 
1060
706 G 40 4 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
4/32 
missense_va
riant 
PKH_14
2200 
ordered_PKN
H_14_v2 
1060
713 G 47 13 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
13/32 
missense_va
riant 
PKH_14
2200 
ordered_PKN
H_14_v2 
1060
725 T 59 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_14
2200 
ordered_PKN
H_14_v2 
1060
738 G 72 41 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
31/32 
synonymous
_variant 
PKH_14
2200 
ordered_PKN
H_14_v2 
1060
749 C 83 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_14
2200 
ordered_PKN
H_14_v2 
1060
759 C 93 5 
cluster
1:3/8 
cluster
2:1/5 
cluster3:
1/32 
synonymous
_variant 
PKH_14
2200 
ordered_PKN
H_14_v2 
1061
007 T 119 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 NA 
PKH_14
2200 
ordered_PKN
H_14_v2 
1061
073 C 185 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_14
2200 
ordered_PKN
H_14_v2 
1061
080 A 192 37 
cluster
1:8/8 
cluster
2:1/5 
cluster3:
28/32 
synonymous
_variant 
PKH_14
2200 
ordered_PKN
H_14_v2 
1061
083 A 195 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_14
2200 
ordered_PKN
H_14_v2 
1061
094 C 206 9 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_14
2200 
ordered_PKN
H_14_v2 
1061
117 C 229 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_14
2200 
ordered_PKN
H_14_v2 
1061
127 C 239 3 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
3/32 
missense_va
riant 
PKH_14
2200 
ordered_PKN
H_14_v2 
1061
162 C 274 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_14
2200 
ordered_PKN
H_14_v2 
1061
207 C 319 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
missense_va
riant 
PKH_14
2200 
ordered_PKN
H_14_v2 
1061
210 G 322 2 
cluster
1:2/8 
cluster
2:0/5 
cluster3:
0/32 
missense_va
riant 
PKH_14
2200 
ordered_PKN
H_14_v2 
1061
214 T 326 1 
cluster
1:1/8 
cluster
2:0/5 
cluster3:
0/32 
missense_va
riant 
PKH_14
2200 
ordered_PKN
H_14_v2 
1061
220 A 332 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_14
2200 
ordered_PKN
H_14_v2 
1061
265 C 377 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
missense_va
riant 
PKH_14
2200 
ordered_PKN
H_14_v2 
1061
267 G 379 3 
cluster
1:2/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_14
2200 
ordered_PKN
H_14_v2 
1061
496 C 608 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
missense_va
riant 
PKH_14
2200 
ordered_PKN
H_14_v2 
1061
497 A 609 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
synonymous
_variant 
PKH_14
2200 
ordered_PKN
H_14_v2 
1061
511 G 623 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_14
2200 
ordered_PKN
H_14_v2 
1061
560 A 672 36 
cluster
1:8/8 
cluster
2:1/5 
cluster3:
27/32 
synonymous
_variant 
PKH_14
2200 
ordered_PKN
H_14_v2 
1061
694 G 806 8 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
0/32 
missense_va
riant 
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PKH_14
2200 
ordered_PKN
H_14_v2 
1061
773 A 885 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_14
2200 
ordered_PKN
H_14_v2 
1061
788 A 900 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_14
2200 
ordered_PKN
H_14_v2 
1061
806 C 918 43 
cluster
1:8/8 
cluster
2:3/5 
cluster3:
32/32 
synonymous
_variant 
PKH_14
2200 
ordered_PKN
H_14_v2 
1061
822 T 934 8 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
8/32 
synonymous
_variant 
PKH_14
2200 
ordered_PKN
H_14_v2 
1061
912 G 1024 7 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
7/32 
missense_va
riant 
PKH_14
2200 
ordered_PKN
H_14_v2 
1061
945 A 1057 22 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
22/32 
missense_va
riant 
PKH_14
2200 
ordered_PKN
H_14_v2 
1061
948 G 1060 3 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
3/32 
missense_va
riant 
PKH_14
2200 
ordered_PKN
H_14_v2 
1061
978 C 1090 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
229 G 21 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
359 T 151 20 
cluster
1:6/8 
cluster
2:2/5 
cluster3:
12/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
360 C 152 20 
cluster
1:6/8 
cluster
2:2/5 
cluster3:
12/32 stop_gained 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
362 T 154 8 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
7/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
365 G 157 8 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
7/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
367 T 159 6 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
5/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
374 G 166 15 
cluster
1:6/8 
cluster
2:2/5 
cluster3:
7/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
376 T 168 7 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
7/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
378 C 170 8 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
7/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
382 C 174 22 
cluster
1:6/8 
cluster
2:2/5 
cluster3:
14/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
383 C 175 6 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
6/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
410 G 202 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
411 C 203 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
418 T 210 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
436 C 228 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
472 T 264 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
505 C 297 1 
cluster
1:1/8 
cluster
2:0/5 
cluster3:
0/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
514 C 306 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
540 A 332 23 
cluster
1:6/8 
cluster
2:3/5 
cluster3:
14/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
544 C 336 3 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
3/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
601 G 393 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
671 T 463 32 
cluster
1:0/8 
cluster
2:2/5 
cluster3:
30/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
694 G 486 1 
cluster
1:1/8 
cluster
2:0/5 
cluster3:
0/32 
synonymous
_variant 
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PKH_07
2850 
ordered_PKN
H_07_v2 
1277
730 T 522 30 
cluster
1:4/8 
cluster
2:3/5 
cluster3:
23/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
739 A 531 6 
cluster
1:4/8 
cluster
2:1/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
755 A 547 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
780 A 572 18 
cluster
1:4/8 
cluster
2:3/5 
cluster3:
11/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
784 C 576 33 
cluster
1:8/8 
cluster
2:3/5 
cluster3:
22/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
790 T 582 11 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
11/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
791 C 583 30 
cluster
1:8/8 
cluster
2:3/5 
cluster3:
19/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
802 T 594 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
804 C 596 29 
cluster
1:8/8 
cluster
2:3/5 
cluster3:
18/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
809 A 601 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
813 C 605 20 
cluster
1:5/8 
cluster
2:1/5 
cluster3:
14/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
821 G 613 8 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
8/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
824 G 616 12 
cluster
1:4/8 
cluster
2:0/5 
cluster3:
8/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
830 C 622 2 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
1/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
850 C 642 12 
cluster
1:4/8 
cluster
2:0/5 
cluster3:
8/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
852 C 644 5 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
5/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
856 C 648 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
859 G 651 3 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
3/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
976 A 768 13 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
13/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
978 A 770 10 
cluster
1:3/8 
cluster
2:0/5 
cluster3:
7/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
979 C 771 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
983 G 775 12 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
12/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
985 C 777 9 
cluster
1:2/8 
cluster
2:0/5 
cluster3:
7/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1277
996 T 788 26 
cluster
1:3/8 
cluster
2:0/5 
cluster3:
23/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
012 T 804 21 
cluster
1:5/8 
cluster
2:3/5 
cluster3:
13/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
020 T 812 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
021 C 813 3 
cluster
1:3/8 
cluster
2:0/5 
cluster3:
0/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
069 T 861 16 
cluster
1:2/8 
cluster
2:1/5 
cluster3:
13/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
081 C 873 9 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
9/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
084 G 876 3 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
3/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
088 T 880 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
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PKH_07
2850 
ordered_PKN
H_07_v2 
1278
108 C 900 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
118 T 910 33 
cluster
1:8/8 
cluster
2:1/5 
cluster3:
24/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
136 A 928 32 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
22/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
138 C 930 31 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
21/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
141 G 933 26 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
16/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
144 G 936 31 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
21/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
146 A 938 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
151 C 943 31 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
21/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
190 A 982 11 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
10/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
194 C 986 11 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
10/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
219 C 1011 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
235 A 1027 4 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
4/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
243 C 1035 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
252 A 1044 8 
cluster
1:6/8 
cluster
2:0/5 
cluster3:
2/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
255 G 1047 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
277 C 1069 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
290 T 1082 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
303 G 1095 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
318 G 1110 1 
cluster
1:1/8 
cluster
2:0/5 
cluster3:
0/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
330 G 1122 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
339 G 1131 3 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
3/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
351 A 1143 1 
cluster
1:1/8 
cluster
2:0/5 
cluster3:
0/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
369 A 1161 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
372 C 1164 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
374 C 1166 2 
cluster
1:1/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
411 C 1203 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
414 A 1206 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
525 A 1317 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
537 T 1329 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
567 G 1359 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
568 G 1360 4 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
4/32 
missense_va
riant 
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PKH_07
2850 
ordered_PKN
H_07_v2 
1278
597 G 1389 3 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
3/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
609 A 1401 17 
cluster
1:6/8 
cluster
2:0/5 
cluster3:
11/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
618 A 1410 29 
cluster
1:6/8 
cluster
2:3/5 
cluster3:
20/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
627 A 1419 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
629 A 1421 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
646 G 1438 21 
cluster
1:6/8 
cluster
2:3/5 
cluster3:
12/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
650 A 1442 21 
cluster
1:6/8 
cluster
2:3/5 
cluster3:
12/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
651 A 1443 27 
cluster
1:6/8 
cluster
2:3/5 
cluster3:
18/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
658 C 1450 20 
cluster
1:6/8 
cluster
2:2/5 
cluster3:
12/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
672 T 1464 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
676 C 1468 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
678 A 1470 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
689 A 1481 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
731 G 1523 29 
cluster
1:8/8 
cluster
2:3/5 
cluster3:
18/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
752 A 1544 32 
cluster
1:8/8 
cluster
2:3/5 
cluster3:
21/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
756 G 1548 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
761 A 1553 29 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
19/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
764 C 1556 9 
cluster
1:2/8 
cluster
2:2/5 
cluster3:
5/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
784 G 1576 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
798 C 1590 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
801 C 1593 8 
cluster
1:6/8 
cluster
2:0/5 
cluster3:
2/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
843 A 1635 7 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
7/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
885 T 1677 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
888 G 1680 19 
cluster
1:1/8 
cluster
2:3/5 
cluster3:
15/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1278
915 G 1707 9 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
9/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1279
047 A 1839 25 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
24/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1279
068 A 1860 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1279
089 A 1881 9 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1279
107 T 1899 29 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
19/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1279
143 G 1935 2 
cluster
1:2/8 
cluster
2:0/5 
cluster3:
0/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1279
170 T 1962 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
synonymous
_variant 
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PKH_07
2850 
ordered_PKN
H_07_v2 
1279
176 A 1968 16 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
16/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1279
209 C 2001 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1279
218 G 2010 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1279
241 C 2033 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1279
254 A 2046 6 
cluster
1:6/8 
cluster
2:0/5 
cluster3:
0/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1279
265 A 2057 6 
cluster
1:6/8 
cluster
2:0/5 
cluster3:
0/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1279
269 C 2061 3 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
3/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1279
281 G 2073 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1279
284 C 2076 10 
cluster
1:0/8 
cluster
2:2/5 
cluster3:
8/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1279
287 A 2079 2 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1279
304 C 2096 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1279
309 T 2101 7 
cluster
1:4/8 
cluster
2:0/5 
cluster3:
3/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1279
776 A 2568 23 
cluster
1:7/8 
cluster
2:2/5 
cluster3:
14/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1279
779 A 2571 23 
cluster
1:7/8 
cluster
2:2/5 
cluster3:
14/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1279
782 G 2574 3 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
3/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1279
791 G 2583 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1279
800 C 2592 3 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
3/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1279
809 T 2601 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1279
830 T 2622 3 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
3/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1279
851 G 2643 39 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
29/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1279
872 A 2664 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1279
914 G 2706 8 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
0/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1279
920 G 2712 4 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
4/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1279
938 G 2730 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1279
983 C 2775 4 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
4/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1279
994 A 2786 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
004 C 2796 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
020 C 2812 32 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
32/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
029 G 2821 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
073 A 2865 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
085 A 2877 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
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PKH_07
2850 
ordered_PKN
H_07_v2 
1280
094 G 2886 8 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
0/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
114 A 2906 41 
cluster
1:8/8 
cluster
2:1/5 
cluster3:
32/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
132 T 2924 27 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
26/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
141 C 2933 3 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
3/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
146 G 2938 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
154 A 2946 1 
cluster
1:1/8 
cluster
2:0/5 
cluster3:
0/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
155 G 2947 16 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
15/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
157 A 2949 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
176 G 2968 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
179 C 2971 10 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
10/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
182 G 2974 10 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
10/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
242 A 3034 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
264 C 3056 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
278 A 3070 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
294 G 3086 14 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
14/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
303 C 3095 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
306 C 3098 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
316 A 3108 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
317 G 3109 15 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
15/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
318 G 3110 15 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
15/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
319 C 3111 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
320 G 3112 15 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
15/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
332 A 3124 2 
cluster
1:0/8 
cluster
2:2/5 
cluster3:
0/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
334 T 3126 31 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
21/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
340 G 3132 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
341 A 3133 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
342 C 3134 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
344 A 3136 3 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
3/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
347 C 3139 33 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
23/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
350 G 3142 33 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
23/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
353 A 3145 29 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
19/32 
missense_va
riant 
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PKH_07
2850 
ordered_PKN
H_07_v2 
1280
365 G 3157 8 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
7/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
371 G 3163 27 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
17/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
372 G 3164 27 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
17/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
374 G 3166 37 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
27/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
378 T 3170 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
380 A 3172 19 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
9/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
385 G 3177 21 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
11/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
386 C 3178 7 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
7/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
391 T 3183 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
393 G 3185 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
400 A 3192 22 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
21/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
425 A 3217 10 
cluster
1:8/8 
cluster
2:1/5 
cluster3:
1/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
433 A 3225 41 
cluster
1:8/8 
cluster
2:1/5 
cluster3:
32/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
469 G 3261 16 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
16/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
494 T 3286 32 
cluster
1:8/8 
cluster
2:1/5 
cluster3:
23/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
502 A 3294 42 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
32/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
519 C 3311 26 
cluster
1:0/8 
cluster
2:2/5 
cluster3:
24/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
523 T 3315 25 
cluster
1:0/8 
cluster
2:2/5 
cluster3:
23/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
529 T 3321 25 
cluster
1:0/8 
cluster
2:2/5 
cluster3:
23/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
540 C 3332 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
553 T 3345 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
567 C 3359 1 
cluster
1:1/8 
cluster
2:0/5 
cluster3:
0/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
568 A 3360 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
581 G 3373 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
637 C 3429 5 
cluster
1:4/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
656 T 3448 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
682 G 3474 4 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
4/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
712 A 3504 3 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
3/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
716 C 3508 23 
cluster
1:8/8 
cluster
2:3/5 
cluster3:
12/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
718 G 3510 5 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
5/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
725 T 3517 8 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
0/32 
synonymous
_variant 
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PKH_07
2850 
ordered_PKN
H_07_v2 
1280
733 C 3525 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
751 A 3543 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
754 T 3546 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
757 C 3549 24 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
24/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
761 A 3553 43 
cluster
1:8/8 
cluster
2:3/5 
cluster3:
32/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
781 G 3573 12 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
12/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
823 G 3615 30 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
30/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
830 T 3622 8 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
0/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
892 C 3684 6 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
6/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
897 G 3689 15 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
15/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
907 A 3699 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
928 C 3720 3 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
3/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
934 C 3726 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1280
935 C 3727 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
051 G 3843 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
069 C 3861 9 
cluster
1:0/8 
cluster
2:2/5 
cluster3:
7/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
087 C 3879 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
090 C 3882 2 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
111 A 3903 8 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
8/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
135 T 3927 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
156 G 3948 9 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
9/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
174 C 3966 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
177 A 3969 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
186 T 3978 43 
cluster
1:8/8 
cluster
2:3/5 
cluster3:
32/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
202 G 3994 8 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
0/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
204 A 3996 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
215 T 4007 26 
cluster
1:8/8 
cluster
2:2/5 
cluster3:
16/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
225 A 4017 6 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
6/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
231 T 4023 3 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
3/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
474 C 4266 11 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
11/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
500 T 4292 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
missense_va
riant 
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PKH_07
2850 
ordered_PKN
H_07_v2 
1281
585 G 4377 6 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
6/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
594 G 4386 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
600 C 4392 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
609 A 4401 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
684 C 4476 16 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
16/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
696 T 4488 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
714 C 4506 2 
cluster
1:0/8 
cluster
2:2/5 
cluster3:
0/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
732 A 4524 3 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
3/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
735 C 4527 3 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
3/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
747 C 4539 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
760 T 4552 8 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
0/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
777 C 4569 8 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
0/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
789 C 4581 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
792 A 4584 43 
cluster
1:8/8 
cluster
2:3/5 
cluster3:
32/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
795 C 4587 7 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
7/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
798 A 4590 40 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
32/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
801 A 4593 5 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
5/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
828 C 4620 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
829 C 4621 2 
cluster
1:0/8 
cluster
2:2/5 
cluster3:
0/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
873 G 4665 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
876 C 4668 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
882 G 4674 29 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
29/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
891 T 4683 41 
cluster
1:8/8 
cluster
2:1/5 
cluster3:
32/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
906 C 4698 2 
cluster
1:0/8 
cluster
2:2/5 
cluster3:
0/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
921 G 4713 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
928 C 4720 41 
cluster
1:8/8 
cluster
2:3/5 
cluster3:
30/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
970 G 4762 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
982 G 4774 5 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
4/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1281
986 A 4778 5 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
4/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1282
003 G 4795 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1282
005 T 4797 9 
cluster
1:8/8 
cluster
2:1/5 
cluster3:
0/32 
synonymous
_variant 
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PKH_07
2850 
ordered_PKN
H_07_v2 
1282
006 C 4798 6 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
5/32 
missense_va
riant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1282
017 G 4809 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1282
069 C 4861 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1282
122 C 4914 3 
cluster
1:3/8 
cluster
2:0/5 
cluster3:
0/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1282
170 A 4962 9 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1282
242 A 5034 43 
cluster
1:8/8 
cluster
2:3/5 
cluster3:
32/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1282
311 A 5103 4 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
4/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1282
410 C 5202 5 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
4/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1282
440 C 5232 7 
cluster
1:7/8 
cluster
2:0/5 
cluster3:
0/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1282
467 G 5259 9 
cluster
1:8/8 
cluster
2:1/5 
cluster3:
0/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1282
470 A 5262 16 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
15/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1282
473 G 5265 16 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
15/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1282
542 G 5334 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1282
584 T 5376 34 
cluster
1:0/8 
cluster
2:2/5 
cluster3:
32/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1282
608 C 5400 25 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
25/32 
synonymous
_variant 
PKH_07
2850 
ordered_PKN
H_07_v2 
1282
618 C 5410 8 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
0/32 
synonymous
_variant 
PKH_07
3420 
ordered_PKN
H_07_v2 
1489
352 A 181 2 
cluster
1:1/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_07
3420 
ordered_PKN
H_07_v2 
1489
582 G 411 10 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
2/32 
synonymous
_variant 
PKH_07
3420 
ordered_PKN
H_07_v2 
1489
615 G 444 20 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
20/32 
missense_va
riant 
PKH_07
3420 
ordered_PKN
H_07_v2 
1489
646 A 475 32 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
32/32 
missense_va
riant 
PKH_07
3420 
ordered_PKN
H_07_v2 
1489
655 C 484 40 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
32/32 
missense_va
riant 
PKH_07
3420 
ordered_PKN
H_07_v2 
1489
666 T 495 8 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
0/32 
synonymous
_variant 
PKH_07
3420 
ordered_PKN
H_07_v2 
1489
714 G 543 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
synonymous
_variant 
PKH_07
3420 
ordered_PKN
H_07_v2 
1489
720 C 549 8 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
0/32 
synonymous
_variant 
PKH_07
3420 
ordered_PKN
H_07_v2 
1489
737 T 566 32 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
32/32 
missense_va
riant 
PKH_07
3420 
ordered_PKN
H_07_v2 
1489
755 G 584 8 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
0/32 
missense_va
riant 
PKH_07
3420 
ordered_PKN
H_07_v2 
1489
806 T 635 8 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
0/32 
missense_va
riant 
PKH_07
3420 
ordered_PKN
H_07_v2 
1489
810 A 639 8 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
0/32 
missense_va
riant 
PKH_07
3420 
ordered_PKN
H_07_v2 
1489
839 T 668 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_07
3420 
ordered_PKN
H_07_v2 
1489
867 C 696 11 
cluster
1:8/8 
cluster
2:1/5 
cluster3:
2/32 
synonymous
_variant 
PKH_07
3420 
ordered_PKN
H_07_v2 
1489
981 G 810 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
missense_va
riant 
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PKH_07
3420 
ordered_PKN
H_07_v2 
1490
026 G 855 8 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
0/32 
synonymous
_variant 
PKH_07
3420 
ordered_PKN
H_07_v2 
1490
030 G 859 8 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
0/32 
missense_va
riant 
PKH_07
3420 
ordered_PKN
H_07_v2 
1490
065 C 894 1 
cluster
1:1/8 
cluster
2:0/5 
cluster3:
0/32 
synonymous
_variant 
PKH_07
3420 
ordered_PKN
H_07_v2 
1490
077 C 906 32 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
32/32 
missense_va
riant 
PKH_07
3420 
ordered_PKN
H_07_v2 
1490
092 A 921 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_07
3420 
ordered_PKN
H_07_v2 
1490
099 G 928 21 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
21/32 
missense_va
riant 
PKH_12
0020 
ordered_PKN
H_12_v2 
2142
094 T 1253 7 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
7/32 
missense_va
riant 
PKH_12
0020 
ordered_PKN
H_12_v2 
2143
133 G 219 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_12
0020 
ordered_PKN
H_12_v2 
2143
226 A 126 3 
cluster
1:3/8 
cluster
2:0/5 
cluster3:
0/32 
synonymous
_variant 
PKH_12
0020 
ordered_PKN
H_12_v2 
2143
259 A 93 3 
cluster
1:3/8 
cluster
2:0/5 
cluster3:
0/32 
synonymous
_variant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2906
373 C 7 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
missense_va
riant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2906
403 G 37 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
missense_va
riant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2906
411 C 45 1 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
0/32 
synonymous
_variant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2906
470 A 104 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2906
491 A 125 23 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
23/32 
missense_va
riant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2906
519 G 153 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2906
679 A 313 8 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
0/32 
missense_va
riant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2906
703 G 337 40 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
32/32 
missense_va
riant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2906
704 T 338 40 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
32/32 
missense_va
riant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2906
710 G 344 40 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
32/32 
missense_va
riant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2906
731 A 365 39 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
31/32 
missense_va
riant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2906
741 T 375 17 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
17/32 
synonymous
_variant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2906
756 G 390 40 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
32/32 
synonymous
_variant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2906
766 T 400 40 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
32/32 
missense_va
riant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2906
767 C 401 15 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
7/32 stop_gained 
PKH_12
1770 
ordered_PKN
H_12_v2 
2906
775 G 409 3 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
3/32 
missense_va
riant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2906
778 A 412 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
missense_va
riant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2906
867 C 501 14 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
14/32 
synonymous
_variant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2906
871 G 505 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2906
884 C 518 10 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
10/32 
missense_va
riant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2906
892 G 526 10 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
10/32 
missense_va
riant 
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PKH_12
1770 
ordered_PKN
H_12_v2 
2906
933 C 567 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2906
943 C 577 32 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
32/32 
missense_va
riant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2906
953 A 587 32 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
32/32 
missense_va
riant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2907
016 G 650 8 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
0/32 
missense_va
riant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2907
154 C 788 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2907
157 T 791 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
missense_va
riant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2907
179 G 813 23 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
23/32 
synonymous
_variant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2907
204 G 838 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2907
206 T 840 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
missense_va
riant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2907
209 A 843 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
missense_va
riant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2907
245 C 879 8 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
8/32 
synonymous
_variant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2907
251 C 885 1 
cluster
1:1/8 
cluster
2:0/5 
cluster3:
0/32 
synonymous
_variant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2907
254 A 888 2 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
2/32 
synonymous
_variant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2907
296 G 930 3 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
3/32 
missense_va
riant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2907
317 T 951 41 
cluster
1:8/8 
cluster
2:1/5 
cluster3:
32/32 
synonymous
_variant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2907
322 G 956 2 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
1/32 
missense_va
riant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2907
359 C 993 35 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
27/32 
synonymous
_variant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2907
383 C 1017 5 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
5/32 
synonymous
_variant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2907
385 C 1019 8 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
0/32 
missense_va
riant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2907
389 C 1023 2 
cluster
1:0/8 
cluster
2:2/5 
cluster3:
0/32 
missense_va
riant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2907
431 C 1065 26 
cluster
1:0/8 
cluster
2:1/5 
cluster3:
25/32 
missense_va
riant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2907
435 T 1069 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2907
442 T 1076 13 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
13/32 
missense_va
riant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2907
443 C 1077 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
synonymous
_variant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2907
480 A 1114 32 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
32/32 
missense_va
riant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2907
481 G 1115 8 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
0/32 
missense_va
riant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2907
497 T 1131 33 
cluster
1:0/8 
cluster
2:2/5 
cluster3:
31/32 
synonymous
_variant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2907
507 G 1141 33 
cluster
1:0/8 
cluster
2:2/5 
cluster3:
31/32 
missense_va
riant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2907
513 C 1147 32 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
32/32 
missense_va
riant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2907
537 C 1171 30 
cluster
1:3/8 
cluster
2:1/5 
cluster3:
26/32 
missense_va
riant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2907
559 A 1193 1 
cluster
1:1/8 
cluster
2:0/5 
cluster3:
0/32 
missense_va
riant 
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PKH_12
1770 
ordered_PKN
H_12_v2 
2907
673 G 1307 16 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
16/32 
missense_va
riant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2907
686 C 1320 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2907
687 G 1321 1 
cluster
1:0/8 
cluster
2:0/5 
cluster3:
1/32 
missense_va
riant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2907
697 C 1331 40 
cluster
1:8/8 
cluster
2:0/5 
cluster3:
32/32 
missense_va
riant 
PKH_12
1770 
ordered_PKN
H_12_v2 
2907
698 G 1332 4 
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APPENDIX V: PROTOCOL 
ELISA for Sera (using TMB) – 384 well plates Biomek standard operating 
protocol (SOP) 
1. Overview 
 
This SOP describes the ELISA process in order to estimate levels of specific 
antibodies to malaria antigens, using TMB rather than OPD at the substrate for HRP. 
 
2. Safety 
 
Adhere to local safety regulations. Wear appropriate personal protective equipment. 
 
3. Materials 
Equipment 
a) 384-well ELISA plates: Clear flat-bottom immuno nonsterile  (4titude) 
b) 96 deep well plates (Costar 0.5ml v bottom assay block) 
c) 3 plastic buckets/containers for washing plates 
d) Plastic buckets/containers for storing plates o/n 
e) Plate Reader 
f) Protective latex or nitrile gloves 
g) Multi-channel pipettes (8 or 12 channel 5-50 µl, 30-300 µl) 
h) Range of single channel pipettes 
i) Tips 
 
Documents 
Laboratory Record Book 
 
Reagents 
All reagents should be stored according to the instructions supplied with them and 
disposed of at the expiry date recorded on the product. 
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a)  Antigens 
b) Controls (standard dilutions) 
c) TMB one component HRP microwell substrate (#TMBW-1000-01; Tebu-bio 
laboratories) 
d) Tween 20 (Sigma) 
e) Skimmed milk powder (Supermarket) 
f) Horseradish peroxidase-conjugated rabbit anti-human IgG (#P0214; Dako) 
g) NaH2PO4 (Sodium dihydrogen orthophosphate) (VWR International Ltd) 
h) Na2HPO4 (di-sodium hydrogen orthophosphate) (VWR International Ltd) 
i) NaCl (Sodium chloride) (Fisher scientific) 
j) H2SO4 (Sulphuric acid) (BDH) 
k) Na2CO3 (Sodium carbonate) (Sigma) 
l) NaHCO3 (Sodium hydrogen carbonate) (VWR International Ltd) 
 
4. Preparation of Buffer Solutions  
 
All buffer solutions should be clearly labelled with:  
 * Reagent name  
 * Expiry date  
 * Preparation date  
 * Name of person who prepared the buffer 
 
Reagents should be stored under appropriate conditions. See Table 1 for details on 
preparation and storage.      
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Table 1: Buffer solutions - preparation 
Buffer solution Reagent/chemical Amount/Volume 
Phosphate buffered saline (PBS) 10X pH 7.2  
 
NaH2PO4 5.7 g 
Na2HPO4 16.7 g 
NaCl 85 g 
Distilled water Make up to 1 L 
Store at room temperature, dispose of after one month 
PBS/Tween (0.05%) wash solution  
 
PBS 10X 500 ml 
Tween 20 2.5 ml 
Distilled water 4.5 L 
Make up as needed daily, dispose of unused solution at the end of each day  
Coating buffer pH 9.4-9.6  
 
Na2CO3 1.59 g 
NaHCO3 2.93 g 
Distilled water Make up to 1 L 
Store at 4°C, dispose of after one month, pH should be 9.5 ± 0.2  
BLOCKING SOLUTION: 
1% skimmed milk powder in PBS/Tween 
Skimmed milk powder 10 g 
PBS/Tween 1 L 
Make up as needed daily, dispose of unused solution at the end of each day 
0.2 M H2SO4 
H2SO4 concentrate 10.7 ml 
Distilled water 
Add concentrate to ~800 ml 
of water, then top up to 1 L 
N.B.     Appropriate safety regulations must be adhered to when handling H2SO4  
            Store at room temperature, dispose of after six months  
N.B. Fully dissolve the reagent/chemical prior to use  
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5. Methods 
Drying plates 
a) Expel any excess liquid from the wash process on paper towel, but DO NOT let 
the plates dry out. 
5.1. ELISA  
5.1.1. Day 1: Mark out ELISA plates and record the template for each in laboratory 
record book. Column allocation (figure 1 and 2): 
 Wells 1-20 A-P -samples (tested in duplicate) 
 Wells 23 A-F and 24 A-F -positive control standard curve 
 Wells 23 G-H and 24 G-H are for negative controls (if required) 
 Wells 21 A-P and 22 A-P, 23 I-P and 24 I-P are blank wells 
 
Figure 1 - 384-well ELISA plate layout 
 
Figure 2- Sample positions in 96-well deepwell plate 
1.1.2. Prepare the antigen in coating buffer, taking into account the number 
of plates requiring coating and ensuring the antigen is diluted to the 
correct concentration (as previously determined via antigen titration). 
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Coating antigen must be aliquoted into a 96-well deepwell (DW) plate. Store DW at -
20°C once finished adding to ELISA plates. 
As shown in figure 3, 1 quad (eg. 1A, 1B, 2A, 2B) in the 384-well plate is the 
equivalent of 1 well (eg. 1A plate 1, 1A plate 2, 1A plate 3 and 1A plate 4) in 4 
different 96-well ELISA plates. 
For help calculating volumes plus 20% contingency: 
25μl per well x 384 wells ≈ 10ml (total volume required for one 384-well plate) 
25μl x 4 wells = 1 quad = 100μl (Total volume in 1 quad) 
When preparing the coating buffer with antigen in the DW, the total volume in 1 quad 
is the total volume in 1 well in the DW plate. 
With the 20% added contingency, we will say that the total coating volume in 1 quad 
is 120μl. 
120μl x 96wells in DW x number of 384well plates = Total Coating buffer needed 
120μl x number of 384well plates = Total volume in each well of the DW plate 
 
 
Figure 3- 384 well ELISA plate. Red squares indicate 1 quad 
5.1.3. Set up the Biomek deck as indicated in figure 4. Position TL1 must 
always remain free, allowing the robotic arm to pick up tip boxes and 
switch boxes. Place p250 tips in position P3. Place the coating antigen 
DW in position P6. Place the 384-well ELISA plate to be coated with that 
antigen in position P14. 
Add 25μl of this diluted antigen, prepared in 5.1.2, to all wells of the 384 well 
ELISA plate using program “Lou 1 copy1 Add Coating Antibody” .Tap the 
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plate to ensure the liquid covers the base of the wells or use a pipette tip to burst 
any bubbles. Dispose of tips. 
 
 
Figure 4 – Biomek deck set up for coating step 
5.1.4. Incubate plates overnight at 4°C, to prevent evaporation store plates in a 
plastic bucket/container with wet blue towel. Consider wrapping plates in 
cling film if evaporation is still a problem. 
 
NOTE: Prepare washing buffer, blocking buffer and samples the evening before and 
store at 4°C. 
Roughly a total of 50ml of blocking buffer per 384well plate is required (300μl per 
quad) for both the blocking and sample addition steps. 
 
5.1.5. Day 2:  Set up the Biomek deck as indicated in figure 5. Place p250 tips 
in position P3. Place the blocking buffer container (can be a pipette tip 
box lid) in position P6. Place the 384-well ELISA plate in position P14. 
Place the discard container in position P17. Place the wash buffer 
container in position P18. Wash ELISA plates three times in 100μl 
PBS/Tween wash solution using program “Lou 2 copy1 Wash x3 Add 
Block”. 
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Make sure there is enough wash buffer in the respective container on the deck 
and make sure the waste container does not spill over. Pause the Biomek in 
order to refill or empty containers by either breaching the sensor curtain or by 
manually pausing in overlord. Once all containers have been attended to, click 
play and the Biomek will take over from where it was paused. 
 
Figure 5 – Biomek deck set up for wash and blocking buffer step 
5.1.6. The Biomek program will automatically pause to allow plate drying. Dry 
each plate using method above. Add 75μl of blocking solution to each 
well on the plate using the same program as above (just hit enter and the 
program will pick up where it stopped). 
5.1.7. Incubate plates at room temperature for three hours with a cover plate on 
top to avoid evaporation and to keep safe from dust.   
5.1.8. One hour before the end of this time remove control aliquot from freezer 
and allow to thaw 
5.1.9. Make up standard dilutions in the samples deep well plate, refer to annex 
1, ensuring sufficient volume for each plate being assayed 
5.1.10. Set up the Biomek deck as indicated in figure 6. Use the same p250 tips 
as the wash and blocking buffer step in position P3. Place p20 tips in 
positions P7 and P11. Place the blocking buffer container (can be a 
pipette tip box lid) in position P10. Place the 384-well ELISA plate in 
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position P14. Place the discard container in position P17. Place the wash 
buffer container in position P18. Place sample DW1 in position P5 and 
sample DW2 in position P6. Wash ELISA plates three times in 100μl 
PBS/Tween wash solution using program “Lou 3 copy1 @ 1/1000 Wash 
x3 Add Samples / Milk” or “Lou 3 copy1 @ 1/2000 Wash x3 Add 
Samples / Milk”, or adjust programing to the required dilution. Make sure 
there is enough wash buffer in the respective container on the deck and 
make sure the waste container does not spill over. Pause the Biomek in 
order to refill or empty containers by either breaching the sensor curtain 
or by manually pausing in overlord. Once all containers have been 
attended to, click play and the Biomek will take over from where it was 
paused. Dispose of p20 tips. The p250 tips may still be used the next day 
for the washing step if they appear to be clear and unobstructed. 
 
Figure 6 - Biomek deck set up for washing and sample addition step 
5.1.11. The Biomek program will automatically pause to allow plate drying. Dry 
plates as described above. Add blocking solution, samples and controls 
to the ELISA plate using the same program. The volumes added depends 
on the final dilution of sample required (change Biomek programing for 
different sample dilutions!!). 
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Examples: 
If the sample stock dilution is at 1/200 and a 1/1000 dilution is required for the 
ELISA, the sample stocks will need to be diluted 1 in 5 e.g. 5μl of sample stock 
added to 20μl blocking solution. 
If the sample stock dilution is at 1/200 and a 1/2000 dilution is required for the 
ELISA, the sample stocks will need to be diluted 1 in 10 e.g. 2.5μl of sample stock 
added to 22.5μl blocking solution. 
The samples will be automatically added in duplicates as shown in figure 1. 
Columns 1-5 of the DW (Samples) will be on the first half of the ELISA plate & 
columns 6-10 will be on the second half of the ELISA plate. The volume added will 
depend on the final dilution required. 
5.1.12. Add Negative controls at the required dilution to wells 23 G-H and 24 G-H 
(if required) and blocking solution to 11H and 12H as added for the 
sample Alternatively: Add the same volume, as added for the positive 
control, of blocking solution to 21 A-P and 22 A-P, 23 I-P and 24 I-P (see 
table 1).  
5.1.13. Incubate plates overnight at 4°C, to prevent evaporation store plates in a 
plastic bucket/container with wet blue towel. Consider wrapping plates in 
cling film if evaporation is still a problem. 
 
NOTE: Prepare washing buffer, secondary antibody, TMB and Stop solution 
the evening before and store at 4°C. 
Secondary, Stop solution and TBM should be aliquoted into a 96well DW 
plate. Wrap the TMB DW plate in foil to protect from light. 
 
5.1.14. Day 3: Set up the Biomek deck as indicated in figure 7. Use the same 
p250 tips from day 2 wash step in position P3. Place the secondary DW 
in position P6. Place the 384-well ELISA plate in position P14. Place the 
discard container in position P17. Place the wash buffer container in 
position P18. Wash five times in PBS/Tween wash solution using 
program “Lou 4 copy1 Wash x5 Add secondary”. Make sure there is 
enough wash buffer in the respective container on the deck and make 
sure the waste container does not spill over. Pause the Biomek in order 
to refill or empty containers by either breaching the sensor curtain or by 
manually pausing in overlord. Once all containers have been attended to, 
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click play and the Biomek will take over from where it was paused. Dry 
plates  
 
 
Figure 7 - Biomek deck set up for secondary addition step 
5.1.15. Make the appropriate volume for the number of ELISA plates of 
conjugate solution Preparation: horseradish peroxidase-conjugated rabbit 
anti-human IgG diluted at 1/15,000, in PBS/Tween wash solution. Refer 
to calculations in 5.1.2 to prepare appropriate volumes of secondary 
solution. 
5.1.16. Add 25μl of conjugate solution to each well of the ELISA plates using the 
same program. 
5.1.17. Incubate for three hours at room temperature with a cover plate on top to 
avoid evaporation and to keep safe from dust. 
5.1.18. Set up the Biomek deck as indicated in figure 8. Use the same p250 tips 
from the wash step in position P3. Place new p250 tips in position P7 and 
position P11. Place the TMB DW in position P6 only when the ELISA 
plates are ready to receive it (keep TMB away from light during the wash 
step). Place the stop buffer DW in position P5. Place the 384-well ELISA 
plate in position P14. Place the discard container in position P17. Place 
the wash buffer container in position P18. Wash five times in PBS/Tween 
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wash solution using program “Lou 5 copy1 Wash x5 Add TMB and 
STOP”. 
 
Figure 8 - Biomek deck set up for TMB step 
5.1.19. Add 50μl per well of TMB substrate solution. Leave at room temperature 
in the dark for 15 min for the assay to develop. During the 15 min 
incubation period it is possible to start washing a second ELISA plate and 
have it washed, dried and developing before the end of the incubation 
time of the first plate.  
5.1.20. Stop the reaction by adding 25 µl 0.2 M sulphuric acid (H2SO4) using 
program “Lou 6 copy1 add STOP”.  
5.1.21. Read plates as soon as possible at 450 nm using the Softmax Pro 
program. Open reading template “My Documents/Lou”. Export data to 
“C:/Documents and Settings/iimmhlab/Desktop/LH_ELISA_Reads” folder 
as text file. Softmax Pro will automatically save the plate readings in the 
“My Documents/Lou” but it will only be labelled with the date and time. 
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Annex 1 
Working out control serial dilutions: 
Controls must be prepared in the samples DW columns 11 and 12 when using only 
two DW sample plates. 
Or  
Controls must be prepared in a separate DW plate in columns 11 and 12. 
 
Rather than prepare controls separately, a stock of controls that will be enough for all 
the ELISA plates is made. This cuts down on variability from separate dilutions. 
The examples below are routinely used for MSP-1 and AMA-1 antigens. However, 
control preparations may vary for other antigens (refer to Figure 1 for control 
positions). 
Transfer them to the DW used in the assay (sample transfer DW, not sample storage 
DW). Four fold serial dilutions are prepared at a starting dilution of 1/10: 
 
Serial dilution: 1/10, 1/40, 1/160, 1/640, 1/2560, 1/10240. This is the stock of standard 
control. 
 
To work out how much control you need, you can follow these equations: 
 
Total needed for each plate- 10μl for 1/5 OR 5μl for 1/10 
No. of plates= n 
Blocking solution in positions 12A DW2, 12B DW1, 12B DW2, 12C DW1, 12C DW2 
(A) = 10μl OR 5μl * n + 60μl (for excess) 
Transfer volume between wells (T) = a/3 (this is for a ¼ serial dilution) 
(Transfer from 12A DW1 to 12A DW2 to 12B DW1 to 12B DW2 to 12C DW1 to 12C 
DW2) 
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Total volume in top well (12A DW1) (C) = A + T 
Positive control serum/plasma in top well (12A DW1) = C/10 
Blocking solution in top well (12A DW1) = C/10 x 9  
 
Add at least the same volume of blocking buffer as C in wells 12D-H. 
Add the same volume of blocking buffer as C in wells 11A-H plus an extra 20 µl per 
well. 
 
 
 
 
 
MSP-1: 
1 in 5 dilution of the stock control (stock at 1/200) onto each ELISA plate (20 μl 
blocking solution & 5 μl stock control) – final dilution of sample will be 1/1000 
 Final serial dilution: 1/50, 1/200, 1/800, 1/3200, 1/12800 & 1/51200 
AMA-1: 
1 in 10 dilution of the stock control (stock at 1/200) onto each ELISA plate (22.5μl 
blocking solution & 2.5μl stock control) – final dilution of sample will be 1/2000 
 Final serial dilution: 1/100, 1/400, 1/1600, 1/6400, 1/25600, 1/102400 
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APPENDIX VI: PROTOCOL 
Protein Microarray printing standard operating protocol (SOP) 
 
Author: 
Name:  Tate Oulton 
Position: Scientific Officer 
Signature:     Date:  21/11/2017 
1 Overview 
This SOP describes the methods to print protein microarrays. 
2 Safety 
Adhere to local safety regulations. Wear appropriate personal protective equipment. 
3 Materials 
Equipment 
a) Oncyte NOVA microarray slides (GraceBio Labs) 
b) 384-well microtiter plate(s) (ArrayJet) 
c) JetGuard plate septa 
d) Single/multichannel pipettes and tips 
e) Centrifuge 
f) ‘Command Centre for Marathon’ software (ArrayJet) 
g) Marathon Classic microarray printer (ArrayJet) 
Documents 
a) Laboratory Record Book 
b) Glycerol System Buffer recipe 
c) Glycerol Printing Buffer recipe 
d) Software Application Training 
e) High Pressure Purge Procedure 
Reagents 
All reagents should be stored according to the instructions supplied with them and 
disposed of at the expiry date recorded on the product. 
a) 1x PBS solution (Oxoid) 
b) Ultrapure/distilled water 
c) Purified proteins/antigens of interest 
d) Glycerol printing buffer 
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4  Preparation of Buffer Solutions  
 
All buffer solutions should be clearly labelled with:  
• Reagent name  
• Expiry date  
• Preparation date  
• Name of person who prepared the buffer 
 
Reagents should be stored under appropriate conditions. See Table 1 for details on 
preparation and storage.      
 
 
 
Table 1: Buffer solutions  
Buffer solution Reagent/chemical Amount/Volume 
Phosphate buffered saline (PBS) 1X  
 
PBS tablets 1 
Ultrapure/MilliQ water 100 ml 
Store at room temperature, dispose of after one month 
Glycerol printing buffer See ‘Glycerol Printing Buffer recipe’ 
Store at room temperature, dispose of after 3 months 
Blocking buffer 0.25X 
 
See ‘Glycerol System Buffer recipe’ 
Store at room temperature, dispose of after 6 months 
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5 Methods 
  
Array design 
1. Decide on a panel of proteins/antigens to be included in the arrays. It is useful to 
include ‘reference’ spots to help with finding the arrays during imaging and analysis. 
The material printed as reference spots should be chosen on the basis that it will 
show fluorescence independently of sample reactivity (e.g. purified IgG when using 
an anti-IgG secondary antibody, or the secondary antibody itself). You may also 
wish to include a standard control curve (e.g. serial dilution of purified IgG) to allow 
for approximation of reactivity. 
 
2. Create a .csv file in MS Excel which describes the layout of the array you wish to 
print. For detailed instructions, refer to the ‘Software Application Training’ 
presentation, but briefly; 
2.1. The layout should start at cell A1. Each row should be no more than 12 cells 
long (Figure 1). The number of rows is limited only by the space available to 
print on 
 
 
 
2.2. Note that in a printed array of 24 spots across, the first row of 24 is created by 
the printing of the first 2 rows of 12 in this array layout .csv file. Row A1-L1 is 
Figure 1. A typical array layout .csv file. This file consists of 16 rows of 12 cells, with no row exceeding 12 cells. Note 
the ‘REF’ (reference) and ‘Std…’ (standard curve) spots. Also note that empty cells can be included, as in row 16, as 
these will be interpreted as blank ‘buffer’ spots by the printer. 
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printed from right to left starting in the top right corner of each array. 
Subsequently, row A2-L2 is printed from right to left to the immediate left of 
row A1-L1 (Figure 2a-b). 
 
a. 
 
 
b. 
 
 
 
2.3. This explains the positioning of the ‘REF’ spots in cells L1 and A2 (Figure 3). 
Using this layout, each array will be printed with a ‘REF’ spot in the top right 
and top left corner. 
 
 
 
3. Once the array layout .csv file has been created, open the Command Centre for 
Marathon software. Go to ‘File’ > ‘Generate Microplate Map File’ > ‘Browse’ and 
select the array layout file. Click ‘Generate’ and a new wellplate map file (.csv) and 
an input file (.txt) will be created in the same folder as the array layout file. This file 
provides a map as to which well each antigen should be loaded in to achieve the 
desired printed layout. 
 
Figure 2. A comparison between a) The initial layout of antigens as written in the array layout .csv file, and b) 
The actual printed layout of spots as they would be found on the finished array. 
Figure 3. The positioning of REF spots (highlighted yellow) at L1 and A2 result in a REF spot being printed in the top 
right and top left of each array 
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Microplate preparation 
1. Dilute each antigen/protein to 2X the desired printed concentration in PBS (e.g. to 
print a spot at 0.1mg/ml, dilute to 0.2mg/ml). This allows for a 1 in 2 dilution of 
antigen in printing buffer. 
2. Using a multichannel pipette, load each required well of the 384-microwell plate 
with half the desired final volume, with glycerol printing buffer (e.g. for a final well 
volume of 20µl, add 10µl of glycerol printing buffer. 
3. Then, according to the wellplate map generated in ‘Array design‘ step 3, add 
antigen/protein to each well at a volume equal to the volume of glycerol printing 
buffer already in the well (e.g. add 10µl of antigen to 10µl of glycerol printing 
buffer). In wells marked ‘buffer’, add one part printing buffer to one part PBS. Mix 
very thoroughly by pipetting up and down multiple times. 
4. Once all of the wells have been loaded, spin the plate down at 1800 xg for 5 
minutes and check that no bubbles remain in any wells. If bubbles remain spin again 
and check. Persistent bubbles can be popped with a pipette tip. Fit a septa to the 
plate to prevent evaporation. 
 
Printing 
1. Ensure that the inside of the printer is clean, free from dust and contaminants. Use 
a microfiber cloth to wipe down surfaces, especially areas which the print head will 
pass over. 
2. At least half an hour before printing, switch on the printer and atmospheric 
controller to allow conditions inside the printer to equilibrate. 
3. Open the ‘Command Centre for Marathon’ software and go to ‘Options’ > ‘Initialise 
Instrument’. Follow on-screen instructions. 
4. Check that the waste system buffer bottle is empty and that the clean system buffer 
bottle is sufficiently full of glycerol system buffer (N.B. system buffer is different to 
the printing buffer used in the 384-microwell plate). If emptying/refilling needs to 
be carried out, go to ‘Options’ > ‘Fill/Empty System Buffer Bottles’. Follow on-screen 
instructions. 
5. Carry out system maintenance and checks 
5.1. Perform a JetSpyder purge – Go to ‘Options’ > ‘JetSpyder Purge’; follow on-
screen instructions (installed JetSpyder is 12 capillary). Repeat for a total of 4 
purges. 
5.2. Perform a print head purge x4 – Go to ‘Options’ > ‘Print head purge’ > ‘x4’. 
Follow on-screen instructions 
5.3. Print a test slide – Go to ‘Options’ > ‘Print Test Slide’. Follow on-screen 
instructions. If test slide fails, repeat print head purge x4. If test slide continues 
to fail, nozzle suppression may be required (see ‘Command Centre for 
Marathon’ help). 
5.4. Perfrom a ‘K’ test procedure – Go to ‘Options’ > ‘K Test Procedure’. Follow on-
screeen instructions. If ‘K’ test fails (<220.000kPa), carry out ‘High Pressure 
Purge’ procedure. 
6. Create a new print run file (.prp). In the ‘Command Centre for Marathon’ software 
go to ‘File’ > ‘New’ > ‘Print Run (slides)’ 
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6.1.  Source Microplate Properties tab 
6.1.1. Select ‘Standard 384’ from source microplate type 
6.1.2. Select the number of source microplates used 
6.1.3. Select the total number of wells filled in the last plate (including buffer 
spots – must be a multiple of 12) 
6.1.4. If required, add an additional cleaning routine, and add a plate(s) loaded 
with desired buffer according to the layout and instructions on-screen. 
 
6.2. JetSpyder Properties tab 
6.2.1. Ensure ‘Low Volume – 12 Samples’ JetSpyder is selected 
6.2.2. Nozzles can be suppressed if required 
6.2.3. Option for single pass printing can be selected if required 
 
6.3. Slide Properties tab 
6.3.1. Set number of trays 
6.3.2. Set number of slides in the last tray – note that no spaces can be left 
between slides 
6.3.3. Set up printing area parameters. For 16-pad Oncyte NOVA slides, use the 
following settings: 
 
a) For pads 6.5 x 6.5mm   b) For pads 6.0 x 6.0mm 
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6.4. Spot Properties tab 
6.4.1. Select desired number of spots 
6.4.2. Select gap and pitch between spots. Spacing of 0.230mm is recommended 
6.4.3. Select the number of repeats, e.g. a repeat of 2 will mean every spot is 
printed twice in every array. Note how this will alter the layout of the 
printed array in the ‘Repeat Layout Preview’. This can be altered by 
choosing different options in the ‘Print mode’ settings. Also note that 
increasing the number of repeats may require repeat pick-ups of 
antigen/protein depending on the number of slides and arrays to be 
printed, so ensure adequate volume is available. 
6.4.4. Select regular or hexagonal printing 
6.4.5. Select ‘Centred’ from the ‘Centring’ option 
6.4.6. Note that a warning will appear if your chosen settings would force spots 
to be printed outside the printable area. 
 
 
6.5. Overview tab 
6.5.1. Check that the number of arrays and spots are as expected. Check that 
spots will not be printed too close to the edges of the printable area as 
this is not desirable. 
6.6. Save the created .prp file 
7. Load the microplate(s) and blank slides in the printer. Go to ‘Options’ > 
‘Load/Unload Microplates and Slides’. Place the microplate(s) (and wash plate(s) if 
selected) according to the positions indicated in the .prp file previously created. 
Remove the required number of slide trays, and load the required number of slides 
into sequential positions, taking care not to touch the slide surfaces. Ensure that all 
slides are completely flat (no raised edges) and positioned snugly in each slide 
recess, pushed right to the back. Use a compressed air duster to blow off any dust 
and contaminants on the slides before placing the loaded tray back into the printer. 
Close the doors and follow the on-screen instructions. 
8. Load the .prp file through ‘File’ > ‘Load’ > ‘Print Run (slides)’ and make a final check 
of all settings. Navigate to the ‘Options (Start)’ tab and ensure that ‘Print Run 
Options’ is set to ‘Using source microplates’. Click ‘START PRINT RUN’. You will have 
60 seconds to make a final check that all slides and microplates are ready and in 
position. Printing will then commence. 
9. Once printing is complete, leave slides inside the printer for at least 6 hours with 
the atmospheric controller still on. After this, to shut down the printer got to 
‘Options’ > ‘Shut Down Instrument’. Remove the slides, and store them in boxes at 
4°C in a vacuum dessicator. 
 
Creation of a labelled .gal file 
1. In the ‘Command Centre for Marathon’ software, go to ‘File’ > ‘Merge Samples and 
GAL Files’. For the ‘GAL/CSV file’ option, browse to the .gal log file for the 
completed print run in C: drive > Programme Files (x86) > Arrayjet > Marathon 
software > Log files. For the ‘Samples File’ option, browse to the .txt file created in 
step 3 of Array Design methods. 
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2. Process the files and save the resulting labelled .gal file (generated in C: drive > 
Programme Files (x86) > Arrayjet > Marathon software > Log files) to the scanner 
computer for image analysis. 
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APPENDIX VII: CHAPTER 6 SUPPLEMENTARY DATA 
Supplementary figures for Chapter 5: High throughput serological profiling of 
antibody isotypes in Malaysian hospital case samples using a bespoke protein 
microarray platform.
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Figure 1 IgM isotype reactivity matrices towards P. knowlesi-specific antigens in Malaysian clinical samples at 
days 0, 7 and 28 after diagnosis and treatment. Data is shown as Log2 MFI ratio on both axes. For each 
scatterplot square, the matrix is read with the y axis showing the top antigen and the x axis showing the bottom 
antigen. 
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Figure 2 IgG isotype reactivity matrices towards P. knowlesi-specific antigens in Malaysian clinical samples at 
days 0, 7 and 28 after diagnosis and treatment. Data is shown as Log2 MFI ratio on both axes. For each 
scatterplot square, the matrix is read with the y axis showing the top antigen and the x axis showing the bottom 
antigen. 
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Figure 3 IgA isotype reactivity matrices towards P. knowlesi-specific antigens in Malaysian clinical samples at 
days 0, 7 and 28 after diagnosis and treatment. Data is shown as Log2 MFI ratio on both axes. For each 
scatterplot square, the matrix is read with the y axis showing the top antigen and the x axis showing the bottom 
antigen. 
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Figure 4 P. knowlesi-specific antigen reactivity towards IgM, IgG and IgA across all time points for each antigen. The data is plotted for (A) PkMSP1 ag2; (B) PkSERA3 ag1; (C) PkSERA3 ag2; 
(D) PkTSERA2 ag1; (E) PkTSERA2 ag2; (F) PkSSP2; (G) PKH_031930 ag1; (H) PKH_031930 ag2; (I) PKH_021580 and (J) PKH_080030. The results are presented as geometric mean log2 MFI ratio 
readings. The error bars show the standard deviation.  
 
DEVELOPMENT OF PK SPECIES SPECIFIC REAGENTS TO CHARACTERISE ANTIBODY ISOTYPE PROFILES | LOU HERMAN 
365 | P a g e  
 
 
Figure 5 Specific anti-IgM secondary antibody reactivity towards printed purified isotype standards. Goat anti-
Human IgM Qdot® 655 secondary antibody reactivity towards purified IgM (A), IgG (B) and IgA (C) printed at 
different concentrations and screened with serum from a hospital clinical treatment trial. Results are shown for 
every array (sample) as log2 of the MFI ratio. 
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Figure 6 Specific anti-IgG secondary antibody reactivity towards printed purified isotype standards. Goat anti-
Human IgM Qdot® 655 secondary antibody reactivity towards purified IgM (A), IgG (B) and IgA (C) printed at 
different concentrations and screened with serum from a hospital clinical treatment trial. Results are shown for 
every array (sample) as log2 of the MFI ratio. 
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Figure 7 Specific anti-IgA secondary antibody reactivity towards printed purified isotype standards. Goat anti-
Human IgM Qdot® 655 secondary antibody reactivity towards purified IgM (A), IgG (B) and IgA (C) printed at 
different concentrations and screened with serum from a hospital clinical treatment trial. Results are shown for 
every array (sample) as log2 of the MFI ratio. 
